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Abstract
HIV-2 infected monocyte derived macrophages (MDM) at much lower efficiency 
compared to HIV-1 or to infection of PBMC. After a brief initial burst of replication, 
HIV-2 viral production was terminated. HIV-1 however rebounded cyclically in culture 
over a period of 20 days. Early entry events of HIV-2 in MDM were accommodated 
efficiently and replication could be restimulated with LPS indicating that HIV-2 enters a 
latent phase in MDM. The amino acid charge of the HIV-1 V3 loop is negatively 
correlated with macrophage tropism (Zhong et al., 1995), and I demonstrate that the 
HIV-2 V3 loop charge is also negatively correlated with MDM tropism, albeit weakly. 
This led me to investigate other determinants of HIV cellular tropism. An HIV-2 
primary isolate that is unable to replicate in MDM was molecularly cloned (MCR) and 
the restriction (termed Lv2) mapped to virus env and gag (Schmitz et al., 2004). I show 
that a variety of primary HIV-1 and HIV-2 viruses are susceptible to Lv2 restriction.
Lv2 is a post-entry, post-reverse transcription restriction to HIV infection. To 
incorporate a role for Env, which acts at the cell surface, a model where the Env 
delivers a susceptible Gag into a restrictive cellular compartment was developed 
(Schmitz et al., 2004). The compartmentalisation model of Lv2 was tested using 
compounds that affect endocytic pathways (hypertonic sucrose) and lipid rafts (Methyl- 
p-cyclodextrin) in restrictive cells. With these methods I show that restricted virus can 
be rescued from Lv2 if a lipid raft-dependent endocytic pathway is inhibited. Fusion of 
restricted virus into HeLa/CD4 cells containing a tailless CD4 that located outside lipid 
rafts was fully permissive. The restrictive pathway was further defined using dominant 
negative mutants that specifically inhibit defined endocytic pathways; clathrin, caveolae 
and non-clathrin non-caveolae mediated. A role for an Arf6 non-clathrin non-caveolae 
mediated endocytic pathway in Lv2 restriction was demonstrated. Lastly, env swapped 
viruses demonstrate that delivery to the restriction pathway is Env dependent. In 
keeping with the Lv2 model, the unrestricted virus was unaffected by any of these 
treatments. Thus the route of entry, determined by the viral Env, can influence cellular 
tropism by avoiding intracellular blocks to infection.
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The saturable nature of Lv2 restriction was investigated. HIV-2 Env pseudotypes of El­
and N-tropic MLV pseudotypes saturated Lv2. This observation led me to investigate if 
human tripartite motif protein (TRIM) 5a and members of the human TRIM family of 
proteins, shown to restrict MLV, mediated Lv2.
The TRIM family of proteins have been implicated in retroviral restrictions and even so 
far as to have broad anti-viral activity (Nisole et al., 2005). By choosing TRIM proteins 
with SPRY(B30.2) domains, and an RNA interference (RNAi) screening approach, 
TRIMs 1,18 and 34 were identified as having Lv2 restriction activity. These proteins 
are expressed in restrictive HeLa/CD4 cells but not in permissive ones, thus acting as 
intracellular determinants of retroviral cell-tropism.
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Introduction
1.1 Acquired Immune Deficiency Syndrome
In 1981, several patients were identified who had an insidious immune deficiency . The 
patients presented with opportunistic infections not seen before in the immune- 
competent, such as: oral Candidiasis, Kaposis Sarcoma (KS), Toxoplasmosis, 
Pneumocystis carnii pneumonia (PCP), and Cytomegalovirus (CMV) retinitis (Holland 
et al., 1982; Horowitz et al., 1983). After two years of infection, the case-fatality rate 
was approximately 90% and the cause of death in these immune compromised patients 
was often PCP, normally only seen in immunocompromised patients (Gottlieb et al., 
1983; Groopman and Gottlieb, 1983; Murray et al., 1984). Immunologically, the 
majority of infected individuals appeared normal except for a reduction in their helper T 
cell subset. The percentages of B cells, circulating immunoglobulin levels, and natural 
killer (NK) and antibody-dependent cell-mediated cytotoxic T cell (ADCC) functions 
were normal, however there was a reduction in the patient CD4+/CD8+ T cell ratio. 
Therefore the cause of the immune deficiency appeared to be a loss of CD4+ T cells 
(Gottlieb et al., 1981; Schroff et al., 1983).
1.2 The discovery o f the Human Immunodeficiency Viruses type 1 and type 2
In 1983 a T-Lymphotropic virus was isolated from a patient suffering from 
lymphadenopathy (Barre-Sinoussi et al., 1983). Before this discovery there were 
several hypotheses put forward for the cause of the growing number of 
lymphadenopathy cases, these included drug use, spermatozoa exposure, and even the 
use of amyl-nitrates, or 'poppers' that enhance sexual prowess (Gottlieb et al., 1981; 
Quagliarello, 1982). However, an overwhelming amount of evidence suggested an 
infectious aetiology, in particular, a blood transmitted infectious agent. It became 
apparent that not only homosexuals were susceptible to this new acquired 
immunodeficiency, but cases of infected intravenous drug users, haemophiliacs and
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heterosexuals were becoming increasingly apparent (Evatt et al., 1984; Feorino et al., 
1984; Griffin, 1983). Since a characteristic of the immune deficiency was the loss of 
the T-helper cell subset it was suggested that a T-Lymphotropic virus was responsible 
for the onset of AIDS, possibly even a member of the HTLV retrovirus family (Gallo et 
al., 1983). After sequencing and genotyping it was found that the AIDS virus 
resembled a member of the lentivirus family rather than the HTLV family of delta 
retroviruses and was termed the Human Immunodeficiency Virus type 1 (HIV-1) 
(Alizon and Montagnier, 1986; Coffin, 1986).
The Human Immunodeficiency Virus type 2 (HIV-2) was isolated in 1986 from two 
AIDS patients in West Africa. Then named Lymphadenopathy virus 2 (LAV-2), the 
envelope (Env) of HIV-2 reacted with serum from a macaque infected with STLV- 
Illmac (now known as SlVmac) but not with serum from patients with HIV-1 (Barin et 
al., 198S; Chen et al., 1997; Clavel et al., 1986a; Clavel et al., 1986b; Clavel et al., 
1987; Hahn et al., 2000). The sero cross reactivity of HIV-1 and HIV-2 was restricted 
to the core protein p24 (Barin et al., 1983; Clavel et al., 1986a; Clavel et al., 1987; Hahn 
et al., 2000). This suggested that the new virus, HIV-2, was more closely related to the 
simian virus than to HIV-1 [reviewed in (Hahn et al., 2000)]. The subsequent molecular 
cloning of HTV-2 suggested that it was distinct from both SIV and HIV-1 and more 
closely related to SIV (Clavel et al., 1986a).
1.3 Epidemiology o f HIV-1 and HIV-2
By the end of 2004, approximately 58 million people had died of AIDS or were living 
with HIV infection (UNAIDS, 2004). The region with the greatest number of people 
infected with HIV is sub-Saharan Africa. The number of those currently infected in this 
region (December, 2004) stands at approximately 25 million, with Botswana (37.3% 
adult population as of end 2003), Lesotho (28.9% adult population as of end 2003), 
Swaziland (38.8% adult population as of end 2003), and South Africa (21.5% adult 
population as of end 2003) having the highest percentage of the population infected 
(UNAIDS, 2004).
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1.4 Disease course and mechanism o f  T helper cell loss
1.4.1 Disease course
The first few weeks o f HIV infection are typified by flu-like symptoms (“acute” in fig 
1.1) that are coincident with a high plasma viral load. An adaptive immune response 
controls acute viraemia and restores CD4+ T cell levels, but does not eradicate the virus. 
High virus turnover depletes CD4+ T cell levels gradually over the course of a few 
years. When the CD4 count falls below 500 CD4+ T cells/pl opportunistic infections 
become more frequent, (mean of approximately 10 years) and an individual is 
considered to have AIDS when their CD4 count falls below 200 cells/pl (fig 1.1) 
(Castro et al., 1992; Janeway et al., 2001).
Increasing viral diversity
Acute Chronic AIDS
Weeks
O O
Viral set-pctnt
Primary
infection
—  Plasma viraemia
—  CD4+ T lymphocytes
Years
Figure 1.1. Disease course: CD4 count versus viraemia.
After the acute viraemia stage the CD4 count stabilises with the viral set point. The protracted chronic
phase is clinically “silent” however there is very high virus turnover followed by depleted CD4 counts
and a high level o f viraemia with the onset o f AIDS. From (Simon and Ho, 2003).
1.4.2 Mechanism of T cell loss
HIV preferentially infects HIV specific (Douek et al., 2002), and non-specific Th cells 
(Badley et al., 2000). Autologous T cell death due to toxicity of direct infection is
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thought to be just one of many mechanisms of T cell depletion [reviewed in (Simon and 
Ho, 2003)]. HIV induced enhancement of Fas ligand, TRAIL receptor, and even 
ligation of CD4 by gpl20 have been shown to be a cause of bystander cell death 
[reviewed in (Badley et al., 2000; Simon and Ho, 2003)]. All of the above are thought 
to lead to CD4 counts less than 200 cells/pl that is the hallmark of AIDS (fig 1.1).
1.5 AIDS associated illnesses
Th cell loss is associated with the onset of opportunistic infection. When circulating 
CD4+ T cell levels fall to less than 500 cells/pl HIV infected individuals may start to 
present with opportunistic infections (Castro et al., 1992). The combination of 
declining CD4+ T cells less than 200 cells/ pi with or without presentation of 
opportunistic infections is a characteristic of AIDS (Castro et al., 1992).
The first indications of an emerging HIV epidemic were the appearance of opportunistic 
infections in previously healthy homosexual men (Gerstoft et al., 1982; Gottlieb et al., 
1981). The spectrum of infections presented by AIDS patients varies from the 
cosmetically undesirable KS lesions and oral candidiasis to the more malignant and 
debilitating PCP and atypical mycobacteriosis (Lemer and Tapper, 1984). The 
infections/pathogens involved in AIDS are too numerous to describe here so the 
following is an introduction to four of the more common illnesses associated with HIV 
associated immunodeficiency.
1.5.1 Kaposi’s sarcoma
KS lesions are often the first manifestation of AIDS and appear when the level of 
immunosuppression is still mild (Beral, 1991). Originally described by Moritz Kaposi 
in 1872 (Kaposi, 1872), KS is 20,000 times more common in those with AIDS than the 
general population (USA) and 300 times more common than in other 
immunosuppressed groups (Beral et al., 1990). There is also a correlation between KS 
and HIV infection in South Africa (Sitas et al., 1999). KS lesions are a tumour of 
vascular origin that tend to be brownish-purple and favour the extremities (Ruszczak et 
al., 1987; Samaniego et al., 1995), and are caused by human herpes virus 8 (Boshoff et
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al., 1995; Chang et al., 1994; Dupin et al., 1999; Sirianni et al., 1997; Talbot and 
Crawford, 2004).
1.5.2 Candida
Opportunistic infection patterns vary from region to region, fungal infections were the 
most common opportunistic pathogen in those suffering from AIDS in the USA in 1981 
(Gottlieb et al., 1983; Gottlieb et al., 1981). Primarily the Candida species, these 
infections can become disseminated and are becoming increasingly drug resistant 
(Coleman et al., 1998; Walsh and Groll, 1999). Oropharyngeal candidiasis caused by 
Candida albicans is an early indicator of AIDS that can become systemic if left 
untreated (McCullough et al., 1996). Indeed, the study of fungal infections of AIDS 
patients has led to die discovery of new pathogenic Candida species (Coleman et al., 
1998; Sullivan et al., 1995).
1.53 Pneumocystis carnii pneumonia
Deaths of young homosexual men and injecting drug users (IDUs) in the early 1980s by 
PCP were some of the first indications that an epidemic of acquired immunodeficiency 
was emerging (Masur et al., 1981; Masur et al., 1982). Pneumocystis carinii, once 
thought to be a protozoan is now considered a fungus and causes acute “aggressive” 
pneumonia in immunodeficient humans, and Pneumocystis spp have been reported to 
cause disease in immunodeficient animals (Bartlett and Smith, 1991; Stringer, 1996). It 
is a major cause of “life-threatening” pneumonia and occurs in up to 80% of AIDS 
patients in the USA (Bartlett and Smith, 1991), making it the most common 
opportunistic infection in these patients [reviewed in (Sepkowitz, 2002)]. There is 
however a regional discrepancy; the incidence of PCP is only about 7% in African 
AIDS patients (Bartlett and Smith, 1991).
1.5.4 Typical and atypical Mycobacteriosis
A major cause of death in AIDS patients is the atypical Mycobacterial species. 
Disseminated Mycobacterium avium and CMV infections have been reported to be a 
leading cause of death in AIDS patients in the USA (Lemer and Tapper, 1984).
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“Without HIV, the (Mycobacterium) tuberculosis epidemic would be in decline” (Nunn 
et al., 200S). Tuberculosis is the second leading cause of death world-wide and the 
leading cause of death of HIV patients in Africa (Frothingham et al., 2005; Nunn et al., 
2005).
1.6 The immune response to H IV infection
1.6.1 Iaterferon response
A type 1 (cell mediated) immune response has been associated with suppression of viral 
load and long-term non-progression, with high IL-2 and IFNy levels as strong correlates 
of maintenance of healthy CD4 cell counts (Clerici et al., 1996a; Salvaggio et al., 1996). 
Indeed, high IL-10 levels, indicating a switch to a predominantly humoral response 
(type 2), have been associated with a poor prognosis (Clerici et al., 1996b; Clerici et al., 
1994).
1.6.2 y8T cells
The VyV82+ T cells recognise small organic phosphate antigens (Ag) and alkyl amines 
from a variety of bacterial and protozoal parasites without the need for MHC 
presentation or Ag processing (Janeway et al., 2001). There is no evidence that HIV 
encodes peptide Ags that are recognised by VyV62+ T cells (Chen and Letvin, 2003). 
However, the VyV82+ T cells can inhibit HIV replication in vitro because P-chemokines 
(MIPl-o, MEPl-p, and RANTES), shown to block entry of CCR5 (R5) using HIV 
viruses, are produced by phospho-Ag stimulated VyV82+ T cells (Poccia et al., 1999).
1.63 Natural Killer cells
Natural killer (NK) cells comprise about 15% of the peripheral blood lymphocytes, 
display a CD56+CD3‘ phenotype and do not express specific Ag receptors like B and T 
cells. They are considered the “first line of defense”, secreting cytokines and 
chemokines upon activation, modulating other immune cells (Jacobs et al., 2005). Low
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NK cell numbers in the blood of HTV-infected individuals are associated with a more 
rapid progression to disease that has been suggested to indicate the importance of NK 
cell functions in controlling HIV infection (Jacobs et al., 2005). HIV-1 accessory genes 
Vpu and Nef down-regulate MHC-I from the cell surface of HTV infected cells, 
hindering immune recognition and clearance by cytotoxic T-lymphocytes (CTL). 
However NK cells are able to recognise these MHC-corrupted cells and lyse them 
(Martin et al., 2002b).
1.6.4 CD8+ cytotoxic T celb
CTL (CD8+ VaVp T cells) detect virally infected cells by recognition of foreign 
peptides associated with MHC-I. Detection of foreign peptide leads to lysis and 
apoptosis of the infected cell by CTL secreted perforin and granzyme, respectively. 
Professional antigen presenting cells (APCs) are needed for optimal activation and 
expansion of CTL (Collins, 2004). The importance of CTL in controlling HIV viral 
load is underlined by the coincident appearance of anti-HIV CTL and control of initial 
acute HIV viraemia (Borrow et al., 1994). Also, the breadth of HIV Ag recognition by 
CTLs may determine the chronic viraemia set point after the acute viraemia stage of 
infection (Jones et al., 2004).
1.6.5 Human leukocyte antigen genotype associations to prognosis
The human major histocompatibility complex (MHC) is composed of genes located on 
the short arm of chromosome 6 [reviewed in (Janeway et al., 2001)]. The MHC class I 
proteins encoded in this complex are expressed on all nucleated cells and the class II 
proteins are expressed constitutively on APCs, T cells and endothelial cells when 
activated [reviewed in (Janeway et al., 2001)]. The MHC proteins express foreign and 
‘self peptides that are recognised during infection and immune surveillance to discern 
between healthy and infected host cells. The most polymorphic region of the human 
genome is the MHC [reviewed in (Horton et al., 2004)], so some individuals may 
express HIV Ag via MHC class II more efficiently and control viral load better than 
others. Human leukocyte antigen (HLA) haplotypes DQ2-DR3-B8-Cw7-Al and DQ1- 
DR1-B35-Cw4-Al 1 have been associated with rapid progression to AIDS (Just, 1995), 
whereas HLA-Bw4, B44 and B57 have been associated with long-term non-progression
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to AIDS (Flores-Villanueva et al., 2001; Migueles et al., 2000), however the 
mechanism(s) that contribute^) to the haplotype specific prognosis is still not known.
Homozygosity for any 2 Bw4 alleles is a marker for delayed AIDS progression. This 
raises the possibility that NK cells are involved in regulating AIDS progression since 
HLA-B molecules with the Bw4 motif serve as ligands for the natural killer cell 
receptor, killer immunoglobulin receptor (KIR) 3DL1 (Carrington and Bontrop, 2002). 
KIRs expressed on NK cells regulate inhibition and activation of NK cell responses 
through recognition of HLA class I molecules on the cell surface (Janeway et al., 2001).
1.6.6 T helper cells
There are two subsets of T helper cells (Th cells): Thl and Th2. Thl cells stimulate the 
CD8+ CTL, and macrophage (M0) cell-mediated immune response through secreted 
IFN-y and IL12 [reviewed in (Janeway et al., 2001)]. Th2 cells stimulate (antibody) Ab 
production by B cells through secretion of IL4, IL6, and IL10 (the humoral response) 
[reviewed in (Janeway et al., 2001)]. The activation of a naive Th cell by a professional 
APC is via MHC class II interaction with the Th cell receptor and CD4 [reviewed in 
(Janeway et al., 2001)]. Whether the Th cell becomes type 1 or type 2 depends on the 
costimulation it receives at the point of Ag presentation [reviewed in (Janeway et al., 
2001)].
Strong cell-mediated immunity is associated with low HIV viral loads (Clerici et al., 
1996a; Clerici et al., 1996b; Clerici et al., 1993; Clerici et al., 1994; Clerici and Shearer, 
1996; Kalams and Walker, 1998), and a strong Thl cell response is required to drive this 
response. Indeed, HIV-1-specific CD4 Thl cells expressing IFN-y, combined with IgG2 
antibodies are “predictors” of long-term non-progression to AIDS (Clerici et al., 1996a; 
Clerici et al., 1996b; Clerici et al., 1993; Clerici et al., 1994; Martinez et al., 2005).
The Thl and Th2 response in HIV infection is skewed toward a Th2 response in those 
individuals that progress to AIDS (Clerici et al., 1996b; Clerici et al., 1994; Clerici and 
Shearer, 1996). Cytokines of a type 2 profile (IL-4, 6,10) are associated with the onset 
of disease, in addition to the inability of peripheral blood mononuclear cells (PBMC) 
taken from these patients to be unreactive to in vitro Influenza and HIV Env Ag
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stimulation as measured by IL-2 production (Clerici et al., 1996b; Clerici et al., 1993; 
Clerici et al., 1994).
1.6.7 Humoral immunity
B cells produce Abs in response to stimulation by Th2 cells [reviewed in (Janeway et al.,
2001)]. If an Ab inhibits virus infection then it is considered neutralising: “the loss of 
infectivity which ensues when Ab molecule(s) bind to a virus particle, and usually 
occurs without the involvement of any other agency” (Dimmock, 1993). Neutralising 
antibodies (NAbs) probably work in concert with cell-mediated immunity to help 
control viral infection (Burton, 2002).
NAbs to HIV cannot be detected until after the initial peak viraemia, sometimes they do 
not appear until 17 months after acute infection (Aasa-Chapman et al., 2004), so they 
may play a role in control of the later stages of infection (Ferrantelli and Ruprecht,
2002). However, studies have suggested that complement (a cascade of proteins that act 
to form pores in and opsonize pathogens) in conjunction with non-NAbs directed 
against virus Env may help suppress initial peak HTV viraemia (Aasa-Chapman et al., 
2005).
Seroconversion is the point at which anti-HIV-1 antibodies can be detected in the blood. 
HIV-1 infection is diagnosed by detecting antibodies specific to the virus which show- 
up 6-8 weeks after infection (Gurtler, 1996). This period is called “serological latency” 
and may be shorter than 6 weeks or several weeks longer, however inability to detect 
antibodies 3 months after infection is rare (Gurtler, 1996). Antibodies to Env, the 
immunodominant epitope of gp41 and Gag (p24 and p i7) are detectable first. 
Following are antibodies to reverse transcriptase RT (p51 and p66) and integrase (IN) 
(p32). Antibodies to all of these HIV proteins persist for life (Gurtler, 1996).
1.7 Highly Active Anti-Retroviral Therapy: triple therapy.
The treatment of HTV infection with anti-retroviral drugs involves blocking viral 
replication [reviewed in (Dalgleish and Weiss, 1999)]. The purpose of highly active 
anti-retroviral therapy (HAART) is to lower plasma viraemia to restore circulating
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CD4+ T cell levels, thus the patient is able to fight opportunistic infection and live 
longer [reviewed in (Back et al., 2002)]. The first of these drugs to be used was 
Zidovudine [Azidothymidine(AZT)], which was licensed for symptomatic disease in 
1987 [(Brook, 1987; Fischl et al., 1987; Parks et al., 1988; Yarchoan et al., 1986; 
Yarchoan et al., 1988) reviewed in (Dalgleish and Weiss, 1999)].
1.7.1 Nucleoside reverse transcriptase inhibitors
NRTIs like AZT, lamivudine (3TC), didanosine (ddl), zalcitabine (ddC) and stavudine 
(d4T) are converted to their active triphosphate forms within cells [reviewed in (Back et 
al., 2002)]. The mode of anti-retroviral action is to act as viral DNA chain terminators 
as the proviral genome is reverse transcribed from the viral RNA [reviewed in 
(Hightower and Kallas, 2003)].
1.7.2 Non-nucleoside reverse transcriptase inhibitors
The non-nucleoside reverse transcriptase inhibitors (NNRTls), Nevirapine and 
Efavirenz have an aromatic structure and bind to a hydrophobic pocket near the 
polymerase active site [reviewed in (Hightower and Kallas, 2003)]. Unlike HTV-1, 
these drugs do not affect the in vitro replication of HTV-2 [reviewed in (Hightower and 
Kallas, 2003)]. It is thought that this natural resistance is conferred by amino acid Leu- 
188 that is in close proximity to one of the two hydrophobic pockets of RT [reviewed in 
(Hightower and Kallas, 2003)].
1.73 Protease inhibitors
The HTV-1, HTV-2, and SIV proteases belong to the aspartyl-protease family. They are 
required to post-translationally cleave polyproteins into structural proteins and 
functional enzymes required for infectivity [reviewed in (Hightower and Kallas, 2003)]. 
Protease inhibitors such as Indinavir, Saquinavir, Nelfinavir, and Ritonavir compete for 
the protease active site and have been shown to bind HTV-1 protease with 10 to 100 
times greater affinity than the HTV-2 protease (Tomasselli et al., 1990), and are 
therefore much more effective against HIV-1 than HTV-2 infection.
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1.7.4 Fusion inhibitor
Enfuvirtide is a 36 amino acid peptide specific for a portion of the gp41 HR2 region of 
the HTV-1 laboratory strain LAI but is ineffective at inhibiting HIV-2 or STV replication 
[reviewed in (Greenberg et al., 2004)], it is also effective at inhibiting HTV-1 group O 
Replication (Poveda et al., 200S). Enfuvirtide binds to the six-helix bundle 
conformation, of the gp41 portion of the Env protein, which forms during the fusion 
process [reviewed in (Greenberg et al., 2004)]. Fusion is therefore blocked mid process 
and the virion remains tethered to the cell via the fusion peptide.
1.7.5 Integrase inhibitors
The p-diketo acids have been described as potent inhibitors of HIV IN activity (Hazuda 
et al., 2000). Their specific action is to inhibit strand transfer (3* end-joining step) 
during the integration reaction (fig 1.7)(Marchand et al., 2002). The p-diketo acids are 
specific for the strand transfer reaction in the nanomolar range, do not affect 3’ 
processing in treated cells, so they were ‘proof of concept’ that inhibition of strand 
transfer activity equates to antiviral activity [reviewed in (Pommier et al., 2005)]. A 
diketo acid is in phase I clinical trials as of March 2005 [reviewed in (Pommier et al., 
2005)].
1.7.6 Small molecule receptor-binding inhibitors
A small molecule HTV replication inhibitor has been reported that blocks the binding of 
HTV to its primary CD4 receptor and is a promising candidate for clinical trials (Lin et 
al., 2003; McKnight and Weiss, 2003). However, coreceptor and receptor blocking 
drugs are currently unavailable for treatment of HIV infection [reviewed in (Pommier et 
al., 2005)].
1.7.7 Drug resistance
The list of amino acids associated with HTV-1 drug resistance is too long to discuss here 
but there are some interesting comparisons between HIV-1 and HIV-2. Some HTV-1 
resistance mutations occur naturally in HIV-2, such as Leu-188, as described earlier in 
‘Non-nucleoside reverse transcriptase inhibitors’ section. The RT error rate, diploid
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RNA genome recombination, and the high rate of HIV replication all contribute to the 
generation of resistance mutations to anti-retroviral drugs (Mansky and Temin, 1995; 
Rezende and Prasad, 2004). Drug resistance has been mapped to numerous mutations 
in the HTV genome for each of the categories of antiretroviral drugs currently in use 
[reviewed in (Back et al., 2002)], even for the IN inhibitors that have yet to see 
widespread use [reviewed in (Pommier et al., 2005)].
1.8 The retroviruses and their phytogeny
Retroviruses are defined by the reverse transcription of their RNA genome into DNA 
for integration into the host genome. They carry a diploid RNA genome in the virion 
that is of positive polarity. The spumaviruses, however, carry a partially and 
completely reverse transcribed DNA genome in the particle that was formed in the 
producer cell (Delelis et al., 2003; Moebes et al., 1997; Yu et al., 1999).
HIV-1 and HIV-2 are “complex” retroviruses in the family Retroviridae of the genus 
lentivirus. MLV is a “simple” retrovirus in the gamma retrovirus genus. In the 
Retroviridae, the simple retroviruses are divided into the alpha, beta, and gamma 
retroviruses (fig 1.2). The delta and epsilon retroviruses, lentiviruses and spumaviruses 
make up the complex retroviruses (fig 1.2) [reviewed in (Coffin et al., 1997)]. There 
are four human retroviruses, and they all cause disease in humans: HTLV-1, HTLV-2, 
HTV-1, HTV-2; and the simian foamy viruses (SFVs). HTLV-1 infection is associated 
with tropical spastic paraperesis (TSP) or HTLV-1 associated myelopathy (HAM), and 
adult T cell leukaemia (ATL) (Gallo et al., 1981; Gessain et al., 1985; Hinuma et al., 
1981; Miyoshi et al., 1981; Poiesz et al., 1980; Roman et al., 1987). The pathogenic 
role of HTLV-2 remains unclear except in the presence of rare cases of CD8 lympho- 
proliferative disorders and neuromyelopathies (Fouchard et al., 1995; Hall et al., 1996). 
HIV-1 and HTV-2 both cause AIDS in infected individuals. The SFVs don’t cause any 
known disease because animal keepers who seroconvert to SFV as a result of being 
bitten or scratched by a range of Old World primates, and a laboratory worker 
accidentally infected with SFV, have all remained healthy for over a decade (Heneine et 
al., 1998). However the first human foamy virus (HFV) isolate to be described was
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isolated from nasopharyngeal carcinoma tissue from a Kenyan patient (Achong et al., 
1971; Epstein et al., 1974).
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Figure 1.2. Unrooted phylogenetic tree of the Retroviridae.
SlV-agni -  simian immunodeficiency virus isolated from African green monkeys, M W  -  Maedi-Visna 
virus, FIV -  feline immunodeficiency virus, EIAV * equine infectious anaemia virus, RSV * Rous 
sarcoma virus, MMTV = mouse mammary tumour virus, MPMV = Mason-Pfizer monkey virus, 
WEHV-I and 2 * walleye epidermal hyperplasia viruses 1 and 2, PEHV = Perch epidermal hypoplasia 
virus, WDSV -  walleye dermal sarcoma virus, GALV -  gibbon ape leukaonia virus, MLV = murine 
leukaemia virus, FeLV * feline leukaemia virus, HFV » human foamy virus, BFV = bovine foamy virus, 
SaRV « snakehead retrovirus, SSSV -  salmon swim bladder sarcoma virus, BLV =* bovine leukaemia 
virus, HTLV-1 and 2 -  human T cell leukaonia virus 1 and 2. Adapted from (Knipe et al., 2001).
1.8.1 Complex versos simple
The complex retroviruses, unlike the simple retroviruses, have accessory genes. The 
simple retroviruses encode only the Gag, Pro, Pol, and Env gene products, with some 
exceptions (see below). The complex retroviruses encode all of these products in 
addition to accessory genes that have a range of functions as described for HTV in The 
HIV life cycle section [reviewed in (Knipe et al., 2001)]. The genome structures of 
complex retroviruses HIV-1 and HIV-2 along-side the simple retrovirus MLV are 
shown in fig 1.3.
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1.8.2 Genome structure
The alpha, beta and gamma retroviruses have “simple lifestyles,” as introduced above 
(Coffin et al., 1997). Simple retroviruses do not encode additional proteins that directly 
and specifically affect viral RNA synthesis or processing. This simple pattern of RNA 
regulation is correlated with the simple pattern of mRNA splicing. Most of the simple 
retroviruses make only one spliced env mRNA, none of the simple retroviruses make 
multiply spliced mRNAs as is the case with MLV in fig 1.3, below.
MMTV, a member of the beta retrovirus genus (fig 1.2), encodes a superantigen (sag) 
that overlaps U3 of the LTR and this adds another spliced mRNA in addition to the 
spliced env transcript Though several members of this genus are associated with 
neoplastic disease none encode a known oncogene.
Complex retroviruses like the delta retroviruses, lentiviruses and spumaviruses have 
multiple splice donor sites in their genomes which give rise to complex patterns of 
mRNA (fig 1.10), a greater variety of gene products and the encoding of viral proteins 
in all three reading frames, like HTV-1 and HTV-2 in fig 1.3.
The epsilon retroviruses have singly spliced genomes to accommodate translation of env 
but are complex in that they encode from one to three open reading frames (ORF). 
ORFa, present in all three walleye retroviruses is a viral homologue of cyclin D.
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Figure U . Comparison of the genome structure of complex retroviruses HIV-1 
and HTV-2, and the simple retrovirus MLV.
The gag gene encodes for die principle structural protein group specific antigen (Gag), is packaged as a 
full-length protein or as a fusion with Pol (Gag-Pol). After virion budding from the producer cell Gag is 
cleaved by the viral protease into HIV-1 and HIV-2 matrix (MA), capsid (CA), nucleocapsid (NC), spacer 
peptide 1 (SP1), spacer peptide 2 (SP2) and P6. MLV Gag is also cleaved post-budding into MA. CA, 
NC, and P12. The pot gene encodes for Polymerase (Pol) that is also cleaved by the viral Protease into 
Reverse transcriptase (RT), Integrase (IN) and Protease (PR), required for reverse transcribing the 
virus RNA genome into DNA (RT), integrating die viral cDNA genome into the host DNA (IN) and 
cleavage (PR) and maturation of virus proteins (PR). Pol is not expressed as efficiently as Gag and is 
expressed as a fusion with Gag (Gag-Pol) by -1 ribosomal frame-shifting (HIV) during gag translation or 
termination suppression (MLV). All retroviruses contain 5* and 3* long terminal repeats (LTRs) that 
contain promoter, polyadenylation and transcriptional start sequences. The env gene encodes for the 
Envelope (Env) surface gpl20 (SU) and gp 41 (TM) subunits of HIV-1 and gpl05 (SU) and gp36 (TM) 
of HIV-2. The MLV Env is also expressed from a spliced mRNA and produces a glycosylated precursor, 
gPr80 Env that is cleaved by a cellular signal peptidase and cellular furin to produce the mature SU and 
TM proteins. SU (gp70) is glycosylated but TM is not and the two are non-covalently linked by 
disulfide bridge(s) (Opstelten et al., 1998). TM pl5E is further cleaved by MLV PR to produce pl2E
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and p2E (the R peptide) (Green et al., 1981). This processing is required for fusion of the virion 
membrane and the host-cell plasma membrane, mediated by Env, during infection. Viral infecthity 
fhctor (Vif), viral protein R (Vpr), viral protein X (Vpx), viral protein U (Vpn), negative inactivity 
iK tor(N ef), transactivator of transcription (Tat), regulator of expression of viral proteins (Rev).
a
I A 3 Epideariology and classification of the primate lentivinises
The HIVs and SIVs are currently classified into six groups of primate lentivinises (table 
1.1) (Barlow et al., 2003; Hahn et al., 2000), and additional groups will probably 
emerge as more full-length sequences are elucidated from different primate species 
(Peelers et al., 2002). There are at least 18 distinct lentivinises that naturally infect 
African primate species (Hahn et al., 2000) and over 40 different SIVs have been 
described from their natural or heterologous species (Apetrei et al., 2004).
Table 1.1: The dz groups of primate lentivinises.
Group Virus Host species
1 HIV-1 (Barre-Sinoussi et al., 1983) Homo sapiens 
Human
SIVcpz (Peeters et al., 1992; Peeters et al., 1989) Pan troglodytes 
Chimpanzee
2 HTV-2(Clavel et al., 1986a), Homo sapien 
Human
SIVsmm (Mutphey-Coib et al., 1986), Cercocebus atys 
Sooty mangabey,
SIVmac (Daniel et al., 1985) M acacaspp
Macaques
3 SlVagm (Ohta et al., 1988) Cercopithecus spp 
African green monkeys
4 SIVmnd (Tsujimoto et al., 1988) Papio sphinx 
Mandrill
5 SIVsyk (Emau et al., 1991) Cercopithecus cdbogaris 
Sykes monkey
6 SIVcol (Courgnaud et al., 2001) Colobus Guerza 
Colobus monkeys
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HIV-1 consists of groups M (main), N (new), and O (outlier). Group M is responsible 
for the current pandemic and has been further subdivided into 11 clades, A through K. 
Subtype C predominates globally with 47% of new infections in the year 2000, clade A 
accounted for 30% (including AE and AG), circulating recombinant forms (CRFs) 
accounted for 18%, and clade B accounted for 12% of all new infections in 2000 (Julg 
and Goebel, 2005). Clade B is found in North America, South America, Europe and 
Southeast Asia. Clade C predominates in sub Saharan Africa and Southeast Asia with 
BF, AE, BC, AG, and AB CRFs in South America, southeast Asia, China, Eastern 
Europe and central Africa, respectively
[http://www.iavireport.org/issues/0803/images/HrV-clademap.pdf, accessed October, 
2005; (Julg and Goebel, 2005)].
HIV-2 is categorised into 7 subtypes, A through G. Subtypes A and B cause AIDS and 
have been isolated from individuals as infectious virus whereas only partial nucleotide 
sequences have been obtained for subtypes C through G (Gao et al., 1994). HIV-2 is 
found primarily in West Africa; subtype A is the most prevalent and found in The 
Democratic Republic of the Congo, Mali, Gambia, Cape Verde Islands, Guinea Bissau, 
Ghana, Senegal, and Liberia whereas subtype B is found almost exclusively in the Ivory 
Coast and Ghana (Ellenberger et al., 1999; Ishikawa et al., 2001; Peeters et al., 2003; 
Pieniazek et al., 1999). In contrast to HTV-1, the HIV-2 epidemic is waning with a 
gradual decrease in the trend of HTV-2 seroprevalence (Bouckenooghe and Shandera, 
1999).
1.8.4 The origins of HIV-1 and HTV-2
Geographical location and sequence data suggest that HIV-2 was derived from SIV of 
Sooty Mangabeys, STVsmm- The presence of HIV-2 was confirmed through molecular 
characterisation (Clavel et al., 1986a), approximately one year after serological 
screening suggested it’s presence (Barin et al., 1985). HIV-2 and STVsmm share 
identical genome structure (Hirsch et al., 1989), they do not separate into distinct 
phylogenetic lineages based on their species of origin (table 1.1) (Hahn et al., 2000), 
and there is “geographic coincidence” between the natural habitat of the Sooty
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Mangabey and where HIV-2 is endemic (Chen et al., 1996b; Hahn et al., 2000). Each 
of the seven subtypes of HIV-2 are as divergent in sequence as the SIVsmm sequences 
are from each other, in the same geographic location, which supports the hypothesis that 
each HIV-2 subtype is the result of an independent zoonotic event of Sooty Mangabey 
to Human (Apetrei and Marx, 2004; Apetrei et al., 2004; Chen et al., 1997; Chen et al., 
1996b; Gao et al., 1994; Gao et al., 1992; Hahn et al., 2000).
HTV-1 is similar to SIV from chimpanzees. However, the origin of HIV-1 was more 
difficult to elucidate than that of HIV-2 (table 1) (Hahn et al., 2000). At one point, there 
were only two full-length sequences of STVcpz: STVcpz-gabi, SIV cpz-ant and a partial 
Pol sequence named SIVcpz-gab2 (Vanden Haesevelde et al., 1996), which did not 
provide a clear epidemiological STVcpz to HIV-1 link. A clearer association between 
HTV-1 and STVcpz was not made until additional SIVcpz sequences were obtained 
[(Bibollet-Ruche et al., 2004; Gao et al., 1999; Rambaut et al., 2001; Switzer et al., 
2005; Worobey et al., 2004) reviewed in (Hahn et al., 2000)]. The phylogenetic 
starburst of group M HIV-1 sequences and the interspersed STVcpz sequences between 
HTV-1 groups M, N and O suggest that these three HTV-1 groups are derived from three 
independent zoonotic transfers of virus from chimpanzee to human (Bibollet-Ruche et 
al., 2004; Gao et al., 1999; Hahn et al., 2000; Rambaut et al., 2001; Worobey et al., 
2004), so all of the circulating subtypes of group M were derived from one zoonotic 
event. The circulating subtypes of HTV-2 however were each thought to have been 
derived from separate zoonotic events [reviewed in (Hahn et al., 2000)]. It is deduced 
that the current (December, 2004) 39 million HIV-1 group M infections worldwide are 
the result of 1 zoonotic transfer of STVcpz to a human.
1.9 Cellular tropism and receptors o f H IV
The cell tropism of HTV is best explained in the context of receptor and, most 
importantly, coreceptor usage. Therefore the receptor and coreceptors of HTV will be 
discussed before the cellular tropism of HIV.
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1.9.1 The HTV receptor
It has been shown that CD4 is the primary receptor for HIV-1 (Clapham PR, 2001; 
Clapham and McKnight, 2002; Dalgleish et al., 1984; Klatzmann et al., 1984). Anti- 
CD4 mabs and soluble recombinant CD4 (sCD4) can block infection of HIV-1, HTV-2 
and SIV viruses (Clapham et al., 1989; Sattentau et al., 1988; Weiss et al., 1988), 
suggesting that CD4 is the main receptor for all of the primate lentivinises.
1.9.2 Coreceptors
It was observed two years after the discovery of the CD4 receptor that additional 
cofactors were required for HIV entry and infection. It was shown that HTV-1 could 
bind murine cells and non-permissive human cells expressing CD4, but could not fuse 
and enter (Harrington and Geballe, 1993; Maddon et al., 1986). However, HeLa/non- 
permissive cell fusions were permissive to infection suggesting the presence of an entry 
cofactor (Harrington and Geballe, 1993; Maddon et al., 1986). Fusin (CXCR4) was the 
first identified coreceptor required for HIV infection of SI isolates (Feng et al., 1996), 
and discovery of the R5 coreceptor (Dragic et al., 1996), required for M 0 tropism 
(Alkhatib et al., 1996), followed (table 1.2). Also, the discovery of dual coreceptor and 
broad coreceptor using isolates helped to explain dual M 0 and T cell tropic isolates 
(table 1.2) (Berson et al., 1996; Doranz et al., 1996).
All of the HTV coreceptors are members of die 7-TM spanning receptor superfamily. 
These receptor proteins signal through the heterotrimeric G-proteins upon chemokine 
ligation.
HIV-2 has been shown to use a broader range of coreceptors than HTV-1 in vitro 
(Guillon et al., 1998; McKnight et al., 1998; Momer et al., 1999; Momer et al., 2002; 
Owen et al., 1998), but this does not correlate with HTV-2 pathogenicity in vivo (Blaak 
et al., 2005; Momer et al., 1999; Momer et al., 2002; van Der Ende et al., 2000). A 
comprehensive list of HIV-1 and HIV-2 coreceptors is listed in table 1.2. The HIV 
coreceptors and associations with cell tropism are discussed in more detail in chapter 3.
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Table 1.2: Coreceptors used by HIV-1, HTV-2, and SIV.
Coreceptor Virus Cell/tissue type Reference
CCR1 HIV-2 Activated T cells, 
mono, DC
(Guillon et al., 1998; 
McKnight et al.,
* 1998)
CCR2b HIV-1,
SIV
HIV-2, Mono, T cells (Chen et al., 1998; 
Doranz et al., 1996)
CCR3 HIV-1, HIV-2 Eosinophils, (Choe et al., 1996;
microglia, Th2 Sol et al., 1997)
CCR4 HIV-2 Th2, (McKnight et al., 
1998; Owen et al., 
1998)
CCRS (R5) HIV-1, HIV-2, Activated T cells, (Deng et al., 1996;
SIV mono, DC Sol et al., 1997)
CCR8 HIV-1,
SIV
HIV-2, Th2, brain, 
thymocytes
(Rucker et al., 1997)
CCR9 HIV-1 Lymphocytes, 
brain, placenta
(Choe et al., 1998)
CXCR2 HIV-2 Neutrophils, brain (Bron et al., 1997)
CXCR4 (X4) HIV-1, HIV-2, Lymphocytes, (Feng et al., 1996;
SIV, FIV memo, brain, Schols and De
progenitor cells Clercq, 1998; Willett 
etal., 1997)
CXCR5 HIV-2 B cells (Kanbe et al., 1999)
CX3CRI HIV-1, HIV-2 NK cells, CD8 T (Reeves et al., 1997;
cells, brain Rucker etal., 1997)
GPR1 HIV-1,
SIV
HIV-2, M0, brain (Farzan et al., 1997; 
Shimizu et al., 1999)
GPR15 (BOB) HIV-1,
SIV
HIV-2, T cells, colon (Deng et al., 1997; 
Farzan et al., 1997)
STRL33 (Bonzo) HIV-1, HIV-2, T cells, mono, (Deng et al., 1997;
SIV placenta Liao etal., 1997)
APJ HIV-1, HIV-2, CNS (Choe et al., 1998;
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SIV Edinger et al., 1998)
ChemR23 HIV-1, SIV M0, DC (Samson et al., 1998)
RDC1 HIV-1, HIV-2, Lymphocytes, brain (Shimizu et al., 2000)
SIV
Ldikotriene B4 HIV-1 Leukocytes (Owman et al., 1998)
receptor (BLTR)
U S 2 8 cmv HIV-1, HIV-2 CMV-infected cells (Pleskoff et al., 1997)
D6 HIV-1, HTV-2 M0,PBMC, brain (Neil etal., 2005)
1.93 Attachment receptors
Depending on the route of transmission, time are several factors that affect virion-cell 
landing, such as extracellular fluid (Maher et al., 2005), and host cell surface attachment 
proteins and proteoglycans (Ugolini et al., 1999).
Abs directed against the cell-cell attachment protein, ICAM-3 have been shown to 
inhibit HIV infection (Sommerfelt and Asjo, 1995) and it was once thought that LFA-1 
was required for HIV fusion because mabs to LFA-1 could block syncitium formation 
(cytopathic cell fusion effect of HIV in culture) (Hildreth and Orentas, 1989; Ugolini et 
al., 1999). Intercellular attachment proteins already present on the surface of producer 
cells may bud off with virions so incorporation of these cellular proteins on the virion 
may be a non-selective/random process (Tremblay et al., 1998). ICAMs on the surface 
of virions may aid virion-target cell attachment by interaction with the associated ICAM 
receptor and enhance infectivity (Fortin et al., 1997), and can even make the virus 
refractory to Ab neutralisation (Fortin et al., 2000).
Heparin sulphate proteoglycans (HSPG) are expressed to high levels on epithelial and 
endothelial cells attracting engagement of HTV virion with their net anionic charge 
(Ugolini et al., 1999), thus supporting virus absorption to the cell surface. The preferred 
binding of X4 viruses with HSPG is associated with the higher V3 loop charge 
compared to R5 viruses (HTV V3 loops are explained in greater detail in chapter 3) 
(Ohshiro et al., 1996; Ugolini et al., 1999).
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The binding of virus by dendritic cells (DCs) at sights of virus exposure (mucosal 
tissue) may lead to unwitting presentation of infectious virus to target T cells in lymph 
nodes (van Kooyk and Geijtenbeek, 2003). The DC C-type lectin, specific intercellular 
adhesion molecule-grabbing nonintegrin (DC-SIGN) (Geijtenbeek et al., 2000), and the 
endothelial cell expressed DC-SIGNR (Pohlmann et al., 2001), have been shown to bind 
HIV (or any particles with high mannose sugars on glycoproteins) and promote 
internalisation/protection of virus by DCs, until presentation via the immunological 
synapse to the unsuspecting T cell. The DC-SIGNs are internalisation receptors that 
internalise with bound ligand (van Kooyk and Geijtenbeek, 2003) and therefore 
promote internalisation and protection of virus by DCs, allowing virion to remain 
infectious for prolonged periods (van Kooyk and Geijtenbeek, 2003).
Galactosyl ceramide and its derivatives (sulphated) have been implicated as alternative 
receptors for HIV entry (Bhat et al., 1991; Harouse et al., 1991), although at much 
lower efficiency than via preferred receptor and coreceptor. The bond between the 
galactose sugar residue and the ceramide-lipid backbone is required for binding to HTV 
gpl20 Env protein (Bhat et al., 1991). This glycolipid may be used by HTV to infect 
CD4( ) colon epithelial cells in the gastrointestinal tract (Yahi et al., 1992), and may be 
of particular importance because anti-CD4 Ab doesn’t inhibit HTV infection of human 
colon epithelial cells (Fantini et al., 1991). However given how inefficient these 
processes are in vitro it is difficult to envisage a major in-vivo role.
1.9.4 Cells infected: transmission through to onset of AIDS 
HIV preferentially infects haematopoietic cells that express CD4 and the relevant 7-TM 
coreceptor(s), namely; DCs, M 0 and T cells (Clapham and McKnight, 2002). During 
transmission of HIV, immune cells of the mucosae are infected and those cells that 
express the pertinent receptor and coreceptor are the targets of attachment and infection 
(Clapham and McKnight, 2002; de Roda Husman and Schuitemaker, 1998; Moore et 
al., 2004). The most relevant cells infected, during transmission, in-vivo are the R5 
expressing cells such as resident M0S, T cells and DCs (Clapham and McKnight, 2002; 
Davis and Dorns, 2004; de Roda Husman and Schuitemaker, 1998; Miller and Shattock, 
2003; Moore et al., 2004; Schuitemaker, 1994; Wilflingseder et al., 2005).
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A model of transmission that has gained acceptance is the one where DCs [e.g. 
Langerhans cells (LCs)] and M0s present in the mucosae become productively infected 
(via CD4 receptor and R5 coreceptor) or transport virus particles via C-type lectins (e.g. 
DC-SIGN). These HIV containing ‘Trojan horses” then migrate to draining lymph 
nodes, producing/presenting HIV for subsequent infection of susceptible T cells 
(Clapham and McKnight, 2002; Davis and Dorns, 2004; Moore et al., 2004; 
Wilflingseder et al., 2005). Activated CD4+ T cells are present in ample numbers in 
inflamed mucosae during ulcerative genital diseases so these cells are also a target for 
HIV infection during transmission (Ho et al., 1995).
Follicular dendritic cells (FDCs) are not infected by HIV but enhance cell-free virus 
infection by promoting die upregulation of X4 on surrounding T cells In vitro (Estes et 
al., 2002; Taruishi et al., 2004). FDCs, present in the lymph nodes, may create a more 
suitable microenvironment for virus transmission in the host.
X4 strains emerge in 40-50% of subtype B infections (Connor et al., 1997), and X4 
viruses in symptomatic individuals demonstrate a broader tropism for different T cell 
subsets (Clapham and McKnight, 2002). A nomenclature system has been derived for 
HIV viruses where those that use CCR5 as a coreceptor for entry are termed R5, those 
that use CXCR4 are termed X4 and those that can use both coreceptors equivalently for 
entry are R5X4 viruses (Berger et al., 1998).
In T cells, R5 expression is found primarily on memory T cells whereas X4 is more 
widespread and is expressed to higher levels on naive T cells (Bleul et al., 1997). 
Accordingly, in the blood of individuals carrying R5 viruses the CD4+CD45RO+ 
memory T cells carry most of the proviral load, with a minority of CD4+CD45RA+ 
naive T cells infected, and when X4 viruses emerge a greater proportion of 
CD4+CD45RA+ naive T cells become infected (Blaak et al., 2000; Clapham and 
McKnight, 2002; Ostrowski et al., 1999). Also, with regards to cells in general, X4 is 
more widely expressed than R5, which would lend a broader cell tropism to X4 using 
HIV viruses than R5 viruses (Moore et al., 2004). The infection of M0s by HIV and 
the role that these cells play in infection is discussed in more detail in chapter 3.
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1.10 H IV Vaccines and microbicides
There is currently no prospect for an efficacious vaccine against HIV-1 infection 
(Desrosiers, 2004; Letvin, 2005). Nothing tried thus far has provided therapeutic 
assistance to help fight infection let alone sterilising immunity (Desrosiers, 2004; 
Letvin, 2005; McMichael and Hanke, 2003). Therefore there is more research than ever 
on topical microbicides and chemical prophylaxis.
1.10.1 Vaccines
The results of the first phase 3 HIV-1 vaccine trials were released in 2003. The Vaxgen 
gpl20 trials were considered a “failure” because they did not provide protection against 
infection and did not lower viral loads (Desrosiers, 2004). It is becoming increasingly 
apparent that traditional vaccine approaches will not work to vaccinate against HIV and 
more novel strategies are starting to be adopted (Desrosiers, 2004; Letvin, 2005; 
McMichael and Hanke, 2003). As of March 2004, there were 13 different products at 
various stages of clinical testing in more than 20 individual human trials (Desrosiers, 
2004).
1.10.2 Microbicides
Microbicides are topical formulations designed to block HIV-1 infection when applied 
to genital mucosal surfaces before sexual intercourse.
A surfactant called nonoxynol-9, known to non-specifically disrupt enveloped viral 
particles, was shown in clinical trials to destroy membranes of epithelial cells lining 
mucosal surfaces (Shattock and Moore, 2003). As a result, nonoxynol-9 did not protect 
against HIV infection but increased the chances of becoming infected (Shattock and 
Moore, 2003). Therefore any potential microbicide must not reduce natural defences 
against HIV infection.
The most appealing microbicide candidates will specifically target the HIV virus, such 
as: antibodies, proteins and small molecule inhibitors that bind the viral Env 
glycoproteins gp 120 and gp 41 or glycan residues present on the surface of the viral
48
Chapter 1 Introduction
Env. These will ideally inactivate the virus before it has the chance to infect (Shattock 
and Moore, 2003).
Chemical approaches are also being pursued in light of promising pre-clinical results. 
(R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA) has proven effective at 
preventing SIV infection of macaques when delivered subcutaneously, once daily, as 
pre- and post-exposure prophylaxis (Tsai et al., 199S). An RT inhibitor, with few side 
effects, tenofovir disoproxl fumarate (TDF) is currently in clinical trials to determine its 
efficacy as preexposure prophylaxis (Grant et al., 2005).
1.11 The H IV infecHon cycle
‘The HTV infection cycle* section of this thesis describes the viral and cellular proteins 
when their action becomes relevant to the retroviral replication cycle. The pertinent 
viral and cellular proteins are discussed in detail in the subsection where they have been 
highlighted in bold. Therefore there is not a specific section in this thesis that lists the 
HTV gene products and their multitude of functions.
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Figure 1.4. HIV replication cycle.
Step 1: virion engages CD4 receptor and 7-TM coreceptor. Step 2: conformational change caused by 
coreceptor engagement initiates fusion and mixing of virus and cell membranes, resulting in the delivery 
of the virus contents into the cell. Step 3: reverse transcription o f the virus RNA into DNA. Step 4: 
integration o f the viral DNA provirus into the host genome. Host genomic DNA is shown in blue and the 
integrated proviral cDNA is shown in grey. Step 5: the integrated provirus is transcribed by RNA 
polymerase II to produce spliced and unspliced RNA species. Step 6 and 7: the transcribed RNA is 
translated and viral proteins and RNA are assembled into immature virion that buds from host cell 
membranes. Step 8: maturation of the budded particle by virus encoded PR that results in formation of 
the conical shaped capsid that is typical o f lentiviruses.
1.11.1 The infectious retrovirus particle
Like many other types of viruses not all retroviral virions are infectious. Typically the 
ratio of physical to infectious particles can be from 100:1 to 10 000:1 or greater (for a 
comparison of physical to infectious particle ratio between HIV-1 and HIV-2 see fig 3.5 
in chapter 3). Retroviral particles are composed of, typically, 1-2% RNA, 35% lipids, 
and 60-65% proteins (Aloia et al., 1993; Coffin et al., 1997; Quigley et al., 1971), and
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although the particles are derived from host membranes their composition differs 
somewhat from the plasma membrane (PM), with enrichment of sphingomyelin and 
cholesterol (lipid rafts) (Aloia et al., 1993; Liao et al., 2001; Liao et al., 2003; Nguyen 
et al., 2003).
Mature infectious retroviral particles have a condensed core of electron dense material 
that is thought to form as a result of proteolytic processing of Gag-Pol by the virus 
protease (PR) (Coffin et al., 1997). The MLV type-C retrovirus morphology is a dense 
round core centred in the middle of the particle while Lentiviruses have a cone shaped 
core (Coffin et al., 1997). The type-B retroviruses (MMTV) have an eccentrically 
placed core and the type-D viruses (M-PMV) have a rod shaped one (Coffin et al., 
1997).
Env SU (blue)
TM (fuchsia) 
Lipid bilayer
p17,MA (yellow)
p9, NC (green)
p11, PR~1 
p63, RT r grey 
p32, IN J
RNA genome (brown) 
p24, CA (orange)
Env TM (fuchsia)
Vpr
Figure 1.5. Composition of the HIV-1 virion (authors rendition).
Conformation of V1-V3 loops within trimeric Env was obtained from (Chen et al., 2005). The interaction 
o f Env TM gp41 (fuchsia) with MA is derived from molecular modelling in (Forster et al., 2000). The 
dimeric RNA genome (brown) is shown coated in nucleocapsid (NC, green), spilling out o f the orange 
capsid core, with the 5’ ends exposed.
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1.11.2 Receptor engagement
Initial HIV-receptor interaction during successful virus entry occurs when CD4 binds 
the CD4 binding site of the Env gpl20 (SU) subunit (figs 1.4 and 1.5). CD4 receptor 
binding induces a conformational change in Env that allows a positively charged region 
near the bridging sheet that lies at the base of the V1V2 and V3 loops, to interact with 
the coreceptor (Doms, 2000; Rizzuto and Sodroski, 2000; Rizzuto et al., 1998). 
Successful coreceptor binding results in conformational rearrangement of gp41 (TM) 
(fig 1.5), and fusion (fig 1.4).
1.11.3 Fusion
The fusion process is mediated by the gp41 subunit of Env. The purpose of fusion is to 
1, force a fusion pore that makes the viral Env continuous with the host cell membrane 
and 2, allow mixing of the two membranes to enable delivery of all of the virions 
contents into the cell (Doms, 2000). At least six R5 molecules are required for the 
successful formation of a fusion pore. This number is based on a number of scientific 
assumptions but is compatible with what is known about influenza virus hemagglutinin 
(Doms, 2000; Ellens et al., 1990). However, a more recent study on HIV-1 Env trimers 
themselves has suggested that just one Env trimer on the virion is required to effect 
virus-host fusion (Yang et al., 2005).
1.11.4 Fusion mechanism
1, Prior to fusion each gp41 molecule is in a high energy, tightly packed state with the 
N-terminal fusion peptide folded back towards the viral membrane. 2, Attachment of 
gpl20 to the CD4 receptor exposes a coreceptor-binding region on gpl20. 3, 
Coreceptor engagement causes a conformational change and release of gp41 from its 
high-energy state. 4, The fusion peptide extends out towards, and inserts into, the target 
cell membrane. 5, The HR1 and HR2 regions of gp41 are in consecutive alignment at 
this stage and they then Told in' to meet each other, which results in the formation of 
the six-helix bundle. The purpose of the formation of the six-helix bundle is to bring
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the host cell and virus membranes into 6, close apposition to promote virus-cell 
membrane fusion and formation of the fusion pore.
1.11.5 Entry
The term ‘entry’ is used here to describe the topographical region of the cell where 
fusion takes place. This is especially relevant to chapter 4 of this thesis, which deals 
with endocytosis of virus particles and the resulting restriction of HIV-1 and HIV-2.
Several endocytic pathways have been implicated in the productive entry of viruses into 
the host cell (Marsh and Pelchen-Matthews, 2000; Sieczkarski and Whittaker, 2002a). 
One of the first viruses shown to utilise the clathrin endocytic route was Semliki forest 
virus (Helenius et al., 1980), also demonstrated to require low pH to initiate fusion 
(Helenius et al., 1982; Marsh et al., 1982). The SV40 polyoma virus uses caveolae and 
the more recently described non-clathrin non-caveolae route of entry. Amphotropic 
MLV (MLV-A) has recently been shown to prefer entry via caveolae endocytosis as 
well (Beer et al., 2005). Influenza virus can enter by both clathrin and the non-clathrin 
pathways but has a specific requirement for entry via a specific Rab 5 early endosome. 
Semliki forest and influenza viruses are pH-dependent and require entry via 
endocytosis but SV40 and MLV-A are pH-independent viruses so despite no 
dependence on delivery into an acidified vesicle to trigger fusion, these pH-independent 
viruses prefer endocytic entry. HIV is also a pH-independent virus that may, in some 
circumstances, use endocytosis for productive entry (Daecke et al., 2005; McClure et 
al., 1988).
The site of fusion for a pH-independent retrovirus can be the inside of an endosome or 
the cell surface given that there is a sufficient level of receptor/coreceptor at both sites. 
A virus can bind the cell surface and be ‘taken up’ by the cell coincident to a ligand 
triggered or constitutive endocytic process. It is also conceivable that a cell-free virus 
could be taken up with the fluid phase by macropinocytosis as has been postulated as a 
route of productive entry for HIV in M0s and microvascular endothelial cells (binding 
and fusion would then occur within the macropinocytic vesicle) (Liu et al., 2002; 
Marechal, 2001).
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The various endocytic pathways used by HTV, and other viruses, to enter cells is 
discussed in more detail in chapter 4.
1.11.6 Early entry and reverse transcription events
The viral CA enters the cell and uncoats after fusion takes place. The contents of the 
capsid empty into the cell: reverse transcription complex (RTC) which includes 
Integrase (IN), reverse transcriptase (RT), viral protein R (Vpr), and matrix (MA), 
not to mention the two copies of the RNA genome (Bukrinsky et al., 1993b; Peterlin 
and Trono, 2003). Also released from the virion are negative infectivity factor (Nef), 
P6, Vpr, and viral infectivity factor (Vif), and the capsid (CA) protein of the now 
uncoated capsid (fig 1.4) [reviewed in (Cullen, 2001; Peterlin and Trono, 2003)].
The RT starts to reverse transcribe the RNA genome into a double-stranded 
complementary viral DNA for integration into the host genome, after cell entry but 
before nuclear translocation (Peterlin and Trono, 2003). For this to begin, the cortical 
actin cytoskeleton has been implicated as a scaffold for the formation of the RTC and 
initiation of reverse transcription (Bukrinskaya et al., 1998). Initial strong stop DNA 
has been reported to be reverse transcribed in the virion itself, before cell entry (Zhang 
et al., 1995), but the majority of viral DNA synthesis is thought to occur in the 
cytoplasm of the host cell (Bukrinsky et al., 1993b; Famet and Haseltine, 1991; 
Karageorgos et al., 1993; Kim et al., 1989).
It has been shown that HTV uses the microtubule network for transport during entry 
(McDonald et al., 2002). More specifically, it has been suggested that a minus-end 
directed microtubule motor, dynein, might be used by HIV to shuttle the RTC towards 
the MTOC, which is adjacent to the nucleus (McDonald et al., 2002). This data on HIV 
is concurrent with what is known about the transport of adenoviruses and herpesviruses 
because Ad-2 and HSV-1 have been shown to use dynein for transport along 
microtubules to the nucleus (Dohner et al., 2002; Martin et al., 2002a; Sodeik, 2000; 
Sodeik et al., 1997; Suomalainen et al., 1999; Yedowitz et al., 2005).
Nef is packaged into the virion (Kotov et al., 1999; Welker et al., 1996), and this form 
of Nef has been shown to boost infectivity 10-fold over ANef virions (Kotov et al.,
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1999). It has been postulated that since an endocytosis directing VSV Env relieves 
HTV from its Nef dependence (Aiken, 1997), with an HTV Env, Nef may help direct the 
RTC to an endocytic location that is more conducive to reverse transcription and 
productive entry (Kotov et al., 1999).
1.11.7 Reverse transcription
Retroviral reverse transcription is highly error prone allowing a high rate of mutation 
and adaptation. The presence of two RNA molecules in the virion allows for crossover 
events during reverse transcription and can be especially advantageous if a virion is 
produced with two heterologous RNA strands from a superinfected cell. The RT 
enzyme is highly recombinogenic helping to facilitate this action. There is no proof 
reading mechanism in the RT enzyme or in the host RNA polymerase II that transcribes 
the integrated retroviral genome, resulting in an estimated 1 nucleotide mutation per 104 
nucleotides per round of replication. The onward transmission of recombinant HIV 
viruses with mixed genomes from different clades is referred to as CRFs.
The Vif protein acts indirectly at this stage by preventing the packaging of 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) 3G, F and B 
into the viral particle at the stage of assembly (see also virus budding section) (Kao et 
al., 2003; Mariani et al., 2003; Marin et al., 2003; Mehle et al., 2004; Navarro and 
Landau, 2004; Sheehy et al., 2002; Sheehy et al., 2003). APOBECs 3G, F and B 
packaged with the virus particle cause cytosine to uracil deamination of the negative 
sense viral DNA during reverse transcription (Bishop et al., 2004a; Bishop et al., 
2004b; Harris and Liddament, 2004; Mangeat et al., 2003; Newman et al., 2005; 
Sheehy et al., 2002; Stopak et al., 2003; Zheng et al., 2004). APOBECs packaged into 
the virion of A vif viruses cause cytosine to uracil deamination resulting in nonsense 
mutation of the viral genome, and abortive replication (Harris and Liddament, 2004; 
Navarro and Landau, 2004).
RT reverse transcribes the packaged viral RNA into cDNA for integration into the host 
genome that is illustrated in fig 1.6.
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After reverse transcription, IN remains bound to the viral cDNA and contains a nuclear 
localisation signal (NLS) that assists in nuclear translocation of the PIC (Bouyac- 
Bertoia et al., 2001).
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Figure 1.6. The process of reverse transcription.
Step I: Phis sense, virion packaged RNA is shown in light blue, minus-sense DNA in orange and plus- 
sense DNA is shown in red. Step 2: Formation of negative-sense strong-stop DNA. RT is initiated 
from the paired 3' OH of a primer lysine-tRNA molecule (contained within the virion) complementary 
base paired to the viral RNA PBS. DNA is synthesised from the primer towards the 5’ end of the RNA 
using the viral RNA as a template. The US and R regions are formed, RNAse H activity degrades the 
RNA of the newly formed DNA/RNA hybrid, the tRNA molecule remains bound, and negative-sense
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strong-stop DNA is formed. Step 3: First jump. RNAse H activity in step 2 is required for the first 
jump to take place. The strong-stop DNA anneals to the R region at the 3* end of the RNA and 
formation of the minus strand DNA continues to the 5’ end of the viral RNA molecule. ‘Jumping’ may 
go to the same viral RNA strand or may occur in trans, however there is evidence that jumping is 
completely random in this respect (Yu et al., 1998). Long minus strand DNA is formed and transcription 
normally stops in the vicinity of the PBS. RNAse H activity degrades the RNA of the DNA/RNA hybrid 
when it is formed. Step 4: Primer formation for plus strand DNA synthesis. The central polypurine tract 
(cPPT) and the 3’ PPT are resistant to RNAse H activity and thus able to act as primers for the synthesis 
of the plus sense DNA strand, using the minus sense DNA strand as a template. DNA is copied into the 
primer binding sequence of the tRNA. When this happens RNAse H degrades the tRNA. Step 5: The 
removal of the tRNA of the minus strand tRNA exposes the PBS on the plus strand DNA which allows 
the plus strand molecule to anneal to the PBS at the 3’ end of the minus strand DNA in the second jump. 
Step 6: The second jump annealing forms a circular structure (not shown) and both minus and plus sense 
strands are completed. Step 7: Reverse transcription is completed with linearising of the circular 
structure and formation of a 99 nt central DNA flap. In Lentiviruses, RT is terminated at the central 
termination sequence (CTS) beyond the cPPT, which results in the formation of a 99 nt DNA flap 
(Chameau et al., 1994)
1.11.8 Retroviral restriction and virus entry
Refl, Lvl and Fvl are retroviral restriction factors in human, simian and mouse cells, 
respectively [reviewed in (Bieniasz, 2003; Bieniasz, 2004)]. These factors terminate 
retroviral replication at the entry stage. However, where Fvl allows reverse 
transcription to be completed, Refl and Lvl block replication before reverse 
transcription (Bieniasz, 2003). Human and rhesus macaque TRIM 5a have been shown 
to be responsible for the majority of Refl and Lvl restriction, respectively, and are 
thought to reside in cytoplasmic bodies within the cell (Stremlau et al., 2004). The 
anti-MLV restriction factor Fvl has been shown to localise to a microtubule localised 
compartment, adjacent to the trans-Golgi network (Yap and Stoye, 2003), so the 
different cellular localisations of these factors may influence whether or not reverse 
transcription is blocked during restriction.
The action of retroviral restriction factors in intrinsic immunity is discussed in more 
detail in chapters 5 and 6.
57
Chapter 1 Introduction
1.12 Into the nucleus...
1.12.1 Nuclear import of the pre-integration complex
At the end of reverse transcription there is an apparent change in the protein 
composition of the RTC. The sub-viral unit, at the completion of reverse transcription, 
is referred to as the pre-integration complex (PIC), and this may shed the RT and MA 
that were associated with the RTC and remain associated only to IN (Famet and 
Haseltine, 1991; Karageorgos et al., 1993). So it has been argued that the PIC may 
only require the NLS of IN for translocation across the nuclear envelope in non­
dividing cells (Famet and Haseltine, 1991; Karageorgos et al., 1993). The size and the 
proteins that associate with the HTV PIC are, however, controversial as will be 
discussed later.
As entry progresses, smaller RTC species appear and the smallest species localise to the 
nucleus at late post-entry time points, indicated by decreasing sedimentation (‘S’) 
values (Fassati and Goff, 2001; Karageorgos et al., 1993), this alteration in size may 
assist the PIC to traverse the small 25 nm pore size of the NPC. Reports of the PIC 
nucleoprotein complex size vary from 56 nm (Sherman and Greene, 2002), to sizes of 
400 to 700 nm (McDonald et al., 2002) and 200nm (Nermut and Fassati, 2003). 
Nevertheless, the PIC is complex and probably requires the action of several NLSs to 
effect nuclear entry (Bukrinsky and Haffar, 1999) including those of cellular proteins 
that have been recruited to die viral PIC (Maertens et al., 2004). In addition, nuclear 
import/export is a redundant system and PIC nuclear translocation may involve 
numerous nuclear import pathways (Jenkins et al., 1998; Kuersten et al., 2001).
Vpr is packaged into virus particles through its interaction with the C-terminal p6 
domain of the p55 Gag polyprotein (fig 1.5 and 1.11), at roughly 14 molecules per 
virion (Sherman and Greene, 2002). Vpr has been shown to induce “disruptions” in the 
nuclear envelope, which may facilitate trafficking of the 56-700 nm PIC across the 
nuclear membrane where nuclear pores are normally only 25nm across (de Noronha et 
al., 2001). Vpr may also utilise its two novel NLSs for PIC nuclear import, one of 
which results in the direct association of Vpr with the nuclear pore complex (NPC) 
(Jenkins et al., 1998).
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Beside its role for providing structure to the virus particle, MA, like Vpr, displays 
nucleocytoplasmic shuttling and is thought to contribute to the nuclear localisation of 
the PIC (Jenkins et al., 1998). MA is a part of the PIC and contains a classic NLS that 
is thought to contribute to nuclear localisation (Jenkins et al., 1998; Peterlin and Trono,
2003). It has been shown that lentiviral nuclear localisation in non-dividing cells 
requires the NLS of MA (Bukrinsky et al., 1993a; Bukrinsky et al., 1993b; Dubrovsky 
et al., 1995), however there are other reports that claim MA is not required for PIC 
nuclear translocation (Famet and Haseltine, 1991; Fouchier et al., 1997).
A 99 nt DNA flap, formed by strand displacement at the cPPT just before RT 
termination at the CTS (fig 1.6; step 7) (Zennou et al., 2000), has been shown to 
enhance nuclear localisation of lentiviral vectors (Dardalhon et al., 2001; Sirven et al.,
2000). Later studies have shown that the 99 nt flap may be repositioned at a wide range 
of locations within the viral cDNA for enhancement of nuclear localisation (De Rijck et 
al., 2005).
Viral protein x (Vpx) is an accessory gene found in viruses of the HIV- 
2/SIVsmm/SIVmac group of primate lentiviruses, but not HIV-1 (fig 1.3). Vpx is 
proposed to have arisen as the result of a gene duplication of Vpr since the two genes 
share sequence homology (Tristem et al., 1990). The gene redundancy of Vpx and Vpr 
does not equate to a functional redundancy since the roles of Vpr in HIV-1 have been 
split-up in HIV-2 Vpx and Vpr (Fletcher et al., 1996): the PIC nuclear localisation and 
G2-M cell cycle arrest activities of HIV-1 Vpr are delegated to HIV-2 Vpx and Vpr, 
respectively (Fletcher et al., 1996), and the Vpx NLS has been shown to be necessary 
and sufficient for nuclear localisation of the HIV-2 PIC into die nucleus in non-dividing 
cells (Belshan and Ratner, 2003).
1.12.2 Cellular genes involved in HTV nuclear import
The importins mediate the majority of traffic into and out of the nucleus by interacting 
with the RanGTP/GDP system which is governed by the RanGTP/GDP concentration 
gradient between the nucleus and cytoplasm; low levels of RanGTP in the cytoplasm 
allow the binding of importins to their cargoes, whereas high RanGTP levels in the
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nucleus induce their dissociation [reviewed in (Gorlich and Kutay, 1999)]. It is 
therefore conceivable that one of these proteins may mediate the nuclear translocation 
of HIV-1 PICs. Indeed, Importin 7, a member of the importin p superfamily, has been 
implicated in the nuclear import of HIV-1 PICs into the nucleus (Fassati et al., 2003).
Lens epidermal growth factor (LEDGF) is a cellular protein that has been shown to 
associate with and promote the nuclear localisation of the PIC (Maertens et al., 2004), 
and chromosome tethering of IN (Emiliani et al., 2005).
1.123 Integration
Integration is the process whereby the viral cDNA genome is inserted into the host 
DNA genome. IN remains associated with the PIC after translocation into the nucleus 
and performs the integration reaction.
Following reverse transcription, the viral cDNA is “primed” for integration in the 
cytoplasm by IN mediated 3’ trimming of the DNA ends, termed *3* processing* (fig 
1.7) [reviewed in (Pommier et al., 2005)]. Trimming is a 3* endonucleolytic cleavage 
of 2 bases exactly 3* of a CA motif that creates 3* CA ends on the viral DNA (Pommier 
et al., 2005). The 3* CA-OH ends are 3* reactive intermediates required for strand 
transfer to occur (Pommier et al., 2005).
Following entry into the nucleus, IN catalyses the insertion of the viral DNA into a host 
chromosome. IN remains bound to the viral cDNA as a multimeric complex bridging 
the viral DNA ends. The 3’-OH ends of the PIC are joined to the 5* ends of a host 
chromosome, catalysed by IN (fig 1.7). This joining event leads to a canonical five 
base stagger. Completion of integration requires trimming of two nucleotides from the 
5* proviral ends and gap filling from the 3’-OH chromosomal DNA ends (fig 1.7). It is 
likely that cellular enzymes are involved in 5* processing however their identity 
remains uncertain (Daniel et al., 2004; Yoder and Bushman, 2000).
Cellular proteins have been shown to have IN binding and catalysis of integration 
activities (Pommier et al., 2005). Inil (integrase interactor protein 1) was the first 
discovered cellular IN binding protein that promotes integration (Turelli et al., 2001;
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Turlure et al., 2004). Since then, heat shock protein 60 (Hsp60) has been shown to 
bind IN and stimulate in vitro processing and end-joining (Parissi et al., 2001), LEDGF 
is an IN to chromatin tethering factor that is not absolutely necessary for integration but 
may play a chromosomal DNA targeting role (Cherepanov et al., 2003; Llano et al., 
2004), embryonic ectoderm development protein (EED) has been suggested to help 
traffic or “convoy” the PIC to the nucleus, during entry (Violot et al., 2003), and 
radiation sensitivity protein 18 (Rad 18) may be involved in the post-integration 
“translesion repair” that must take place to seal the gap between the viral 5* and 
chromosomal 3* DNA ends (fig 1.7c) [(Mulder et al., 2002) reviewed in (Turlure et al.,
2004).
Cellular proteins barrier to auto-integration factor (BAF) (Lee and Craigie, 1998; 
Lin and Engelman, 2003), and high mobility group protein Al (HMGA1) bind DNA 
directly and regulate integration of HIV and MLV [(Li et al., 1998; Li et al., 2000) 
reviewed in Pommier et al, 2005]. HMGA1 stimulates IN activity either by 
condensation of reactant DNA or the binding of HMGA1 monomers to multiple DNA 
sites may fold reactant DNA into conformations that favour IN catalysis and assembly 
(Famet and Bushman, 1997; Li et al., 1998; Li et al., 2000). BAF stimulates 
intermolecular integration by binding the double stranded DNA of the PIC (rather than 
intramolecular integration resulting in 2 LTR circles) (Harris and Engelman, 2000; Lee 
and Craigie, 1998).
PML (TRIM 19) has been shown to associate with HIV-1 RTCs in the target cell (in 
the cytoplasm) and interfere with integration (Turelli et al., 2001).
61
Chapter Introduction
B-diketo
acids
3’
5’
Figure 1.7. HIV integration.
(A) 3’ processing: viral cDNA genome is shown in black and the host genomic DNA is grey, 3’ ends are 
denoted by blue circles and the 5’ ends are denoted by red circles. IN catalyses an endonucleolytic 
cleavage o f two bases from the 3’ CA ends. HIV-2 is unique among the lentiviruses, and indeed the 
Retroviridae, in that an asymmetric 3 bases are removed from the U5 LTR and 2 bases from the U3 LTR 
(Whitcomb and Hughes, 1991). (B) Strand transfer is catalysed by IN mediated ligation o f the viral 3 ’- 
OH ends (created in the 3’ processing reaction) to 5’ phosphate groups o f the host DNA. (C) This 
joining event leads to a canonical five base stagger. Completion of integration by gap filling from the 3 ’- 
OH chromosomal DNA ends (Pommier et al., 2005).
1.12.4 Integration site selection
In vitro integration systems have shown that IN prefers to integrate the viral genome 
into severely kinked DNA regions within the nucleosome (Pruss et al., 1994a). The 
curvature induced by the nucleosome may widen the DNA major groove and thus 
promote the interaction of host DNA with IN (Pruss et al., 1994b). Human genome- 
wide screens have shown that HIV-1 integration favours active genes (Schroder et al., 
2002; Wu et al., 2003) whereas MLV favours integration in transcription start regions 
(Wu et al., 2003).
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1.12.5 HTV transcription
Once integrated in the host genome, the provirus behaves like a human gene with 
transcription initiated at the 5* end and terminating at the 3* end (Jones and Peterlin,
1994).
Both HIV-1 and HTV-2 have very similar binding sites and mechanisms of LTR driven 
transcription. Their LTRs share 40% sequence identity (Guyader et al., 1987) and their 
promoter binding sites share 50% sequence identity (Tong-Starksen et al., 1990). 
However the HTV-1 LTR responds better to T cell activation signals than HIV-2 
(Hannibal et al., 1993); the HTV-2 LTR contains only one NF-kB binding site whereas 
HIV-1 has two (Tong-Starksen et al., 1990), and this has been proposed to be a factor 
contributing to the longer latency of HTV-2 (Hannibal et al., 1993; Tong-Starksen et al., 
1990). NF-kB is activated in the cytoplasm by proteolytic cleavage of inhibitor of kB 
(IkB) during T cell activation leading to localisation to the nucleus, LTR binding and 
up-regulation.
The majority of the HTV promoter is contained within the U3 region, with reported SP1 
transcription factor binding sites in the HTV-1 leader region (Logan et al., 2004). The 
LTR contains enhancer and promoter regions with binding sites for several 
transcription factors and a polyadenylation signal (fig 1.8) (Marciniak et al., 1990; 
Southgate and Green, 1991). Moving upstream from the transcription start site, the 
initiator (Inr), the TATA box, and 3 SP-1 sites are found (Berkhout and Jeang, 1992). 
These sites position RNA polymerase II at the correct site for initiating transcription 
(Berkhout and Jeang, 1992). The NF-AT and NF-kB transcription factor binding sites 
allow maximum levels of viral transcription in activated T cells and M0s (fig 1.8) 
(Griffin et al., 1989; Griffin et al., 1991; Jones and Peterlin, 1994).
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Figure 1.8. Promoter and primer binding sites and key RNA structural features of 
the HIV-1 LTR
Key promoter binding sites are shown in addition to the polyadenylation site (pA), the position of the 
RNA TAR loop (TAR), transcription initiator (Inr), primer binding site (PBS), dimer initiation site (DIS), 
and die y  packaging signal. SD “  gag splice donor site. The LTR is not drawn to scale (Logan et al.,
2004).
Early events of HIV transcription involve transactivator of transcription (Tat) and 
regulator of expression of viral proteins (Rev). HIV remains in a transcriptionally 
latent state after integration with only the appearance of short TAR transcripts in the 
nucleus (Adams et al., 1994; Feinberg et al., 1991). Cellular activation signals improve 
the rate of transcription and full-length, fully spliced 2 kb mRNA transcripts appear (fig 
1.10) (Jones and Peterlin, 1994). These 2 kb mRNA species encode for Tat, Rev and 
Nef (fig 1.10) (Kim et al., 1989). Tat and Rev both contain NLSs so after translation 
they are transported back into the nucleus and dramatically improve the processivity 
and fidelity of HIV transcription (Malim et al., 1989a; Perkins et al., 1989; Ruben et al., 
1989). Tat then interacts with TAR and greatly improves the quantity of 
polyadenylated genome length transcripts in die nucleus (fig 1.9)(Adams et al., 1994; 
Feinberg et al., 1991).
1.12.6 Mechanism of Tat transactivation
The TAR element, which forms an RNA stem loop, is the target RNA sequence for Tat 
transactivation (Feng and Holland, 1988; Muesing et al., 1987; Peterlin et al., 1986). 
Tat in conjunction with positive transcription elongation factor B (p-TEFb), binds TAR 
with high affinity that allows elongation of viral RNA transcripts through activation of
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RNA polymerase II (fig 1.9a) (Kao et al., 1987; Wei et al., 1998). The p-TEFb 
complex consists of cyclin T1 and CDK9 (fig 1.9b) (Wei et al., 1998), and once 
recruited to the nascent RNA complex, CDK9 phosphorylates the C-terminal domain of 
RNA polymerase II and negative transcription elongation factor (N-TEF) (Yamaguchi 
et al., 1999), leading to high fidelity and processive transcription (fig 1.9c) (Peterlin and 
Trono, 2003; Price, 2000).
Figure 1.9. HIV transcription: the initiation complex.
(A) The RNA polymerase II holoenzyme complex (RNA Pol II) binds to upstream basal transcription 
promoters in U3 o f the LTR (fig 1.8) and, without Tat, transcription will begin but elongation is 
inefficient. The nascent TAR RNA folds into the TAR stem loop structure and recruits cyclin T1 and 
Tat. (B) Tat binds the 5’ bulge and Cyclin T1 binds the central loop of TAR. CDK9 o f the p-TEFb 
complex phosphorylates the C-terminal domain (CTD) of RNA Pol II (C), which results in the 
displacement of TAR from the polymerase, and efficient transcription/elongation of the viral genome by 
RNA Pol II (Jones and Peterlin, 1994; Kam, 1999).
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Tat functions poorly in mouse cells, however mouse human chromosome 12 somatic 
hybrids have been shown to recover Tat transactivation (Hart et al., 1989; Hart et al., 
199S; Newstein et al., 1990). An 83 kDa protein expressed from human chromosome 
|2  was identified as human Cyclin Tl, the cofactor required for efficient Tat 
transactivation (Hart et al., 199S). A Cyclin Tl homologue is encoded by mice but it 
does not support Tat and TAR interactions like its human homologue (Bieniasz et al., 
1998; Wei etal., 1998).
1.12.7 Viral RNA species
HIV RNA species are capped at their 5’ end and polyadenylated at their 3* end much 
like cellular mRNA species (Bohnlein et al., 1989; Chiu et al., 2001; Chiu et al., 2002; 
Das et al., 1999; Zhou et al., 2003). The genome length viral RNA contains 
approximately 9 different primary splice sites that produce more than 30 different RNA 
species [(Bohne et al., 2005) reviewed in (Coffin et al., 1997)], which can be detected 
in the cell. Most of these species are three sizes; 2 kb, 4 kb and 9 kb species (fig 1.10): 
the 2 kb fully spliced class encode for Tat, Rev, and Nef (Robert-Guroff et al., 1990; 
Schwartz et al., 1990), die 4 kb species encode for Vpu, Vif Vpr, and Env (Arrigo et 
al., 1990). The complete and unspliced species provide the RNA coding sequence for 
Gag and Pol expression (fig 1.10) (Arrigo et al., 1990; Kim et al., 1989; Neumann et 
al., 1994; Schwartz et al., 1990).
\
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Figure 1.10. HIV-1 messenger RNA expression.
The three mRNA species present during active infection are shown in red. TAR is present in all o f the 
species (solid red dot) and the Rev response element (RRE) is shown as a red diamond in the 4 and 9 kb 
RNAs. The splice donor sites are the arrows pointing down and the splice acceptor sites are the arrows 
pointing up. The 2 kb ‘early’ transcripts produced first do not require the action o f Rev and the RRE 
because they are fully spliced. The full-length and partially spliced late transcripts are produced by the 
assistance of Tat and Rev. Positions are approximate. Derived from (Arrigo et al., 1990; Dalgleish and 
Weiss, 1999).
Sites of HIV gene transcription repression have been mapped and one study has 
revealed that repression of HIV transcription is associated with gene deserts, 
centromeric heterochromatin and very highly expressed cellular genes (Lewinski et al.,
2005). Even though HIV integration has been shown to prefer transcriptional units 
integration into very highly expressed genes can silence provirus transcription 
[(Lewinski et al., 2005; Schroder et al., 2002; Wu et al., 2003) reviewed in (Bushman et 
al., 2005)]. Read-through transcription of cellular genes into provirus can dislodge HIV 
transcription factors, or “train wrecking”, the colliding of converging RNA polymerase 
complexes (Lewinski et al., 2005). Gene deserts however may be enriched with
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binding sites for transcriptional silencing proteins (Lewinski et al., 2005), and 
centromeric heterochromatin adopt a condensed structure that inhibits access to 
transcriptional machinery. Thus integration into these areas represses retroviral 
transcription (Jordan et al., 2003; Jordan et al., 2001; Lewinski et al., 2005).
HIV latency is covered in more detail in chapter 3.
1.13 ...and out (o f the nucleus)
1.13.1 Export of viral RNA from the nucleus
Rev mediates the export of unspliced viral RNAs from the nucleus. Cellular 
commitment factors localised in die nucleus recognise intron splice sites and monitor 
mRNA to inhibit the export of unspliced pre-mRNA (Cullen, 2003b; Legrain and 
Rosbash, 1989). HIV depends on the action of Rev to bypass these commitment factors 
and export the unspliced 4 and 9 kb late viral RNA species from the nucleus (Malim et 
al., 1989a; Malim et al., 1989b). Rev usurps control over nuclear export inhibition of 
unspliced RNA species by binding the RRE that lies within the env gene, thus 
promoting the export of unspliced viral RNA (Fischer et al., 1995; Malim et al., 1989b). 
The RRE is a 240 bp long stretch of complex secondary RNA structure that interacts 
with the Rev arginine-rich RNA binding motif (ARM) (Malim et al., 1990; Zapp and 
Green, 1989). Export of viral mRNA is driven by interaction with the cellular CRM1 
protein known to export host U snRNA and rRNAs (Bogerd et al., 1998; Fomerod et 
al., 1997; Neville et al., 1997; Stade et al., 1997), this is intriguing since the CRM1 
pathway isn’t thought to be an export pathway for cellular mRNAs (Cullen, 2003b).
Step 1: in order for CRM 1 to bind the viral export cargo (Rev: RRE-RNA) it must 
first bind the Ran-GTP nuclear export factor (Askjaer et al., 1998; Fomerod et al., 
1997). Multiple Rev molecules assemble onto the RRE-RNA using the ARM sequence 
and recruit several CRM 1 Ran-GTP complexes to the RRE (Askjaer et al., 1998; 
Fischer et al., 1995; Fomerod et al., 1997; Henderson and Percipalle, 1997; Malim et 
al., 1989a; Malim et al., 1989b; Malim et al., 1990; Olsen et al., 1990).
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Step 2: CRM 1 targets the viral ribonucleoprotein complex to the nuclear pore (Cullen, 
2003a; Fomerod et al., 1997; Neville et al., 1997), where the CRM 1-Ran-GTP-Rev: 
RRE-RNA complex traverses the nuclear envelope to the cytoplasm.
$tep3: in the cytoplasm, Ran BP1 and Ran GAP induce the hydrolysis of Ran-GTP to 
GDP, triggering the release of CRM 1 from the Rev NES, exposing the Rev NLS and 
as a result, Rev in addition to CRM 1 are transported back into the nucleus (Askjaer et 
al., 1998; Cullen, 2003a; Fischer et al., 1999; Henderson and Percipalle, 1997). The 
incompletely spliced viral RNA, now in the cytoplasm, is available for translation by 
ribosomes or packaging into virions.
1.13.2 Particle formation and budding
Once the HIV viral proteins have been translated they must then be assembled in the 
cytoplasm, and trafficked to the site of budding. This requires targeting of viral 
proteins so that all constituents, required to make an infectious particle, are assembled 
properly and in the same place. From the point of view of a handful of different viral 
proteins, the inside of the cell is a very large and viscous place (300mg protein/ml) 
(Sodeik, 2000). Molecules are therefore incapable of 1, diffusing freely through the 
cytoplasm to reach the point of assembly and 2, randomly assembling into a highly 
organised viral particle. This section will discuss the recruitment of cellular protein 
expression and budding machinery by HTV to transport viral particle constituents and 
assemble them into full-infectious viral particles. The mechanism of viral protein 
assembly will also be discussed.
Full-length/uncleaved Gag-Pol and p55-Gag (fig 1.11) precursors play major roles 
during assembly and form the bulk of virion structure. It has been estimated that the 
Gag shell of the immature retrovirus particle is built up of 1500-1800 Gag monomers 
(Adamson and Jones, 2004). However the retroviruses only require about 1 Pol for 
every 10-20 Gag proteins so Gag-Pol production must be less frequent or efficient than 
Gag production [reviewed in (Coffin et al., 1997)]. HIV therefore prevents Pol read- 
through by a retroviral mechanism called “frameshift suppression”, where the ribosome 
must slip back -1 nucleotides in order to complete the Gag-Pol precursor protein (Jacks 
et al., 1988; Wilson et al., 1988). The gag and pol genes of HIV are out of translational
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phase and -1 frameshifting puts them back into the same reading frame, essentially 
increasing the size of the gag ORF to include pol. The 0 to -1 frameshift occurs at a 
specific codon of the RNA, 5’ of the gag-pol overlap region (fig 1.3) (Jacks et al., 
1988; Wilson et al., 1988). MLV uses a read-through suppression mechanism called 
^termination suppression” whereby the ribosome reads through the gag termination 
codon as though it were a sense codon. Therefore MLV gag and pol are encoded in the 
same reading frame (fig 1.3). The efficient packaging of Pol (Pr, RT and IN) by 
orthoretroviruses depends upon fusion with Gag since the targeting sequence for 
budding is within Gag and not Pol. In fact, expression of Gag and Gag-Pol alone will 
drive the formation of retrovirus-like particles that are indistinguishable from full 
infectious particles (Coffin et al., 1997).
1.133 RNA encapsidatkm
Encapsidation of genomic length HIV-1 and HTV-2 RNA depends upon the binding of 
the RNA packaging signal f  to dual zinc fingers of NC within p55-Gag [(Aldovini and 
Young, 1990; Dannull et al., 1994; Dorman and Lever, 2000; South and Summers, 
1993; Tsukahara et al., 1996) reviewed in (Coffin et al., 1997)]. Only genome length 
viral RNAs of HIV-1 contain the Y signal because ¥  exists in the leader region of the 
genome, downstream of the gag SD site. However, all RNA transcripts of HTV-2 
contain the Y signal since it lies upstream of the gag SD site (Griffin et al., 2001; Kaye 
and Lever, 1998; Kaye and Lever, 1999; McCann and Lever, 1997). In this instance, 
HTV-2 uses a novel mechanism to select for genome length viral RNAs: cotranslational 
packaging of the RNA by the nascent NC and competition for limiting concentrations 
of Gag polyprotein (Griffin et al., 2001), so translation of gag and packaging of RNA 
occur cotranslationally. This is in contrast to simple retroviruses, such as MLV, where 
the RNA that is translated is compartmentally separate from the RNA that is 
encapsidated (Levin and Rosenak, 1976).
During budding, Gag egress requires the binding of RNA via Y for transport along 
actin microfilaments (Mouland et al., 2001; Poole et al., 2005; Rey et al., 1996), 
suggesting an intracellular targeting role for the RNA, whereas microtubules have been 
implicated in trafficking of RTCs during viral entry (McDonald et al., 2002).
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The MA region of p55-Gag forms the final contacts with the inside of the virion. It 
does this via the M domain that is myristoylated in order to target Gag to the PM and or 
membrane surfaces within the cell (figs 1.4 and 1.11) (Adamson and Jones, 2004).
1.13.4 Virus budding and the endosomal sorting complex required for transport 1 
machinery
The type-C retroviruses, which include the alpha and gamma retroviruses and 
Lentiviruses, assemble their cores at the PM (fig 1.4, step 7) [reviewed in (Demirov and 
Freed, 2004)]. The type-B, D and spuma retroviruses assemble their cores in the 
cytoplasm. The fully assembled cores, known as intracytoplasmic A-type cores, are 
then trafficked to the PM for budding and particle release (Coffin et al., 1997).
HIV and type-C retroviruses like MLV depend upon interactions with cellular 
endosomal sorting complex required for transport (ESCRT) machinery to effect 
budding from cell membranes. The p6 and pl2 proteins of Gag are required for 
particle budding in HIV and MLV, respectively (Gottlinger et al., 1991; Huang et al.,
1995). The PTAP and PPPY motifs in p6 of HTV and pl2 of MLV, respectively, have 
been shown to be absolute requirements for particle release and have been aptly named 
the Mate domains' (fig 1.11) (Gottlinger et al., 1991; Huang et al., 1995; Wills and 
Craven, 1991; Yuan et al., 2000; Yuan et al., 1999). The requirement of the late domain 
for particle release is illustrated by the incomplete budding and 'tethering' of virus 
particles to the surface of the producer cell ("stalk mutants”) when the PTAP motif of 
HTV-1 is mutated (Gottlinger et al., 1991). The host cell protein TSG101 interacts with 
the PTAP motif in the L domain of p6 in HIV-1 Gag (fig 1.11) (Garrus et al., 2001; 
VerPlank et al., 2001), which couples virion formation to the cellular ESCRT 
trafficking machinery (Katzmann et al., 2001; Pomillos et al., 2002; Vogt, 2000). 
Depletion of TSG 101 does not inhibit budding by MLV but experiments inhibiting 
VPS 4 activity block both HTV and MLV budding (Garrus et al., 2001).
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Figure 1.11. HIV-1 p55 and MLV p65 Gag polyprotein schematic.
Uncleaved Gag polyprotein showing regions important for virus budding. M = membrane association 
domain of Gag that is myristoylated (myr) at the N-terminus. MHR = major homology region, present in 
the capsid o f all retroviruses is important for Gag-Gag interactions during budding, however it is absent 
in the spumaviruses (Maurer et al., 1988; Renne et al., 1992). I = interaction domains important for Gag- 
Gag and Gag-i|f RNA interactions during particle assembly. Basic residues are important for Gag-Gag 
interaction and the Zn 2 fingers formed in these domains are important for interaction with RNA (Lee 
and Linial, 2004). L = late domain shown to bind TSG 101 (HIV-1) for particle budding via the ESCRT 
1 machinery. Spl and Sp2 = spacer peptide 1 and 2.
The PTAP motif o f HIV-1 p6 Gag binds the N-terminal region of TSG 101. The C- 
terminal portion of TSG 101 binds VPS 28 such that prevention of VPS 28 to TSG 101 
interaction abolishes the ability of TSG 101 to mediate particle budding (Martin- 
Serrano et al., 2003). An ATPase called VPS 4 has also been implicated as an 
additional factor required for budding because ATPase defective VPS 4 mutants inhibit 
HIV-1 and MLV budding (Garrus et al., 2001), which is consistent with an earlier 
finding that depletion of ATP potently inhibits budding (Tritel and Resh, 2001). TSG 
101 and VPS 28 are normally associated within the cytoplasm for regulation of traffic 
to and from the multi vesicular body (MVB) and late endosomes, but their interaction 
with HIV-1 Gag results in the budding of particles from the PM (Martin-Serrano et al., 
2003). Moreover, consistent with the normal localisation of TSG 101 and VPS 28,
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budding of HIV-1 in M0s has been reported to occur in late endosomes and not the PM 
(Pelchen-Matthews et al., 2003).
1.13.5 Down regulation of the CD4 receptor
An excess of CD4 on the surface of a producer cell greatly diminishes the infectivity of 
virus, either by inhibition of Env incorporation into the particle or even inhibition of 
particle release (Lama et al., 1999; Ross et al., 1999), so HIV has incorporated 
mechanisms to down regulate cell receptor expression during budding. The three viral 
genes responsible for CD4 down regulation by HIV-1 are env, vpu and nef Most 
viruses achieve cell receptor down modulation by Env sequestration of receptor in the 
ER [reviewed in (Dorns and Trono, 2000)]. However HIV has adapted two additional 
genes, vpu and nef, to help effect this task (Aiken et al., 1994; Bour et al., 1995; Chen 
et al., 1996a; Margottin et al., 1998; Rhee and Marsh, 1994).
Nef carries out its functions by establishing connections between proteins. It has no 
enzymatic activity and is essentially a conglomerate of protein-protein interaction 
domains (Dorns and Trono, 2000; Peterlin and Trono, 2003). Nef down regulates cell 
surface CD4. During CD4 down modulation, Nef acts as a connector to the 
cytoplasmic tail of CD4 and clathrin adaptor proteins, thereby directing CD4 into a 
clathrin-mediated degradative pathway (Aiken et al., 1994; Bresnahan et al., 1998; Foti 
et al., 1997; Margottin et al., 1998; Schwartz et al., 1995). Considerably less is known 
about the function of HIV-2 Nef, but this protein has also been shown to down 
modulate the expression of CD4 and MHC-I (Munch et al., 2005).
Vpu acts in a very similar way to Nef in that it too is an adaptor for directing CD4 into 
a degradative pathway. Vpu bridges the cytoplasmic tail of Env trapped CD4 receptors, 
in the ER, to proteolysis machinery. Vpu bound to CD4 binds a protein called 0TrCP, 
which in turn links this protein complex to the proteasome (Bour et al., 1995; Margottin 
et al., 1998; Schubert et al., 1998), and Env is then free to make its way to the cell 
surface (Bour and Strebel, 2003; Willey et al., 1992).
Vpu is also thought to improve particle release via a poorly defined, CD4 and Env 
independent mechanism (Paul et al., 1998; Schubert et al., 1996; Schubert and Strebel,
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1994). It has been suggested that Vpu enhances particle production by counteracting a 
cell-type dependent virus assembly restriction (Varthakavi et al., 2003).
HTV-2 does not encode for Vpu (fig 1.3), however enhancement of HIV-2 virus particle 
please, has been attributed to the cytoplasmic tail of HTV-2 Env (Bour et al., 1996; 
Bour and Strebel, 1996; Ritter et al., 1996). A membrane proximal GYXX motif in the 
cytoplasmic domain has been reported as necessary for this activity (Abada et al.,
2005).
1.13.6 Immune evasion
Nef decreases the expression of MHC-I molecules from the cell surface, helping virus 
infected cells to avoid recognition and killing by CTLs (Peterlin and Trono, 2003). 
Since Nef is an early expressed protein (fig 1.10) it is a well-chosen candidate to 
prevent immune recognition by MHC-I. The rest of the HTV replication cycle may 
proceed uninterrupted because the bulk of virus protein production can then proceed 
without the pressure of virus protein being presented by MHC-I to cytotoxic T cells at 
the cell surface. Nef appears however, to be selective in its down regulation of only 
HLA-A and B, but not HLA-C or HLA-E, perhaps to avoid detection from a lack of 
MHC expression and subsequent killing by NK cells (Cohen et al., 1999; Kasper and 
Collins, 2003; Williams et al., 2005; Williams et al., 2002).
1.13.7 Apolipoprotein B mRNA-editing enzyme catalytic polypeptide restriction of 
HIV and MLV
Vif acts at the point of assembly by promoting the degradation of hAPOBEC 3G 
proteins that would otherwise be packaged into the virion (Sheehy et al., 2002; Sheehy 
et al., 2003). Cytidine deamination of the RT minus strand DNA by hAPOBEC 3G 
during RT then occurs upon entry of the RTC, inhibiting virus replication (see also 
reverse transcription section) (Bishop et al., 2004a; Bishop et al., 2004b; Mangeat et 
al., 2003; Newman et al., 2005). In this regard Vif acts directly at the point of assembly 
but indirectly at entry and RT.
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Vif and hAPOBEC 3G co-immunoprecipitate suggesting that they bind one another 
(Mariani et al., 2003; Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 2003). One 
report has shown that Vif may inhibit hAPOBEC 3G translation from mRNA in 
infected cells (Stopak et al., 2003). Proteasome inhibitors can partially reverse the 
effect of Vif mediated decrease on hAPOBEC 3G steady state levels and Vif-APOBEC 
complexes can then be seen packaged into virions (Kao et al., 2003; Marin et al., 2003; 
Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003). In addition, the Vif- 
APOBEC complexes were shown to maintain the antiviral activity of APOBEC (Mehle 
et al., 2004).
Human APOBEC (hAPOBEC) 3G, 3F and 3B inhibit HIV replication and 
hAPOBECs 3B and 3C can inhibit infection by some SIV isolates (Yu et al., 2004). 
Murine APOBEC 3 and rat APOBEC I can both inhibit HTV infection when expressed 
in human cells (Bishop et al., 2004a; Bishop et al., 2004b; Mariani et al., 2003).
Like HTV, MLV packages hAPOBEC 3G which inhibits replication of this retrovirus 
in human cells (Bishop et al., 2004a; Harris et al., 2003; Mangeat et al., 2003). 
However, murine APOBEC 3 does not inhibit MLV replication (Bishop et al., 2004a). 
Unlike HIV, MLV is not A-T rich with regard to nucleic acid content so it may not be 
under ‘ A’ pressure as is the case with HTV (Navarro and Landau, 2004).
1.13.8 Particle maturation
Newly budded virions, whether they are from the cell surface or intracellular vesicles, 
are immature. The activity of PR is required to mature the particle by cleaving p55 
Gag into MA, CA, spacer peptide 1 (Spl), NC, spacer peptide 2 (Sp2) and p6. Pol 
must also be cleaved into RT, IN and PR for reverse transcription and integration to 
proceed efficiently in the next round of infection (fig 1.4). Mature, infectious particles 
of the lentivirus family have cone shaped capsids (figs 1.4 and 1.5) whereas MLV and 
the other C-type retroviruses have spherical capsid cores. Once matured, the infectious 
virion may infect the next target cell and the virus life cycle begins anew (fig 1.4, step 
8).
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1.14 Scope o f this thesis
HIV-1 and HTV-2 both infect M0s and T cells. Monocyte derived macrophages 
(MDM) and PBMC are used to compare the relative infectivity and the replication 
kinetics of HIV-1 and HTV-2 in these two key infectable cell types. HTV-2 infects 
PBMC as efficiently as HIV-1, however HIV-2 replicates to much lower levels in 
MDM. A brief and early burst of replication followed by an inability to spread through 
MDM culture and an apparent latency of remaining provirus is observed for HTV-2. 
The HIV-2 V3' loop charge was found to be associated with coreceptor usage but there 
is only a weak correlation to M0 tropism (chapter 3), so other factors affecting HTV 
tropism were investigated.
The primary isolate, piCBL 23 was remarkable as being particularly refractory to 
replication in MDM, and has been shown to be restricted post-entry and post-reverse 
transcription in these cells (McKnight A, 2001). PrCBL 23 was further shown to be 
permissive for some cell lines such as U87/CD4/CXCR4 and restricted in HeLa/CD4 
cells. This restriction was termed Lv2 (Schmitz et al., 2004). I show that about one- 
third of HIV-1 and HIV-2 viruses are susceptible to Lv2 restriction (chapter 3) 
(Marchant et al., 2005).
MCR is a molecular clone of prCBL 23 and the env and gag genes are shown to act in 
concert to mediate Lv2 restriction in HeLa/CD4 cells. To explain the involvement of 
Env in a post-entry event, a compartmentalisation model was developed (Schmitz et al.,
2004). I tested this model with hypertonic sucrose inhibition of endocytosis and 
interruption of lipid rafts to implicate an endocytic lipid raft pathway of restriction for 
restricted HIV-2 MCR. Dominant negative endocytosis mutants, a more specific tool 
for studying endocytosis, implicate an Arf6 and dynamin dependent pathway of entry 
(chapter 4).
Chapter 5 demonstrates that Lv2 is indeed a saturable restriction factor, like Refl, Fvl 
and Lvl, but unlike such restrictions, requires an HIV-2 Env to deliver saturable MLV 
doses into the restrictive compartment. This chapter compares the saturable nature of 
Lv2 and other restriction factors with N and B-tropic MLV Gag-Pol cores, expressing 
various Envs. By classic saturation assays and the development of a variation of this
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assay, Lv2 is saturated by both N and B-tropic MLV vector pseudotypes when 
pseudotyped with HIV-2 Envs.
Similarities between Lv2, Refl and Lvl suggest that tripartite motif protein (TRIM) 5a 
<?r a related protein is responsible for Lv2 restriction. RNA interference (RNAi) is 
employed in chapter 6 to screen multiple TRIMs for Lv2 activity. TRIMs 1,18 and 34 
are identified as candidates and investigated further. The 3 TRIMs were cloned and 
over-expressed in permissive cells, rendering these cells restrictive. The TRIM If) 
SPRY/B30.2 domain is implicated as the domain partially responsible for TRIM If) 
restriction activity. Moreover, RNAi knockdown of TRIMs 1, 18 and 34 in HeLa/CD4 
cells and challenge with the HTV-2 Env-MLV pseudotypes suggest that other TRIMs, 
or TRIM like factors, may by Lv2 restrictive (chapter 6).
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2.1 Buffers and solutions
Table 2.1. Buffers and solutions.
40mM dNTP 10mM dATP; 10mM dCTP; 10mM dGTP; 
10mM dTTP.
HEPES-h 10mM HEPES; 1.5mM MgCI2; 10mM KCI; 
0.5mM dithiothreitol.
PBS-A 137mM NaCI; 3mM KCI; 10mM Na2 HP0 4 ; 
2mM KH2 PO4  (pH7.4)
TAE 40mM Tris-HCI pH 7.8; 20mM sodium 
acetate; 1mM EDTA
TBS 20mM Tris-HCI, pH 7.6, 120mM NaCI
TE 10mM TRIS-HCI, pH 7.4; 1mM EDTA
2.2 Eukaryotic cell culture
Table 2.2. Cell lines used.
Cell line Original cell type Reference
293T Human embryonic fibroblasts (Graham et al., 1977)
GHOST Human osteosarcoma (Cecilia et al., 1998)
H399 Human cervical carcinoma (Pitcher et al., 1999)
HeLa/CD4 Human cervical carcinoma (Scherer et al., 1953)
U87/CD4/CCR5 Human glioma (Deng e ta l., 1997)
U87/CD4/CXCR4 Human glioma (Deng et al., 1997)
Mus Dunni tail fibroblasts (M DTF) Mouse fibroblast (Lander and 
Chattopadhyay, 1984)
NP2/CD4/CCR5 Human glioma (Soda et al., 1999)
NP2/CD4/CXCR4 Human glioma (Soda et al., 1999)
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2.2.1 Passaging cells.
Cells were passaged twice weekly. Adherent cells were detached from tissue culture 
flasks with 0.5% Trypsin in 0.02% versene then replated in new flasks at a dilution of 
1/3 to 1/20 in Dulbecco’s modified Eagle's medium (DMEM, Gibco™), 5% fetal calf 
serum (FCS, Biowest™). Cells expressing CD4 were supplemented with 1 mg/ml 
G418 (Gibco™) and those expressing CXCR4 or CCR5 were supplemented with 1 
pg/ml puromycin.
2.2.2 Freezing cells.
Cells were pelleted at 300g for 5 min and resuspended in DMEM, 20% FCS on ice at 
approximately 1.0 x 106 cells/ml, diluted 1:1 with a solution of DMEM, 20% FCS, 20% 
DMSO, 1 ml aliquots were pipetted into cryotubes, placed in a polystyrene container 
and cooled in a -80°C freezer to freeze slowly overnight (approximately 1°C per min). 
Frozen cells were transferred to vapour phase liquid nitrogen for long-term storage.
2.23 Thawing cells.
Frozen aliquots of cells were thawed from liquid nitrogen storage in a 37°C water bath 
and added dropwise to DMEM, 10% FCS. Once optimal growth was achieved medium 
was replaced with normal growth medium and selection antibiotics if applicable 
(DMEM, 5% FCS).
2.2.4 Preparation of peripheral blood mononuclear cells.
For most studies PBMC were prepared from the same donor as the MDM. Cells were 
resuspended to 1.0 x 106 cells/ml in RPMI 1640, 10% FCS and 0.5 pg/ml 
phytohemagglutinin (PHA). Two days later the PBMC were washed twice in serum 
free RPMI 1640 and then suspended in RPMI 1640, 10% FCS, 20 units (U) /ml of 
interleukin-2 (IL-2) for two days so that T cells would be selectively propagated.
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2.2.5 Preparation of monocyte derived macrophages.
MDM were isolated from peripheral blood monocytes by adherence to plastic as 
described previously (Simmons et al., 1995), except, washes were performed with 
serum free RPMI 1640 Penicillin (100 U/ml) and Streptomycin (100 pg/ml). Briefly, 
buffy coats (Brentwood Blood Transfusion Centre, UK) were diluted 1:1 with PBS. 
The blood-PBS mixture was then layered onto Lymphoprep™ and centrifuged for 30 
min at 700g. The white blood cell layer was harvested, washed twice in PBS, and then 
suspended in RPMI 1640. Cells were counted, and then plated at 1.0 x 108 cells per 140 
mm bacterial dish in 5% heat inactivated human serum (HS) RPMI 1640. After 2 hr, 
the plates were washed three times in RPMI 1640 and then left to incubate at 37°C 
overnight. The cells were incubated overnight before washing three times and left to 
differentiate into MDM for 7 days. After 7 days the MDM were washed 3 times in 
RPMI 1640, incubated in PBS, 0.01% EDTA at 37°C, and removed by scraping gently 
with a cell scraper. Harvested cells were pelleted and washed twice, counted, and 
replated at 1 x 106, 2 x 10s, 1 x 10s, and 1 x 104 cells per 6, 24, 48, or 96 well tray, 
respectively.
2.2.6 Transfection of DNA into Eukaryotic cells.
FuGene®-6 was used to transfect DNA into cells as per manufacturers instructions. 
This reagent provided high transfection efficiency (70 to 90%) for both single and 
multiple plasmid transfections. Briefly, 16-18 pi of FuGene®-6 per tissue culture tray 
was added to 500 pi of Optimem® (Gibco™). The Fugene®-6 mixture was added to 3 
pg of DNA (per tissue culture plate), pipetted up and down and incubated for 15 min at 
room temperature. Fresh media (DMEM, 5% FCS) was added to the cells and 10, 20, 
42, 80, and 500 pi of the FuGene®-6-DNA mixture was added to each well of a 48,24, 
12, 6 well, and 10 cm plate, respectively. The transfection efficiency was best when 
transfection complexes were added per well, opposed to batch transfection with 
replating the following day. This was particularly the case with transfection of the 
dominant negative endocytosis mutants (table 2.3).
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Table 2.3. Transfection volumes of dominant negative mutants.
Volume FuGene- 
6/plate
DNA Culture dish Fresh media 
(per well)
Transfection 
mix (per well)
18 Ml 3 MS
48 well 10 0 m> 10 Ml
24 well 200 pi 20 Ml
12 well 400 Ml 40 Ml
6 well 800 Ml 80 M<
10 cm dish 8 ml 500 Ml
Table 2.4. Plasmids
Construct Plasm ids Encode Reference
Env pMDG
pMP11-MCRenv
pMP11-MCNenv
VSV-G (VSV Env) 
MCR Env 
MCN Env
(Yea at al.. 1994) 
(Schmitz at a t. 2004) 
(Schmitz et al., 2004)
Gag-Pol pCK33-MLV-N
pCIG3-MLV-B
pHIT-60-MLV-Mo
p8.2-HIV-1
MLV-N Gag-Pol 
MLV-B Gag-Pol 
MLV-Mo Gag-Pol 
HIV-1 Gag-Pol
(Bock at al., 2000) 
(Bock e ta l , 2000) 
(Soneoka at al., 1995) 
(Zufferey et al., 1997)
Transfer vectors pCNCG
pCNCZ
pC(*TRM)CZ
pCSGW
NaoR, oGFP 
NeoR, ZeoR 
TRIM 1,18, 34ZeoR 
eGFP
(Soneoka at al., 1995) 
Keith Aubin 
Keith Aubin 
(Demaison at al.,2002)
Cloning vectors pGEM-T easy-(HIV-2 env V3 
loops)
TA cloning vector for cloning 
and sequencing HIV-2 V3 
loops.
Promega Madison, Wl, 
USA
Dominant
negative
endocytosie
mutants
pEGFP-C1-DPF 
pEGFP-dnCavl 
pSRa-ArfS(T27N) 
pSRa-Dyn(K44A)
eGFP-Eps15-HA (KanR) 
eGFP-dnCav 1 (KanR) 
Arf8T27N-HA (Amp1*) 
Dynamin K44A-HA (AmpR)
(Benmerah at al.,1998) 
(Pelkmans at al.,2001) 
(Paters at a l, 1995) 
(van dar Bliek 1993)
Infectious 
molecular clonee 
of HIV
HIV-1 89.6 
HIV-1 NL4.3 
HIV-2 MCR 
HIV-2 MCN
HIV-2 MCR, MCN-gsg+env 
swaps
HIV-1 89.6 
HIV-1 NL4.3 
HIV-2 MCR 
HIV-2 MCN
HIV-2 MCR. MCN-gag+env 
swaps
(Collman etal., 1992) 
(Adachi at al., 1986) 
(Schmitz at a I., 2004) 
(Schmitz e ta l ,  2004) 
(Schmitz at al., 2004)
ZeoR ■ Zeomycin resistance, NeoR ■ Nsomycin resistance, dnCavl ■ dominant negative 
caveolin 1, HA ■ haemagglutinin tag
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2.2.7 RNA interference.
To down regulate the endogenous mRNA transcripts of TRIMs 1, 5, 6, 18, 34 and D6 
(control) the following short interfering RNAs (siRNAs) were used: TRIM 1 
(NM_052817) 5’ -aagcgcaacagcgaacuagaa, TRIM 5a 5 ’ -gcucagggaggucaaguuguu, 
TRIM 6 (NM_001003818) 5’-aaccggagacaagugagguuu, TRIM 18 (NM_010797) 5’- 
aacggcucuaucgccuuuuau, TRIM 34 (NM_030684) 5’ -aaguggacguguccaagaaaa and £>6 
5 * -aaggcugccucucugcaaagu.
SiRNAs directed against TRIMs 1,6,18,34, and £>6 control were designed by inputting 
the nucleotide sequence accession number from the NCBI website into the Qiagen 
siRNA design tool (http*7/wwwl.qiagen.com/ Products/ GeneSilencing/ CustomSiRna/ 
SiRnaDesigner.aspx). The sequence with the highest score but the least similarity to 
sequences in other human genes was used.
The huTRIM 5a siRNA sequence was copied from [(Stremlau et al., 2004), sequence 
3].
2.2.8 Transfection of short interfering RNA.
Cells were transfected with siRNA oligonucleotides using Oligofectamine™ 
(Invitrogen™) as per manufacturers instructions. Briefly, cells were plated in 6 well 
and 10 cm dishes such that they were approximately 30-50% confluent on the day of 
transfection. Oligonucleotide (20 pM stock) was diluted in Optimem® and mixed 
gently (table 2.5). Oligofectamine was diluted in Optimem®, mixed gently and 
incubated at room temperature for 10 min. The diluted oligonucleotide and 
Oligofectamine™ were mixed and incubated for a further 20 min. Fresh growth media 
(DMEM, 5% FCS) was added to the cells and oligonucleotide-Oligofectamine™ 
complexes were added to each well (table 2.5). Cells were washed and normal growth 
media was added the following day or replated into 48 and 24 well trays at 4.0 x 104 and 
8.0 x 104 cells per well respectively. Cells were challenged with HTV, MLV vector 
pseudotypes or assayed for gene knockdown the next day (48 hr post-transfection).
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Table 2.5. RNA interference transfection volumes.
Culture dish Oligonucleotide
(Ml of 20 pM 
stock) + 
Optimem9 (per 
well)
Oligofectamine™ 
♦ Optimem9 (per 
well)
Vol. of medium 
per well (fresh 
growth medium 
added before 
complexes).
Transfection 
vol. (complexes 
added to each 
well)
Swell 5 pi ♦ 80 pi 2 pi + 5 pi 800 pi 93 pi
10 cm dish 30 pi + 525 pi 10 pi + 35 pi 5ml 600 pi
2.2.9 Production of tripartite motif protein expressing cell lines.
NP2/CD4/CXCR4 and U87/CD4/CXCR4 cells stably expressing TRIM proteins 1, 18 
and 34 were made by transduction with an MLV derived retroviral vector (table 2.4, fig
2.1). TRIMs amplified from cDNA were subcloned into the pC(TRIM)CZ MLV vector 
by Keith Aubin (table 2.4). Vector pseudotypes were made with VSV Env as described 
in section 2.4.2 ‘virus production by transfection of 293T’ (fig 2.1). Cells were 
transduced with the vector at a multiplicity of infection (MOI) of approximately 1, and 
Zeomycin containing selection medium was added 48 hr post-transduction. Stable 
transductants were infected with HTV after stable growth in Zeomycin selection media 
for about 3 weeks.
2.3 H IV viruses and viral vectors
2.3.1 Viruses and preparation of virus stocks.
All work with primary isolates and molecular clones of HIV-1 and HIV-2 was 
performed in a containment level 3 laboratory. Primary HTV-2 and HIV-1 strains used 
in this thesis were prepared in PHA and IL-2 stimulated PBMC from the peripheral 
blood of infected individuals as described previously (table 2.6) (Reeves et al., 1999; 
Simmons G, 1996). Briefly, stocks of HIV primary isolates were prepared from the 
lowest possible passage stock. PBMC from 2 donors were mixed and 5.0 x 106 cells 
were incubated with 1 ml of virus stock at 37°C for 3 hr. Cell-virus mixture was mixed 
periodically during incubation. Cells were reconstituted in 5 to 10 ml RPMI 1640,10%
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FCS, supplemented with IL-2. To boost virus stock volume 3 to 5 times the original 
number of PBMC were added to the infected cells at the peak of infectious virus 
production, spun at 300g for 5 min and incubated again at 37°C for 3 hr. At the peak of 
virus production infected cells were spun-down at 500g for 10 min to clarify cell free 
virus. Aliquots of 0.S to 1.0 ml were snap frozen in liquid nitrogen and stored in vapour 
phase liquid nitrogen.
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Table 2.6. HIV isolates.
Virus Corscoptor(s) 
CCR8 (R5), 
CXCR4 (X4)
History Source Clade Disease
status
Country of 
origin
NIV-2
MLC R8 pi PBMC A ARC Portugal
TER R8+ R1. R3. 
CXCR8
pi PBMC A AID8 Portugal
AU R8+R1 Pi PBMC A ARC Portugal
JAU R5/X4+ R1, R2b, 
R3. R8
pi PBMC A AIDS Portugal
8T R8/X4+ R1, R2b, 
R3
pi PBMC A AID8 Sanogal
ETP R8/X4+ R1, R2b, 
R3
Pi PBMC A AIDS Portugal
MIR R5/X4+R1, R2b, 
R3
pi PBMC A AIDS Guinoa-Blssau
PrCBL-20 R8/X4+ R1, R2b, 
R3
pi PBMC A AIDS Tho Gambia
PfCBL-23 R5/X4+ R1, R2b, PI /  (MC) PBMC A AIDS Tho Gambia
(MCR) R3
MIL X4 PI PBMC A AIDS Portugal
8AB X4+R3 PI PBMC A AID8 Portugal
AND X4+ R1, R2b, R3 PI PBMC A AIDS Portugal
CBL-23 R8/X4 TCLA/ H9 A AIDS Portugal
(MCN) (MC)
Rod (ACR X4 ♦ R3 TCLA / HO A AIDS Sanagal
23) (MC)
HIV-1
8P1S2 R8 PI / MC Brain B AIDS U8A
8L-2 RS PI PBMC B Asymptomatic Thailand
8F-2 R8/X4 TCLA B USA
2005 X4 PI PBMC NK AIDS UK
2070 R5/X4+ R3, R8, 
STRL-33, OPR-15
PI PBMC B AID8 UK
2028 R8/X4+ R3, R8, 
STRL-33, GPR-15
PI PBMC B AID8 UK
2044 X4 PI PBMC B AIDS UK
NL4.3 X4 TCLA/MC PBMC B AID8 USA/Franca
80.3 R5/X4 TCLA/MC PBMC B AID8 U8A
RF X4 TCLA PBMC B AID8 HaW
M13 R5/X4 PBMC B AIDS USA
HAN-2 X4 PI PBMC B AIDS Garmany
IIIB X4 TCLA PBMC B AID8 Franca
MN X4 TCLA PBMC B AID8 USA
*+’ denotes additional corscsptor uaa as datarmlnad previously (Raavaa at al, 1999; 
McKnlght at al, 1998; Nall at al, 2005), NK*not known, Corscsptor shown In bold 
denotes predominant uaa of that corscsptor. R1 * CCR1, R2b ■ CCR2b, R3 ■ CCR3, 
R8 ■ CCR8. TCLA ■ T-csll line adapted, PI ■ primary Isolate, MC ■ molecular clone, 
ARC ■ AID8 related complex.
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23.2 Virus production by transfection of 293T cells.
HTV molecular clone stocks were prepared in 293T cells in 10 cm culture dish by 
transfection with FuGene®-6 (table 2.4), as described in Transfection of DNA into 
eukaryotic cells' except for some changes: the day after transfection, 8 ml of 
transfection media was replaced with 14 ml of normal growth media in a 10 cm dish to 
boost stock volume. This was replaced the following day with a further 14 ml and the 
virus stocks were then harvested and aliquoted into 0.S ml 72 hr post-transfection. 
Harvests of equal infectivity could be taken at 48, 72 and 96 hr post-transfection. The 
293T cells were cultured in GlutaMAX™ supplemented DMEM (Gibco™) and 10% 
FCS in a 37°C and 10% CO2 incubator.
2.33 N-tropic, B-tropic and Moloney MLV virion pseudotyping.
VSV-enveloped, MLV-N/B-Gag-Pol particles were produced from a combination of 
three plasmids as described previously (fig 2.1, table 2.4) (Towers et al., 2000). MLV- 
N, B and Moloney (Mo) Gag-Pol cores (packaging constructs) were expressed from 
pCIG3-N, pCIG3-B and pHIT60 respectively, and pseudotyped with VSV-G expressed 
from pMDG, or MCR and MCN Env from pSVffl (fig 2.1, table 2.4). The proviral 
reporter genome pCNCG encoding eGFP was packaged into the pseudovirions (fig 2.1, 
table 2.4). Three pg pCNCG, 2 pg pCIG3-N or B, and 1 pg pMDG were mixed and a 
confluent layer of 293T cells in a 10 cm dish was transfected in the presence of 18ul 
FuGene®-6 (see ‘transfection of DNA into eukaryotic cells'). Pseudotype particles were 
harvested 48, 72 and 96 hr post-transfection and viral titres were determined on MDTF 
and by RT-ELISA.
2.3.4 HIV-1 vector pseudotypes.
HIV-1-based vectors were derived from the packaging construct p8.91 (Zufferey et al., 
1997), and the eGFP encoding vector genome pCSGW (table 2.4) (Demaison et al., 
2002), in conjunction with pMPl 1, encoding either MCN or MCR Env (Schmitz et al., 
2004). Molecular clones, pseudotyped viruses, and vectors were produced by transient 
transfection of 293T cells, as described above in ‘N and B-tropic and Moloney MLV 
virion pseudotyping' and fig 2.1.
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Figure 2.1. Production of retroviral vector by triple transfection.
(A) Transfer vector, Gag-Pol and Env expression plasmids were mixed and transfected into (B) 293T 
producer cells. (C) The only construct to contain the packaging signal (y) is the transfer vector (devoid 
of genes required for replication) so it is preferentially packaged and the virions that are produced are 
single round only.
2.4 Injectivity assays
2.4.1 Tissue culture infectious dose §0.
Tissue culture infectious dose 50s (TCID50) of HIV-1 and HIV-2 were estimated on 
both MDM and PBMC. MDM and PBMC were plated on 96 well trays at 104 and 105 
cells per well, respectively. Virus was serially diluted in half logs and 50 pi dilutions 
were incubated with either PBMC or MDMs. After overnight incubation with virus 
inoculum cells were washed 3 times in growth media which was changed every 7 days.
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Supernatant was harvested at day 14 for PBMC and day 21 for MDM. Virus production 
was detected by RT-ELISA (Caviditech) and TCIDsos were calculated by the Karber 
method, described previously (Aine McKnight, 1995). Samples were subject to RT- 
ELISA using the 'detection of RT activity1 protocol outlined in the manufacturers 
instructions. The TCEDso is the dilution where cells become infected in 50% of wells: 
TCID50 = L-d(S-0.5). Where L is the highest dilution to give 100% of positives, while d 
is the dilution factor (for half log dilutions this is 0.5). S is the sum of the number of 
positive wells/total number of wells for all the dilutions to give any positives starting 
from L and going up to the highest dilution to contain positives. An example is given 
below (fig 2.2).
TCIDu-L - d (S - 0.5)
Total no. of 
walla
No. of walla with 
infectad cells
Log dilution aariaa— ►
N -0.5 -1.0 -1.5 -2.0 -2.5
5 5 5 5 5 5
5 5 | 5 | 3 1 0
t
L« -1
L * -1 
d ■ 0.5
3  ■  1 +  0.6 +  0.2 *  1.8
TCIDm-  -1 -0.5 (1.8-0.5)
-  -1 - (0.65)
■-1 .65
-  45 TCIDm/SOmI
■ 8.9 x 102 TCIDS0/ml 
Figure 2.2. Example tissue culture infectious dose 50 calculation.
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2.4.2 Monocyte derived macrophage time courses of infection.
MDM time-courses were done in 6-well trays. Cells were plated at 1.5 x 106 cells per 
well. The following day, 1ml of 104 TCIDso/ml (as determined on PBMC) of virus 
diluted in RPMI 1640, 10% heat-inactivated HS was added to its corresponding well. 
After 3 hr of infection, the virus was removed and the cells were washed with serum 
free RPMI 1640. Fresh 10% HS in RPMI 1640 was added and the first aliquot, time 0, 
was taken. Every two days, an aliquot was removed and stored at -40°C for 
determination of RT activity and focus forming units (FFUs). After the removal of each 
time-point aliquot the MDM were washed once with 10% heat-inactivated HS RPMI 
1640 to eliminate the possibility of measuring carry-over virus in the following time- 
point.
2.43 Cholesterol depletion.
To aid cell adherence during cholesterol depletion, tissue culture surfaces were treated 
with 1 part 2% bovine gelatine (Sigma) to 1 part serum free DMEM for 1 hr at room 
temp. Cells were plated the night before they were needed on 48 well trays at 
approximately 5.0 x 104 cells per well and in 75 cm2 medium flasks at 1.0 x 107 
cells/flask. The best results were obtained when four confluent-medium 75 cm2 flasks 
were split into eight gelatine-coated-medium flasks and fractionated 3 days later.
Prior to virus addition, cells were washed with serum free media then treated with 10 
mM methyl-p-cyclodextrin (MpCD) for 20 min at 37°C. The cells were rinsed once 
with serum free media, virus dilutions were added and allowed to bind to the cells on 
ice for 1 hr. After synchronisation on ice, virus inoculum was removed and serum free 
medium, with or without water-soluble cholesterol, was added to the cells, and 
transferred to a 37°C incubator to allow infection to proceed for 2 hr. Normal growth 
media was added to the cells, fixed and stained for HIV infection 3 days later.
2.4.4 Inhibition of endocytosis with hypertonic sucrose.
Cells were plated at subconfluence, as described for ‘cholesterol depletion’, the day 
before they were needed. The cells were washed once with growth media, virus 
dilutions were added, and placed on ice for 1 hr. Normal growth media (DMEM, 5%
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FCS) was replaced with 0.45 M sucrose, DMEM, 5% FCS for 50 min in a 37°C 
incubator. The sucrose media was then removed and replaced with normal growth 
media. The cells were fixed and stained 3 days later for HIV infection.
To control for possible mitosis effects of hypertonic sucrose the cells were pre-treated 
with sucrose for 20 min prior to addition of virus.
2.4.5 Transfection of dominant-negative mutants.
HeLa/CD4, U87/CD4/CXCR4, and H399 cells were plated the night before. Cells were 
plated on gelatin-coated plates to promote adherence and time courses for optimal 
transfection expression were conducted to minimise duration of the experiment. The 
day of transfection, growth medium was replaced with DMEM, 5% FCS and 
transfections were carried out overnight. The cells were washed once and transfection 
medium was replaced with normal growth medium the following day. Cells recovered 
in normal growth medium for at least 1 day post-transfection to eliminate any effect the 
transfection reagent might have on HIV infection (transfection reagents relieve Lv2 
restriction). Transfection and eGFP expression also proved to be toxic since the eGFP 
control caused extensive cell death in some cases: DNA and FuGene®-6 were titrated 
onto cells to ascertain the optimal DNA and FuGene®-6 concentrations. Cells were 
infected, 48 hr post-transfection, with HIV-1 and HIV-2 on ice for 1 hr, incubated at 
37°C, media was replaced with normal growth media 4 hr later and cells were fixed and 
stained for HIV infection 2 days later (see also table 2.3 and ‘transfection of eukaryotic 
cells’).
H e L a /C D 4
Figure 2.3. Transfection efficiency of dominant negative mutant constructs.
An eGFP expressing plasmid (pCNCG) was used as a transfection control in all dominant negative 
mutant experiments in chapter 4 and transfection efficiency was approximately 100% in HeLa/CD4 cells.
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Cells were transfected with FuGene® (Roche) as described above, and visualised by blue light before 
staining for HIV infection.
2.4.6 Abrogation assays
2.4.6.1 Refl saturation.
Refl abrogation control was conducted as described previously (fig 2.4c) (Schmitz et 
al., 2004; Towers et al., 2002) and in results chapter 5 (fig 5.1). HeLa/CD4, 
U87/CD4/CXCR4, and HOS/CD4/CXCR4 cells were plated in 48 well trays at 5 x 103 
cells per well 24 hr prior to infection. Cells were treated with high doses of MLV- 
Nzeo(VSV) vector pseudotype [approximately 105 IU/ml as determined on MDTF cells 
or 104 pg/ml RT activity (determined by RT ELISA)] for 6 hr. Cells were washed with 
normal growth media and MLV-NeGFp(VSV) was titrated on the cells and eGFP 
transduced cells were detected by flow cytometry 3 days later.
A MLV-NeGFP(VSV)
Permissive cells
& j - i
9 - &  ju
M LV -N ^V S V )
Restrictive cells
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Figure 2.4. Abrogation of restriction factors in restrictive versus permissive cells: 
R efl.
(A) Permissive cells do not express restriction factors, all eGFP encoding virus vectors (shown with green 
nucleic acids) are able to enter and establish productive infection. This scenario also occurs with 
challenge o f restrictive cells with resistant/non-restricted viruses (no restriction). Infected cells express 
eGFP [green cells in (A)]. However, (B) restrictive cells express restriction factors (red) that inhibit all 
challenge virus, thus there is no productive infection in this hypothetical model. (C) Experimental model 
o f Refl abrogation (chapter 5, fig 5.1). The purpose of abrogation experiments is to saturate restriction 
factor with a decoy virus and observe the ‘rescue’ o f a similarly restricted virus with a different reporter 
gene. The challenge and saturating viruses must be detectable by different reporter systems in order to 
detect restriction-saturation and recovery of challenge virus infectivity [The saturating dose conferred 
Zeomycin resistance (Zeo) and the challenge dose was an eGFP reporter in this case (fig 5.1)]. High 
doses of saturating virus are normally required to saturate restriction that is followed by a titration of 
challenge/reporter virus and the cells are temporarily rendered permissive. When the restrictive factor has 
been pre-saturated there is an apparent increase in eGFP expression from challenge virus infection. 
Abrogation does not require that the saturating dose and challenge dose viruses are the same, however 
they must be targeted by the same restriction factor for rescue of restricted virus infectivity.
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2.4.6.2 Refl saturation with an, Lv2 restricted, HIV-2 challenge dose.
HeLa/CD4, U87/CD4/CXCR4, and HOS/CD4/CXCR4 cells were plated in 48 well 
trays at 5 x 103 cells per well 24 hr prior to infection and an abrogation assay was 
conducted as described previously [fig 2.5a for experimental design; chapter 5, fig 5.3 
for results (Schmitz et al., 2004)]. MLV-N and B(VSV) pseudotyped viruses were 
added to the cells at an MOI of approximately 10 (about 1 x 10s IU/ml as determined on 
MDTF cells or 104 pg/ml RT activity as determined by RT-ELISA). After 6 hr, the 
cells were washed 3 times with growth media (DMEM, 5% fetal calf serum), and the 
HTV-2s, MCN and MCR, were titrated onto the cells. Two days post-infection the cells 
were screened for MLV vector transduction by visualisation of eGFP expression, to 
determine whether the dose applied to the cells was sufficient to overcome Refl 
restriction, and then immunostained 3 days later for MCN and MCR infection with 
human polyclonal HIV-2 serum. In this case the saturating dose read-out is eGFP (fig 
2.5b) and the HIV-2 challenge virus reporter is p-Gal, blue spot staining. Monitoring 
eGFP expression was a convenient control to determine whether the MLV-NeGFP dose 
delivered was a Refl saturating one (fig 2.5b).
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A
B
GHOST
HeLa/CD4
/^ "sSrO ■
MLV-N (VSV)
MUV-B (VSV)
Figure 2.5. Determination of relationship between Refl and Lv2.
(A) The experimental model for determining whether Lv2 (purple) and Refl (red) are the same restriction 
factor, (i) If Lv2 and Refl are different restriction factors there would be no expected recovery of Lv2 by 
Refl saturation, (ii) If Refl and Lv2 were the same restriction factor then there would be recovery o f Lv2 
restricted HIV-2 MCR with the saturation of Refl with MLV-N(VSV) vector pseudotypes. (B) EGFP 
expression by MLV-NeGFp(VSV) particles in (A) allowed for monitoring of Refl saturation during Lv2
M L V -N ^ V S  V)
“Saturating dose”
HIV-2 MCR
“Challenge dose”
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saturation control experiment before staining for HIV infection by in-situ {3-Gal staining (blue spots, 
FFU). Saturation of Refl by MLV-N is indicated by eGFP expressing cells. The same dose of MLV- 
B«gfp(VSV) transduced 100% of cells challenged.
2.4.6.3 Lv2 saturation with HTV-2 envelope pseudotypes of MLV.
Abrogation assay set-up was modified to prevent receptor interference when MLV 
pseudotypes with HTV-2 Envs were used as the saturating doses with HIV-1 and HIV-2 
challenge titrations (fig 2.6; results chapter 5, figs 5.6, 5.7, 5.8). The binding of gpl20 
has been reported to result in down modulation of CD4 receptor at the stage of HIV 
entry (Cefai et al., 1992). The HIV indicator doses were plated on ice for 1 hr, later, 
equivalent saturating doses of MLV(HIV-2) (104 pg/ml RT activity per well) were 
added for a further 30 min. Abrogations were incubated at 37°C for 3 hr, media was 
replaced with normal growth media and fixed and stained for HIV infection 3 days later.
Reciprocal abrogations were conducted as above except indicator dose titrations of 
MLVeGFp(HIV-2) were plated for 1 hr and saturating doses of control and HIV-2 
pseudotypes MCR(MCR), MCN(MCN) and MCR(VSV) (104 pg/ml RT activity per 
well) were plated for a further 30 min on ice (fig 2.6). The MCR and MCN backbones 
contained a stop codon before env to prevent further rounds of replication and 
cytopathic effect when saturating doses of HTV-2 were added to indicator cells. 
Abrogations were detected by flow cytometry 3 days later.
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“Saturating dose”
“Indicator/challenge do se” 
HIV-2 MCR,
HIV-1 89.6
Figure 2.6. Abrogation experiment design for preventing receptor interference by 
saturating doses of HIV-2 envelope pseudotypes of MLV.
To prevent down regulation o f CD4 receptor by MLV vectors with HIV-2 Envs both the challenge HIV-1 
and HIV-2, and the saturating MLV(HIV-2) virus doses were bound to the target cells on ice. The 
challenge virus titrations were plated first to prevent occlusion o f available receptor by saturating 
MLV(HIV-2) viruses. Dashed line separates the different outcomes (right) with and (left) without 
MLV(HIV-2) saturation (chapter 5; fig 5.6, 5.7, 5.8). Lv2 restriction factors are shown in red.
2.5 Detection o f infectivity
2.5.1 Immunostaining of HIV-2- and HIV-l-infected cells and calculation of 
restriction.
The immunostaining method has been described previously (Schmitz et al., 2004). 
Briefly, methanol-acetone (l:l)-fixed cells infected with HIV-2 or HIV-1 were 
immunostained with HIV-2 HS diluted 1/4,000 or anti-HIV-1 p24 monoclonal antibody 
diluted 1/100 (1:1 mix of EVA 365 and 366 from the Medical Research Council AIDS 
Reagent Program, Potters Bar, United Kingdom). Second-layer 6-galactosidase
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conjugates of goat anti-human immunoglobulin G (HIV-2) or goat anti-mouse 
immunoglobulin G (HIV-1) were used to detect first-layer antibodies at a dilution of 
1:400 (Southern Biotechnology Associates, Inc., Birmingham, Ala.). Infected cells were 
stained blue with X-Gal (5-bromo-4-chloro-3-indoyl-6-galactopyranoside) in PBS 
Containing 3 mM potassium ferri-cyanide, 3 mM potassium ferro-cyanide, and 1 mM 
magnesium chloride. Foci of infection, which stained blue, were counted, and virus 
infectivity was estimated as FFU per millilitre (FFU/ml). The restriction (n-fold) is 
calculated as the ratio of infectivity of unrestricted to restricted cells (unrestricted + 
restricted).
2.5.2 Flow cytometry.
Flow cytometry was used to detect eGFP transduced into cells by retroviral vectors. 
Cells were plated on 24 or 48 well trays and challenged the following day with 
retroviral vector pseudotypes. Cells were washed with 200 pi 1:5000 versene (Gibco™) 
3 to 5 days post-transduction, detached with a further 200 pi 1:5000 versene, and fixed 
with 200 pi 3.8% formol saline for 20 min at room temperature. At this stage cells were 
deemed safe to remove from the containment level 3 suite and detect eGFP on a Becton 
Dickinson FACScan flow cytometer at containment level 1.
2.53 Reverse transcriptase enzyme linked immunosorbent assay.
RT ELISA kits were purchased from Caviditech. ELISA plates (96 well) are prebound 
with poly-rA and an oligo-dT primer. The poly-rA serves as a template for the sample 
virus RT to build the new DNA strand with bromo-deoxyuridine-triphosphate (BrdU). 
An anti-BrdU mAb conjugated to alkaline phosphatase (AP) detects the nascent BrdU 
strand. This is a colorimetric assay that detects the AP cleavage of para-nitro-phenyl 
phosphate at 405 nm.
2.5.4 Detection of infectivity by gag-LTR polymerase chain reaction (see 
polymerase chain reaction).
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2.6 Polymerase chain reaction
2.6.1 Polymerase chain reaction of HTV-2 sequences from HIV-2 infected 
macrophages.
For gag-LTR and ERV-3 polymerase chain reaction (PCR), MDM were set-up as for 
MDM time-courses (described in ‘infectivity assays’) except the viruses were treated 
with 25 U DNase (Roche) per 0.5ml vial of virus before dilution and incubation with 
cells. At the appropriate time-point the infected or negative control uninfected MDM 
were washed once with versene 1:5000, incubated for 10 min in versene 1:5000 at 
37°C, and harvested by scraping. The mixture was centrifuged at 4000g for 5 min, the 
supernatant was removed, and the cell pellet was stored at -20°C.
DNA was prepared from harvested MDM with the Qia-amp Blood and Tissue Mini Kit 
(Qiagen°). Briefly, cells were spun and resuspended in 200pl of PBS. After addition of 
Qia-amp lysis buffer and proteinase K the cells were digested at 56°C for 3 hr. DNA 
was ethanol precipitated and washed twice on a Qia-amp column, and then eluted in 
lOOpl of distilled water.
2.6.2 gag-LTR polymerase chain reaction.
PCR reactions were run using 5 pi of DNA from a DNA extraction of 1.5 x 106 MDM 
(approximately 250 ng of cellular DNA). The 5' gag-LTR primer 2713 (5- 
TCTCTCCAGCACTAGCAGGTAGAG) is complementary to a sequence in 'R' of the 
HIV-2 LTR. The 3' gag-LTR, 2715 (5'-CAAGACGGAGTTTCTCGCGCCCAT) 
primer is complementary to a sequence within HTV-2 gag. The gag-LTR primers 
measure full-length transcripts of reverse transcription and integrated HTV-2 provirus 
(529-bp fragment). The 5' and 3' ERV-3 primers detect sequences within the env region 
of the human endogenous retrovirus ERV-3 (ERV-3 forward 5'- 
GAGGCATAACTATAGGAGATTGG, ERV-3 reverse 5'-
CCTTTCCAAGTCTGAACTG; 404bp fragment). There is one copy of ERV-3 per 
haploid human genome and therefore ERV-3 PCR acts as a cellular DNA input control 
(Cohen et al., 1985; O'Connell et al., 1984). The gag-LTR reactions were carried out 
with the Roche High-Fidelity PCR system. For a 50 pi reaction the concentrations of
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the reaction components were as follows: buffer 3 (undisclosed concentration of 
DMSO, Tween-20, and Nonidet-P40 to minimise secondary structure) containing 2.75 
mM final concentration MgCh, 1 pmol of each primer, dNTPs were added to a final 
concentration of 4 mM, and 1.75 U of Taq polymerase per reaction. Roche buffer 3 was 
Used to minimise template secondary structure and aid in the amplification of viral 
reverse transcription products. Conditions for gag-LTR PCR were as follows: 4 min at 
94°C, followed by 35 cycles of 94°C for 1 min, 65°C for 1 min, 68°C for 1.5 min. 
Conditions for ERV-3 PCR were as follows: 4 min at 94°C, followed by 35 cycles of 
94°C for 45 s, 60°C for 45 s, 68°C for 45 s. PCR products were run on a 2% agarose 
gel and viewed under UV. The gag-LTR PCR products ran at approximately 0.5 kbp 
and the ERV-3 PCR products ran at approximately 0.4 kbp. An elongation temperature 
of 68°C was chosen because this is the optimal temperature for the Taq Extender 
proofreading activity.
2.63 GAPDH polymerase chain reaction.
The forward (5 ’-TGGTGAAGACGCCAGTGG) and reverse (5’- 
ATGGGGAAGGTGAAGGTC) GAPDH primers were used to detect equal cDNA 
input for RT-PCR (below). The annealing conditions were as follows: 4 min at 94°C, 
followed by 35 cycles of 94°C for 30 s, 60°C for 30 s, 74°C for 30 s.
2.6.4 Reverse transcriptase polymerase chain reaction.
RT-PCR to measure gag-LTR RNA transcripts was conducted on MDM infected with 
HTV-2 JAU and HIV-1 SF162. MDM in 6-well trays were incubated with equivalent 
input (5.0 x 103 FFU) of either JAU or SF162 for 3 hr, time points were harvested eveiy 
24 hr up to and including 5 days post-infection. The infected MDM were harvested 
with Trizol® RNA extraction reagent and the cDNA was prepared. Cells for RT-PCR 
were washed once in PBS and dissolved in-situ with 1ml of Trizol® (Gibco-BRL) RNA 
extraction reagent. RNA was extracted as per manufacturers instructions. Briefly, 
extracted RNA was quantified spectrophotometrically by measuring the absorbance at 
260 nm. One pg of total RNA was DNase treated for 30 min at 37°C. To remove RNA 
secondary structure and to inactivate the DNase, two fifths of the DNase treated RNA 
was heated at 75°C for 10 min in the presence of DNase stop solution and random
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primers, then put on ice. The RNA was added to a mixture that was either RT positive 
or negative (to control for contaminating DNA). RT reactions, plus or minus RT, were 
incubated at the RT reaction temperature of 42°C for 1 hr. Two pi of each RT reaction 
was put into a 50 pi GAPDH and gag-LTR PCR reaction and subject to the PCR 
conditions as mentioned in ‘polymerase chain reaction*.
2.6.5 Quantitative polymerase chain reaction.
U87/CD4/CXCR4, H399, and HeLa/CD4 cells were seeded in 24 well trays at 5 to 8 x 
104 cells per well and treated with 5.0 x 103 FFU (determined on U87/CD4/CXCR4) of 
either MCN or MCR pie-treated with DNasel (Roche) for 1 h at 37°C. 100 ng of total 
DNA was used for qPCR with primers: For HTV-2 gag-LTR: 900 nM forward primer 
(S'-CGGCTGAGTGAAGGCAGTAAG-S1), 300 nM reverse primer (5’-
TTGGCCTGCGCCTTTCTA-3'), 150 nM taqman probe (5'-6-carboxyfluorescein-5'- 
CAGGAACAAACCACGACGGAGTGCTC-3'-6-carboxytetramethyl-rhodamine-3'). 
For HIV-1 packaging signal OF), 300 nM forward primer 
(TGGGCAAGCAGGGAGCTA), 300 nM reverse
(TCCTGTCTGAAGGGATGGTTGT) and 150 nM Taqman probe (5'-6-
carboxyfluorescein-AACGATTCGCAGTTAATCCTGGCCTGTT-6- 
carboxytetramethyl-rhodamine-3').
First strand synthesis of the MLV pCNCG was monitored by amplification of the vector 
eGFP cDNA sequence: 300 nM forward primer (5’-
CAACAGCCACAACGTCTATATCAT-3’), 300 nM reverse (5’- 
ATGTTGTGGCGGATCTTGAAG-3 ’) and 150 nM taqman probe (5'-6-
carboxyfluorescein-CCGACAAGCAGAAGAACGGCATCAA-6-carboxytetramethyl- 
rhodamine-3'). The PCR conditions consisted of one cycle of denaturation (95°C for 10 
min) followed by 45 cycles of amplification (95°C for 15 s, 60°C for 1 min). The 
amplification, data acquisition, and analysis were performed using the ABI PRISM 
7000 sequence detection system.
2.7 Cloning of the HJV-2 envelope third variable loop region
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2.7.1 Cloning and sequencing of the HIV-2 third variable loop.
3-5 x 106 PBMC were infected with HTV-2 virus stocks. Three days after infection the 
infected cells were harvested and DNA extracted with the DNA Blood Mini Kit 
(Qiagen). V3 loops were amplified with primers FI 3418 (5-
GGTTTGGCTTTAATGGCACTAGAG) and F13420 (5'-
TTCTCCTCTGC AGTTAGTCC AC AT) in the HIV-2 V3 region (243-bp fragment). 
The amplified product was purified from ethidium bromide-containing 1% agarose gel 
with the Qiagen Agarose Gel Extraction kit. The V3 region was cloned into pGEM-T 
easy with the pGEM-T easy TA cloning kit (Promega, Madison, WI, USA). Clones 
were screened and sequenced with primers F13418 and F13420. Sequencing was 
carried out with the CEQ-DTCS Beckman Coulter Quick Start kit (Beckman-Coulter, 
Fullerton, CA, USA). The V3 loops from HIV-2 isolates were sequenced from at least 
3 clones or directly from PCR product
Direct sequencing of PCR reactions of the HIV-2 isolates was used to confirm the 
cloned sequences. Briefly, the V3 region was amplified with primers FI3418 and 
FI3420, the product was analysed on an ethidium bromide-containing 1% agarose gel, 
extracted with the Qiagen PCR extraction kit and then sequenced (see 'Cloning and 
sequencing of V3 loops' above).
V3 loop sequences were aligned using the Clustal nucleic acid sequence alignment 
program.
The net charge of each of the V3 loops was estimated from the amino acid sequence by 
totalling the number of positively charged Arginine, Lysine, and Histidine residues and 
then subtracting the number of negatively charged Aspartate and Glutamate residues.
2.7.2 Sequencing sample preparation for Beckman CEQ-2000.
Mini-prep DNA was prepared for sequencing by the dye-labelled-dideoxy-nucleotide 
chain termination method. For each sequencing reaction 6 pi of premix was added to 5 
pmol of primer (T7 and SP6 of pGEM-T easy or F13418 and F13420) and 1 pi of a 50 
pi plasmid miniprep and made up to a total of 10 pi with water. Reactions were run on
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an MJ PCR thermocycler for 24 cycles at the following conditions: 96°C for 30 s, 50°C 
for 15 s, 60°C for 4 min, and finished at 4°C.
Sequencing samples were cleaned-up after the labelling reaction. Fifteen pi of premix 
(2 pi 3 M cold NaOAc, 2 pi 100 mM EDTA, 1 pi glycogen, and 10 pi of water) was 
added to each sample and mixed. Sixty pi of -20°C 95% ethanol was added to each 
tube and vortexed. Samples were left on ice for 10 min then centrifuged at room 
temperature for 15 min to promote the sticking of precipitated DNA to the sample tube. 
Supernatant was removed and 200 pi -20°C 70% ethanol was added for 10 s to wash 
pellet Tubes were left open on bench for 30 min to dry. Pellets were dissolved in 
deionised formamide. Samples were loaded into sequencing plates and overlayed with 
a drop of oil.
2.8 Maxi-prep o f plasmid stocks
2.8.1 Transformation of bacteria.
HB 101 or TOP F10’ bacteria were mixed with plasmid DNA on ice and transformed by 
heat shock at 42°C for 30 s. Transformed bacteria were plated on LB agar plates 
supplemented with 100 pg/ml ampicillin for selection of transformants, or 50 pg/ml 
kanamycin for pEGFP-Cl/C2 (Clontech™) plasmids. Colonies were picked and 
minipreps (Qiagen) were performed on 5 ml overnight cultures of inoculated LB-broth 
with 100 pg/ml ampicillin.
2.8.2 Restriction enzyme digest of plasmid stocks.
Restriction enzyme digests were performed on die above minipreps to confirm the 
identity of transformed plasmid DNA. Digests were performed on 1 pg of total DNA 
with 10 U of restriction enzyme per reaction, between 37 and 65°C (depending on the 
restriction enzyme) for 1 hr. Restriction products were run on a 1.5 % agarose gel for 2 
hr at 60 V and the digestion pattern was compared to that of a positive control run in 
parallel (if available) or the predicted pattern.
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2.83 Hi-speed plasmid maxi kit.
Positive HB 101, TOP FI O’ or STBL 2 bacteria colonies were repicked and plasmid 
stocks were grown using LB culture broth at 37°C (or 30°C for STBL 2) overnight. All 
plasmid-transformed bacteria were grown-up in approximately 150 ml of LB broth, 
except 250 ml for low copy plasmids [pMDG (VSV-G)], with 100 pg/ml ampicillin or 
50 pg/ml kanamycin. Maxi prep was performed as per manufacturers instructions for 
the Hi-speed plasmid maxi kit (Qiagen). Concentration and quality of plasmid DNA 
was determined by the absorbance at 260 nm and the 260/280 nm ratio, respectively, on 
an ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
2.9 Subcellular fractionation
2.9.1 Preparation of cell lysates.
The preparation and fractionation of cell lysates were carried out on ice unless 
otherwise stated. Cells (1.0 x 107 to 5.0 x 107) were harvested with versene 1:5 000 
(Gibco™) and then washed twice with PBS. The cell pellet was resuspended in 1 ml 
hypotonic HEPES-h buffer, Roche EDTA free complete anti-protease pellet, pH 7.9 at 
4°C and centrifuged for 5 min at 5000 rpm (500g) and 4°C in a Fischer refrigerated 
microcentrifuge. 300 pi 1% Triton X-100 HEPES-h buffer was added to the cell pellet, 
left for 30 min on ice, then homogenised with 10 strokes of a Dounce homogeniser. 
The homogeniser was washed with 100 pi of 1% Triton X-100 HEPES-h buffer and 
added to the lysate. To remove nuclei, the lysate was spun at 2000 rpm (300 g) for 3 
min and 4°C, then the supernatant containing cell membranes was transferred to a new 
tube. Nuclei were stored at -20°C for PCR and western blot. The resulting cell lysate 
was loaded onto a sucrose gradient.
2.9.2 Isolation of lipid rafts by sucrose gradient fractionation.
Four hundred pi of cell lysate was mixed with 800 pi 60% sucrose in HEPES-h buffer 
(w/v) to make a 40% sucrose/lysate solution. One hundred pi of the sucrose/lysate 
solution was stored at -20°C as a total membrane input fraction. Sucrose gradients 
consisted of 3 ml of 5%, 6 ml of 36% sucrose (w/v) in HEPES-h on top of 900 pi of
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sample lysate in 40% sucrose 1% Triton X-100 HEPES-h buffer. The gradients were 
loaded into 17ml Sorvall centrifuge tubes as follows: 3 ml of 5% sucrose was added to 
the bottom of the centrifuge tube first, 6 ml of the 36% sucrose was pipetted below, and 
the 1100 pi sample fraction was added last Centrifuge tubes were loaded onto a Sorvall 
§urespin 630 rotor and spun at 100 OOOg for 20 hr at 4°C in a Sorvall Discovery 100S 
centrifuge. One ml Fractions were collected from the top of the tube with a 'trimmed* 
PI000 Gilson pipette tip and stored at -20°C for western blot, slot blot, or PCR. The 
lipid raft fraction was isolated from fraction 3 to 5 that manifested as a flocculent 
(wispy) band at the 5%-36% sucrose interface.
2.93 Sodium dodecyl sulphate polyacrylamide gel electrophoresis.
Fractionations were screened for the presence of cell proteins by SDS polyacrylamide 
gel electrophoresis (SDS-PAGE) and Western blot. Samples were mixed with 6X 
loading buffer (0.25 M TRIS-C1 pH 6.8, 50% glycerol, 5% SDS, 0.2% bromophenol 
blue, 5% P-mercaptoethanol), heated at 90°C for 3-5 min, loaded onto a 3% stacking gel 
(8% acrylamide (40% acrylamide/bisacrylamide (37.5:1) Biorad), 0.1 M TRIS-C1 pH 
6.8, 1.0% SDS, 0.2% TEMED, 0.2% APS) and resolved on a 15% resolving gel (37% 
acrylamide (40% acrylamide/bisacrylamide (37.5:1) Biorad), 0.4 M TRIS-C1 pH 8.8, 
0.1% SDS, 0.1% TEMED, 0.05% APS) beside a Benchmark™ prestained protein 
ladder (Invitrogen™). Gels were run on a Hoefer Mighty Small II SE 250 (Hoefer 
Scientific Instruments©, Inc., California, USA) in protein electrophoresis buffer (250 
mM TRIS, 2 M glycine, 0.1% SDS) at 25 mA per gel and 70 to 100 V until the sample 
front reached the bottom of the gel.
2.9.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis of tripartite 
motif proteins.
Trim proteins were resolved in polyacrylamide gels as above except for the following 
changes: samples were dissolved directly in 2 X loading buffer, sonicated for 10 min in 
a Decon F5 minor sonicating water bath (Decon ultrasonics, Hove Sussex, England), 
and stored at -20°C. When the samples were needed they were boiled for 10 min at 
95°C, sonicated for a further 10 min and loaded onto a polyacrylamide gel.
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2.9.5 Western blot.
Proteins were transferred to PVDF (poly-vinyl-difluoride) membrane in a Mini Trans- 
Blot Cell (Biorad Laboratories0) as per manufacturers instructions. The ( 8 x 6  cm) 
PVDF membrane was activated in methanol then soaked in protein blotting buffer (250 
eiM TRIS, 2 M glycine, 10% ethanol) for 5-10 min. The running gel was separated 
from the stacking gel, placed on the activated PVDF membrane, and sandwiched 
between four pieces of pre-wet 3MM Whatman filter paper (10 x 7.5 cm). This 
assembly was placed in the blotting cell and blotted for 3 hr at 250 mA and 200 V or 
overnight at 125 mA and 50 V at 4°C.
The membrane was removed from the blotting assembly and washed briefly in PBS 
then blocked in PBS, 0.1% TWEEN 20, 5% powdered milk (w/v) for 1 hr with shaking. 
The membrane was incubated with primary antibody diluted 1/500-1/2000 in PBS, 
0.1% TWEEN 20, 5% powdered milk (w/v) for 45 min to 1 hr. The membrane was 
washed 3 x 10 min in PBS, 0.1% TWEEN 20. The horseradish peroxidase-conjugated 
secondary antibody was added at a dilution of 1/2000 in PBS, 0.1% TWEEN 20, 5% 
powdered milk (w/v) for 45 min to 1 hr. The final three washes were done in PBS, 
0.1% TWEEN 20 for 10 min each. The last wash was done in PBS only. ECL™ 
detection substrate and Hyperfilm ECL™ (Amersham Biosciences0) were used for film 
detection and ECL-Plus™ substrate was used for detection of Western blots on a Storm 
860™ (Molecular Dynamics).
2.9.6 Slot blot of fractions derived from sucrose gradient centrifugation.
Dot blotting was used to screen sucrose gradient fractions for lipid raft associated 
proteins and lipids, as per manufacturers instructions. Briefly, a Bio-Dot SF 
microfiltration unit (Bio-Rad) was set-up using Bio-Dot SF filter paper and Amersham0 
Hybond-ECL Nitrocellulose membrane as this yielded the best results. The blotting 
membrane and filter paper were pre-wet in TBS before mounting onto blotting unit. 
The membrane was washed by drawing 200pl of TBS through each well under suction. 
An aliquot of each sample was diluted 1/10 in 200pl TBS, drawn through, then washed 
with 200|d TBS. The membrane was removed from the blotter, washed in TBS for 10 
min, and antibody detection was carried out as for a western blot and detection and
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densitometry were done on a Storm 860™ (Molecular Dynamics) and ImageQuant 
software.
2.10 Microscopy
2.10.1 Intracellular antibody staining for major histocompatibility complex class I 
protein.
HeLa cells were seeded on coverslips. The following day, cells were fixed in freshly 
prepared solution (3% paraformaldehyde, 60 mM sucrose, 0.1 M sodium phosphate pH
7.2) for 30 min at room temperature. After three washes in PBS for 5 min, cells were 
washed with PBS 20 mM glycine for 5 min, permeabilised in PBS 20 mM glycine 0.1% 
saponin for 10 min at room temperature, washed with PBS 20 mM glycine for S min 
and blocked with PBS 20 mM glycine 1% bovine serum albumin (BSA) for 10 min at 
room temperature. Incubation with primary antibodies was done in blocking solution for 
1 h at 37°C. After washing in PBS glycine for 5 min cells were incubated with 
secondary antibodies (donkey antimouse-FITC) in blocking solution for 45 min at 37°C. 
Finally, cells were washed for 10 min in PBS and mounted with mowiol (Calbiochem) 
and analyzed by confocal microscopy (MRC 1024 (BioRad, Hercules, CA, USA) 
equipped with a krypton-argon laser). Pictures were acquired using Kalman averaging 
and analysed with Lasersharp software (BioRad). .
2.10.2 Immunofluorescence microscopy.
Cells were visualised after treatment with either FITC-conjugated transferrin (Trf-FITC) 
or FITC-conjugated cholera toxin B subunit (CTxB-FITC). Slides were mounted with 
immunofluorescence mounting medium (Dako, Carpinteria, CA, USA) and observed by 
confocal microscopy [MRC 1024 (BioRad, Hercules, CA, USA) equipped with a 
krypton-argon laser]. Pictures were acquired using Kalman averaging and analysed with 
Lasersharp software (BioRad).
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2.11 Antibodies
Table 2.7. Antibodies.
Specificity/
(target)
Source/ Ab type Assay Dilution Company Catalogue
no.
Actin Rabbit pAb WB 1/2000 Sigma A-5060
CD4 (Q4120) Mouse mAb SB 1/2000 ARP ARP318
GM1 (CTxB) CTxB-Blotin (ligand) 
CTxB-FITC
SB
IF
1/4000
1/1000
Sigma
C9972
C1655
HIV-1 (p24CA) Mouse mAb IS 1/100 ARP EVA 365, 366
HIV-2 antiserum Human pAb IS 1/4000 HIV-2 patient N/A
huMHC-l Mouse mAb IF 1/200 Serotec MCA81
MID 1(TRIM 18) Rabbit pAb WB 1/1000 Orbigen PAB-11697
MID 2(TRIM 1) Goat pAb WB 1/1000 Imgenex IMX-3087
PIAP Mouse mAb WB/SB 1/2000 Sigma A2951
RNF 21 (TRIM 34) Goat pAb WB 1/1000 abeam ab4509
Transferrin (TrfR) Trf-FITC (ligand) IF 1/1000 Sigma T0288
HA tag Mouse mAb WB 1/3000 Sigma H9658
pAb ■ polyclonal antibody; mAb * monoclonal antibody; CTxB ■ Cholera toxin binding 
subunit; ARP ■ AIDS reagent program, NIBSC, Potters Bar, UK; huMHC-l ■ human MHC-I, 
N/A * not applicable; PIAP * placental alkaline phosphatase; TrfR * transferrin receptor; 
WB ■ western blot; SB * slot blot; IF ■ immunofluorescence.
2.12 Statistical analysis
The mean and the standard deviation of the mean (SDM) were calculated using 
Microsoft Excel.
The Spearman's rank coefficient was calculated for HTV-2 V3 loop charge versus MDM 
tropism as in fig 2.7. The Spearman’s rank coefficient tool was used to calculate Rs: 
http://faculty.vassar.edu/lowry/corr__rank.html.
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H0: there is no correlation between HIV-2 V3 loop charge 
and HIV-2 MDM tropism
Ha: there is a negative correlation between HIV-2 V3 
loop charge and HIV-2 MDM tropism
X: V3 lo o p  
c h a r g e
Y: MDM 
tro p is m
7 6 7 6 8 8 9 8 8
0.03 9.043 9.009 0.004 0.003 0 0.010 0.0001 0.0004
X: R a n k 3.5 1.5 3.6 1.5 6.5 6.5 9 6.5 6.5
Y: R a n k 9 4.5 7 6 4.5 1 8 2 3
d 6.5 3 3.6 4.6 2 5.5 1 4.5 3.5
d> 30 .2 S • 12 .25 20 .26 4 3 0 .26 1 2 0 .26 12 .26
61 d2
d2 ■ the difference between each set of ranks, 
squared * 139.5
R, ■ -0.1625
Where
Rs * -1 to -0.5 ■ strong negative correlation 
Rs < 0 to -0.5 * weak negative correlation 
Rs * 0 ■ no correlation
Figure 2.7. Spearman rank coefficient for HTV-2 third variable loop charge versus 
macrophage tropism.
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HTV macrophage tropism and a post-entry restriction to HIV infection 
in human cells
3.1 Introduction:
HIV-1 HIV-2 both cause AIDS. However HIV-2 causes a slower mean progression to 
disease and is less transmissible than HIV-1 (Marlink et al., 1994). HTV-2 infection is 
found primarily in West Africa (Wilkins et al., 1993) (Pfutzner et al., 1992; Piedade et 
al., 2000). In contrast, HIV-1 infection is found worldwide with particularly high 
prevalence in sub Saharan Africa. UNAIDS report that at the end o f2004 there were 42 
million people living with HIV-1 infection globally (UNAIDS, 2004).
Both viruses use CD4 and a 7-TM coreceptor to gain entry into cells but HTV-2 can use 
a broader spectrum of coreceptors than HTV-1 in vitroy including CCR1, CCR2b, CCR3, 
CCR5, and CXCR4 (Alkhatib et al., 1996; Clapham and McKnight, 2002; Deng et al., 
1996; Maddon et al., 1986; Sattentau et al., 1988). It is likely that CCR5 and CXCR4 
are the most important for infection of primary cells but other coreceptors may be used 
at a lower efficiency (McKnight et al., 1998; Momer et al., 2002).
The HTV-1 and HIV-2 Envs are made up of conserved Cl through to C5 and variable 
VI to V5 domains. The HTV-1 third variable loop (V3 loop) acts as a determinant of 
cell tropism and is the principle neutralising determinant in laboratory isolates (Hwang 
et al., 1991; Hwang et al., 1992; Javaherian et al., 1990; McKnight et al., 1995; 
Westervelt et al., 1992). HTV infection normally begins with slow replicating and low 
titre viruses termed slow/low. A poor prognosis and declining CD4 counts are later 
associated with the appearance of rapid replicating, high titre viruses termed rapid/high. 
There is evidence that the HIV-2 V3 loop is an important neutralisation domain as well 
and an increase in the net positive charge of the V3 loop has been associated with an 
increase in the rapid/high from a slow/low phenotype, of HIV-2 isolates (Albert et al., 
1996; Bjorling et al., 1994)(McKnight, 1995). Isaka et al demonstrated that basic amino 
acid substitutions in the C-terminal half of the HIV-2 V3 loop would cause a coreceptor
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switch from CCR5 to CXCR4 (Isaka et al., 1999). However, it is not known if HIV-2 
coreceptor use or V3-loop charge is associated with cell tropism as it is with HIV-1.
HIV-1 infection of M0s has been well documented both in vitro and in vivo (reviewed 
hy (Martin and Bandres, 1999). The first HTV-1 viruses to emerge in the host are M0 
tropic (M-tropic), CCR5 using, probably because during transmission, CCRS expressing 
M0s and DCs, resident in the mucosae, are the first likely targets. Although there are 
some exceptions, HTV-1 M0 tropism results from the ability to use CCR5 as a 
coreceptor. Like mucosal transmission, M0 tropic CCR5 using viruses isolates emerge 
in preference to CXCR4 using T cell tropic isolates, during intravenous transmission of 
HTV-1. In this case it is speculated that both T cell tropic and M0 tropic isolates are 
transmitted but the isolates that infect M0s flourish. It has been proposed that the 
transmitted M0 tropic virus pool facilitates CTL escape (Schutten et al., 2001), 
((Schuitemaker, 1994). It has been demonstrated that HTV-2 can infect both MDMs and 
T cells in vitro but it is not known what role M0s play in HTV-2 infection (Castro et al., 
1990; Valentin et al., 1994) and the relevance this has to HIV-2 transmission is 
unknown.
In about 50% of untreated HTV-1 subtype B infections there is a switch from M0 tropic, 
CCR5 using viruses to T cell tropic, CXCR4 using viruses. The change in cell tropism 
and coreceptor usage of HTV-1 is often accompanied by a poor prognosis and 
progression to AIDS (Nielsen et al., 1993). The picture for HTV-2 is less well explained 
but one study shows that HTV-2 isolates taken from AIDS patients use CXCR4 whereas 
isolates from asymptomatic patients use CCR5 and CCR3 (Blaak et al., 2005; Sol et al.,
1997). Thus HTV-2 may follow the same coreceptor switch during infection. Whether 
the switch from CCR5 to CXCR4 usage in HTV-2 infection is associated with a switch 
from M-tropism to T-tropism is not known.
The elevation in HIV-1 or HTV-2 RNA plasma viral load is associated with the decline 
in the CD4 count that is the hallmark of the onset of illness (Schuitemaker et al., 1992) 
(Damond et al., 2002). It appears that the CD4 count of patients with HIV-2 remains 
higher than the CD4 count of patients with HIV-1 regardless of recent sero-conversion 
or development of AIDS (Andersson et al., 2000).
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All of the Lentiviruses have a propensity to replicate in M0s and indeed there are 
Lentiviruses that mediate their infection and pathogenicity solely through these cells. 
The non-primate Lentiviruses Maedi-Visna Virus, Caprine-Arthritis Encephalitis Virus, 
and Equine Infectious Anaemia Virus (EIAV) all mediate their pathogenesis by 
infecting M0s. HIV uses M0s as a key infectable cell type and so the propensity of 
HTV-1 and HIV-2 to infect M0s may be a pathogenesis determinant.
In this chapter I characterise the replication of HTV-2 primary isolates in M0s and T 
cells from PBMC and compare it with HTV-1. Thus by comparing the M0 tropism of 
HTV-1 with the less pathogenic HIV-2 this study may provide insight in to why HIV-1 
is significantly more pathogenic than HIV-2. MDM infected with HIV-2 primary 
isolates produced an early and brief burst of replication, followed by a latency, without 
rebound at later time points whereas HTV-1 primary isolates showed a delayed burst of 
replication in MDM but showed stable virus production over 21 days. The V3 loop 
amino acid charges of the HTV-2 isolates were calculated from the sequences and there 
appeared to be an association with coreceptor usage and a weak negative correlation 
with M0 tropism, similar to HTV-1.
3.2 Results:
3.2.1 HTV-2 primary isolates, compared to HIV-1, exhibit poor replication in 
monocyte-derived macrophages.
Infection of MDMs by both R5 and X4 HTV-1 primary isolates has been previously 
described (Clapham PR, 2001; Eckstein et al., 2001; Valentin et al., 1994; von Briesen 
et al., 1990). First I determined how well HTV-2 primary isolates infect MDMs. I 
directly compared the infection of MDM to PBMC by HTV-1 and HIV-2. The viruses 
used here represent a broad range (table 3.1); a spectrum of HIV-2 primary isolates was 
selected that use CCR5, CXCR4, or both coreceptors. The HIV-1 primary isolates 
chosen also have a broad spectrum of coreceptor use and M0 tropism (McKnight et al.,
1998), (Reeves et al., 1999) and (Simmons G, 1998). Supernatants were harvested and 
RT activity was determined by RT-ELISA (Caviditech). TCID50 for each virus was
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determined on both MDMs and PBMC at 21 and 14 days post-infection, respectively, as 
has been described for HIV-1 (fig 3.1a) (Simmons G, 1996).
The HTV-1 isolates efficiently infected MDM whereas the HIV-2 isolates did not, even 
though HIV-2 had higher titres on PBMC. HTV-2 MIL and SAB had TCID50S on 
PBMC of 5.6 x 105 and 8 .6  x 105 respectively, compared to the HTV-ls 2028 and 2076 
that had TCIDsos on PBMC of 2.2 x 105. HTV- 2  was approximately 1 to 2 logs less 
infectious for MDMs than any HIV-1 isolate (fig 3.1a). HIV-2 TER shows the highest 
HIV-2 TCID50 on MDM of 2 .8  x 102 and the lowest TCID50 is that of HTV-2 MLC, 3.6 
x 10*. PrCBL 23 does not have a TCID50 that can be calculated from MDM infection 
since no infection could be detected. This is in contrast to HTV-1 where the lowest 
TCID50 on MDM is SL2,1.0 x 103, the highest is 7.4 x 104 of2076.
To better compare HTV-2 MDM infection the ratio of M0 to PBMC tropism was 
determined from the values in fig 3.1a. The value of the MDM TCID50 was divided by 
the PBMC TCID50 for each isolate and the relative M0 tropism values were plotted (fig 
3.1b). The most ‘macrophage tropic’ HTV-2 was Ali, and then in order of descending 
M0 tropism were MIR, AND, ST, JAU, TER, ETP, MLC, SAB, and MIL. PrCBL 23 
could not infect MDM even when titres of 104 TCID50 were reached on PBMC.
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Figure 3.1. HIV-2 is less efficient at infection of monocyte derived macrophages 
than HIV-1.
(A) Tissue culture infectious dose 50s per ml (TCID5 0/ml) of HIV-2 and HIV-1 primary isolates on MDM 
and PBMC, harvested at 21 days (MDM) and 14 days (PBMC) post-infection. Coreceptor use is 
indicated (see table 3.1). HIV replication was detected by RT ELISA. (B) Tropism scatter plot. To 
illustrate the difference between HIV-2 and HIV-1 M0 tropism a scatter plot was made from the PBMC 
and MDM TCID50s from fig 3.1a. This plot was constructed by dividing the MDM TCID5 0 by the PBMC 
TCIDso. As previously described (Simmons G, 1996).
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Table 3.1. CCR5 and CXCR4 coreceptor use of HIV-1 and HIV-2 primary
isolates.
Isolate Corsoaptor(s) 
CCR5 (R5), 
CXCR4 (X4)
Preferred
coreceptor
Titre on 
NP2/CD4/CXCR4 
(FFU/ml)
Titre on 
NP2/CD4/CCR5 
(FFU/mO
HIV-2
MLC R6 R5* 0 1.0 x104
TER R6+ R1.R9.CXdM 0 4.5 x 104
ALI RS+ r i 0 4.0 x 104
JAU R6/X4+ R1, R2t>, 
RS.RS
5.0x10* 5.0x10*
ST R5/X4+ R1, R2b, RS NT NT
ETP R5/X4+ R1, R2S. RS 1.0x10* 5.0x102
MIR R5/X4+ R1, R2b, RS 5.5 x104 5.0x102
PrCBL-23 R5/X4+ R1, R2b. RS 4.0x10* 5.0 x 10*
MIL X4 2.3 x104 0
SAB X4+ r s i r 4.0 x104 0
AND X4+ R1.R2S.RS X4 1.0x10* 0
HIV-1
SF162 R6 Ri »• 0 2.5 x 10*
SL-2 R6 0 1.0x10*
2076 R5/X4+ r s .  r s .
8TRL-33, OPR-15
2.0 x104 1.8 x104
2028 R6/X4+ RS. RS.
STRL-33, GPR-15 1 r
7.5 x 104 7.3 x 104
2044 X4 Xl 7.8 x104 0
'+’ denotes additional coreceptor use as determined previously 
(Reeves et al, 1999; McKnight et al, 1998; Neil et al, 2005), 
NT=not tested, Coreceptor shown in bold denotes predominant 
use of that coreceptor.
3J2J2 Like HIV-1, the third variable loop charge on the HTV-2 envelope may be 
associated with HIV-2 macrophage tropism.
I set out to determine if the V3 loop charge of HTV-2 is associated with M 0 tropism 
because it has been shown that HIV-1 tropism, coreceptor usage, and V3 loop charge 
are associated (Bieniasz et al., 1997; Kuiken et al., 1992; Shioda et al., 1992). A high 
V3 loop charge on all of the HIV-2 isolates used in this study it may explain the lack of
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M 0 tropism of HIV-2. DNA was harvested from HIV-2 infected PBMC 48 hr post­
infection and the V3 loop region was sequenced from the HIV-2 proviral DNA. The 
number of negatively charged amino acids were subtracted from the positively charged 
amino acids, between the V3 loop cysteines, to obtain the net V3 loop charge. Table
3.2 illustrates how the coreceptor usage of the HIV-2 primary isolates studied is 
associated with the amino acid charge, ranging from +6 to +10, on the Env V3 loop. 
The charge increase is seen primarily in the C-terminal half of the loop and is associated 
with increased CXCR4 use by HIV-2. ETP was the only HIV-2 isolate that exhibited a 
negatively charged amino acid. There is no consistently high V3 loop charge pattern 
but a spectrum of charges.
Table 3.2. HIV third variable loop sequences, charge and coreceptor usage.
HIV-2 Coreceptor* V3 Sequence*? V3 Charge
ALI R5 + c
MLC R5 c
ST R5/(X4) + c
JAU R5/X4 + c
ETP (R5)/X4 + c
PrCBL20 X4/(R5) + c
PrCBL23 X4/(R5) + c
MIR X4/(R5) + c
MIL X4 c
SAB X4 + c
A-nd X4 + c
C^PGNBTWPITlMSGLIFE|SQPINiS-Bp(SQAWC
SQPINN-
SQPLNT P30AWC
30AWC
Q P IIS -
S9PVIN
9Mpcnifevvp
HIV-1 Coreceptor V3 Sequencet V3 Charge
SF162 R5 CT gPNNNTj jS ITIG PG ji AFYATG H H H 3qa C +4
GUN-1 wt R5/X4 CT SPNNNT aSITIGSG.jAF 2i i g n i C +7
SF2 X4 C l SPNNNT. I s is t g p g ; Al ITG 3 i i g 8 i t Sa 3!c +5
IIIB X4 CT 2PNNNTj Ss i E iq EgpgE i
HEH
'Up  ... +9
* (R5), (X4) denote at least 10 fold less efficient CCR5 or CXCR4 usage 
than main coreceptor (table 3.1).
t  Sequences from National Centre for Biological Information (NCBI), 
NIH. Accession no: SF162 AY988107, GUN-1 wt D34598, IIIB M64769, 
SF2 K02007
Interestingly, when the coreceptor use of HIV-2 in table 3.1 is compared to the M0 
tropism in fig 3.1b there is a general correlation between CCR5 use and M 0 tropism 
(table 3.2), those that use CCR5 tend to be the most M 0 tropic as indicated by a slight
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downward slope of the regression trend line in fig 3.2. However there are some 
anomalies: MLC uses CCR5 preferentially to CXCR4 but has rated low on the M 0 
tropism scale and MIR, a CXCR4 using isolate with the highest V3 loop charge is the 
second most M 0 tropic HTV-2. Although, all of the HIV-2 isolates tested (except 
prCBL 23) demonstrated some replication in MDM none could replicate to levels 
comparable to HIV-1.
To determine whether HIV-2 V3 loop charge is negatively correlated with M 0 tropism 
I used the Spearman’s rank correlation (materials and methods). Ho states that there is 
no correlation between HIV-2 V3 loop charge and M 0 tropism, and H, states that there 
is a negative correlation between the two. The Spearman’s rank correlation returns a 
coefficient (Rs) of -0.1625. Where Rs=0 there is no correlation, and Rs between -0.5 
and 0 is a weak negative, and Rs between -0.5 and -1.0 is a strong negative correlation. 
Therefore I reject the null hypothesis and confirm that there is a weak negative 
correlation between HIV-2 V3 loop charge and M 0 tropism (fig 3.2). When the V3 
loop charges of two HIV-1 isolates SF2 and SF162 were compared to their M 0 tropism 
the Spearman’s rank coefficient returned a value of -0.67, which confirms a strong 
negative correlation between HTV-1 V3 loop charge and M 0 tropism, as described 
previously (Hwang et al., 1991; Hwang et al., 1992; Westervelt et al., 1992).
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Figure 3.2. Macrophage tropism versus the third variable loop charge of HIV-2.
The M0 tropism from fig 3.1b was plotted against the net V3 loop amino acid charge in table 3.2. The 
net V3 loop amino acid charge was calculated by subtracting die total charge of die negatively charged 
amino acids from the total of the positively charged amino acids. The coreceptor usage, listed beside
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each isolate, was taken from table 3.1. Hie coreceptor used with greatest efficiency is listed first in bold 
black type. Additional coreceptors are listed in grey. Hie regression trend line was plotted with 
Microsoft Excel. A weak negative correlation between HIV-2 V3 loop charge and M0 tropism is 
supported by a Spearman’s rank coefficient of -0.1625 (above).
3.2.3 HTV-2 reverse transcription in monocyte derived macrophages is transient.
Limiting dilution gag-LTR PCR was used to investigate the efficiency of the HIV-2s 
MIR, TER, MIL, and ETP to enter and reverse transcribe in MDM compared with 
PBMC and with HIV-1. The ERV-3 PCR was used as a DNA input control and to 
show that the host genomic DNA input is equivalent between time points, cell types and 
isolates. ERV-3 is present in one copy per haploid human genome (chromosome 7) that 
allows for camparison to the number of HIV genomes present (Cohen et al., 1985; 
O'Connell et al., 1984). Fig 3.3 shows that a similarly high level of HIV-2 MIR gag- 
LTR DNA was produced at 24hrs post-infection in both MDM and PBMC. At 72 hrs 
MIR gag-LTR continued to increase in PBMC but there was a decrease of 
approximately 2.0 logarithms of HIV-2 gag-LTR DNA in MDM. This same pattern of 
reverse transcription in MDM was seen with all HTV-2s tested. Thus the HIV-2s enter 
and reverse-transcribe in MDM regardless of the V3 loop charge and coreceptor usage.
PBMC and MDM infected with HIV-1 2044 were subject to limiting dilution PCR as 
with HIV-2 above to compare 24 hr and 72 hr time points. I wanted to determine if the 
gag-LTR product was lost in HIV-1 infected MDM similar to HIV-2 infected MDM. In 
contrast, the amount of gag-LTR product increases in PBMC at 72 hr compared to 24 hr 
(fig 3.3). There was approximately a 3-fold loss of gag-LTR product in MDM at 72 hr 
compared to 24 hr, however there was approximately 3-fold less input DNA (see ERV- 
3 control) at this time point suggesting no relative loss in HIV-1 gag-LTR product. 
Therefore, there was less loss of reverse transcription product with HIV-1 infection of 
MDM compared to HIV-2.
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Figure 3.3. Limiting dilution gag-LTR polymerase chain reaction and ERV-3 
polymerase chain reaction analysis of HIV-2 time courses on monocyte derived 
macrophages and peripheral blood mononuclear cells.
(A) To compare the extent of HIV-2 reverse transcription in PBMCs and MDM I measured the final 
stages of reverse transcription by gag-LTR PCR. PBMCs and MDM (106  cells each) were infected with 
103 TCID5 0 of HIV-2 virus [HIV-2 titres were determined in PBMC and coreceptor usage was determined 
in NP2/CD4/CXCR4 and NP2/CD4/CCR5 cells (fig 3.1a and table 3.1)]. Cells were infected with HIV-2 
inoculum for 3 hr and then washed twice with RPMI/10% HS. Serial dilutions were made of the infected 
PBMC or MDM DNA in half logarithm dilutions starting with neat and ending with a dilution of 10‘3.
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M0 tropic HIV-1 2044 is shown for comparison. (B) QPCR was conducted on DNA from MDM 
infected with HIV-2 MIR above, to verify serial dilution method in fig 3.3a.
5.2.4 HIV-2, bat aot HIV-1, infected monocyte derived macrophages exhibit an 
early burst in viral replication.
To investigate M0 tropism further, I conducted a time-course of virus replication on 
HTV-2 and HTV-1 in MDM. MDMs were infected with equivalent amounts of either 
HTV-1 or HTV-2 (determined on PBMC). The input corresponds to approximately 104 
TCIDso/ml as measured on PBMC for each HTV-2 isolate. The inputs for MIL and SAB 
were 5.0 x 104 and 8.0 x 104 TCIDso/ml respectively. At each time point, an aliquot of 
supernatant was taken from the cultures. RT activity of the supernatants was measured 
by RT-ELISA and a time course of RT activity was plotted. Fig 3.4a shows that there is 
a burst of RT activity at day 2 from HIV-2 infected MDM that was not detected at later 
time points. In general, the RT activity measured at the burst of replication for HIV-2 
was higher than in HTV-1 infected MDM. However, HTV-1 MDM virus production 
rebounded at time points beyond the initial replication peak (fig 3.4b). HTV-2 ALI 
produced 150 pg/ml of RT activity at day 2 whereas the highest for HIV-1 is 2076 with 
50 pg/ml RT at day 16 (fig 3.4a and b). As seen here, the infectivity of HTV-2 primary 
isolates may not be truly represented by calculating the TCID50 at 2 1  days after infection 
but by conducting a time-course of HIV-2 replication in MDM (fig 3.4a). The 
continuous and late replication of HTV-1 in MDM has been well established thus the 
measurement of HTV-1 TCID50S 21 days post-infection is appropriate here (Gorry PR, 
2001; Simmons G, 1996).
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Figure 3.4. HIV-2 replication in monocyte derived macrophages is early and 
transient.
(A) Time courses of HIV-2 particle RT production and (B) HIV-1 RT production in MDM. Aliquots 
were taken at 2 day intervals for RT ELISA. Time 0 was measured after inoculum was left on MDM for 
3 hr followed by two washes. (C) Particle infectivity. The ratio of infectivity (FFU/ml) to virus particles 
[RT activity (pg/ml)] of output HIV-2 ALI from PBMC and MDM was used to determine that HIV-2 
virus production in MDM resulted in infectious particles. One time point from ALI in PBMC (day 4) is 
compared to a time point from ALI in MDM (day 2), and HIV-1 2076 (day 16). Shown is the result of 
one experiment on 2 different MDM and PBMC donors. This result is representative of the results from 
at least 4 separate experiments using 2 MDM/PBMC donors per experiment. Error bars represent SDM.
3.2.5 The lack of HIV-2 spread in monocyte derived macrophage culture is not 
because of defective assembly.
It was possible that HIV-2 virion assembly in MDM was inefficient and thus HIV-2 
could not spread through MDM culture by repeated rounds of replication in surrounding 
cells. To determine if infectious virus was produced by HIV-2 ALI infected MDM, 
harvested supernatants were plated onto NP2/CD4/CCR5 cells and the FFU/ml 
estimated. RT ELISA was used to quantify RT activity. The RT activity was compared 
to the number of infectious particles (FFU) by dividing the FFU at a time point by the 
RT activity (pg/ml) from the same time point (infectivity per unit of RT, i.e. virus
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supernatants that have less infectious virus will have more RT compared to infectivity). 
HIV-2 ALI infected MDM had RT activity only at day 2, so this time point was 
compared to one time point, day 4, from ALI infected PBMC that exhibited rebounding 
virus replication. We can see that the ratio of FFU/RT from HIV-2 ALI infected MDM 
js equivalent to that seen at day 4 in ALI infected PBMC (fig 3.5b), thus the lack of 
spread and rebounding replication of HTV-2 in MDM is unlikely to be the inability to 
produce infectious virus alone. HTV-1 2076 demonstrates greater infectivity when 
produced from MDM than when it is produced from PBMC (fig 3.5b), which may 
explain why HTV-1 demonstrates spreading and rebounding replication in MDM 
culture.
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Figure 3.5. HIV-2 ALI produces infectious particles from infected monocyte 
derived macrophages.
The ratio of infectivity (FlFU/ml) to RT activity (pg/ml) of HIV-2 ALI harvested from infected PBMC 
and MDM was used to determine that HIV-2 virus production in MDM resulted in infectious particles 
comparable to PBMC (bottom panel). One time point from ALI infected PBMC (day 4) is compared to a 
time point from ALI infected MDM (day 2), and HIV-1 2076 (day 16) (top panel). Shown are the results 
from samples obtained from the experiment in fig 3.4 and are representative of the result from 2 
independent experiments using 2 MDM and PBMC donors each.
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3.2.6 Latent virus production can be stimulated in HIV-2 infected monocyte 
derived macrophages.
To determine whether latent integrated HTV-2 provirus was present in MDM culture, 
lipopolysaccharide (LPS) was added to a well of infected MDM 4 days post-infection 
and harvested the following day (day 5 post-infection). Stimulation of transcription of 
HTV-2 JAU RNA was evident by gag-LTR RT-PCR (fig 3.6a). The M0 tropic HTV-1 
SF162, maintains gag-LTR RNA production throughout the time-course, indicating 
constant viral replication (fig 3.6b).
3.2.7 There is a loss of HTV-2 gag-LTR RNA production with HIV-2 gag-LTR 
DNA loss.
I next determined whether viral RNA transcripts were being produced over a 5 day 
period because, as fig 3.4a indicates, there is a burst of RT production at early time 
points but not at late ones. I wanted to determine if HTV-2 JAU RNA transcription was 
associated with RT production. RT-PCR to measure gag-LTR RNA transcripts was 
conducted on MDM infected with HTV-2 JAU or HTV-1 SF162. MDM were incubated 
with equivalent input (5.0 x 103 PBMC TCID50) of either JAU or SF162 for 3 hr, time 
points were harvested every 24 hr up to and including 5 days post-infection. The 
infected MDM were harvested with Trizol® RNA extraction reagent and the cDNA was 
prepared. HTV-2 RNA production by MDM peaks at 24 hr post-infection and decreases 
to almost undetectable levels by day 5 (fig 3.6a). Interestingly, JAU transcription could 
be restimulated by addition of LPS and titrated out 100-fold (fig 3.6a), however the 
amount of recovery is not as intense as the expression seen at 24 hr post-infection.
I determined whether the LPS stimulation of HIV-2 viral RNA production in fig 3.5a 
translated to production of virus particles. I detected virus particles in harvested 
supernatants by RT-ELISA and show that HTV-2 JAU can be stimulated to higher levels 
than HTV-1 SF162 at day 5 with LPS stimulation (fig 3.6c). SF162 was apparently 
unaffected by LPS treatment.
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Figure 3.6. HIV-2 infection of monocyte derived macrophages is transient and can 
be restimulated with lipopolysaccharide treatment.
RT-PCR of (A) HIV-2 JAU and (B) HIV-1 SF162 infected MDM harvested at indicated time points post­
infection. LPS (50ng/ml) was added to the HIV-2 JAU culture 4 days post-infection and harvested on 
day 5. RNA was extracted at the time points indicated and cDNA was made for GAPDH and garg-LTR 
PCR. (C) RT activity from the experiment in fig 3.6a and b above. Shown are the results of one 
experiment and they are representative of the results from at least 3 independent experiments. Error bars 
represent SDM.
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3.2.8 The HTV-2 isolate, prCBL23, which displayed no replication on monocyte 
derived macrophages demonstrates a post-entry restriction in HeLa/CD4 cells.
Until this point of the chapter I have described a general post-entry restriction of HIV-2 
isolates in MDM compared to PBMC and HIV-1. In fig 3.1a and b I noted that prCBL 
23 was not able to infect MDM whereas all of the other HIV-2s tested were able to 
replicate, to some degree. At this point I focus on a post-entry restriction of HIV-2 
prCBL 23 (MCR) in HeLa/CD4 cells. It has been reported previously that prCBL 23 
demonstrates a post-entry block to infection in MDM and HeLa/CD4 cells that occurs 
post-reverse transcription (McKnight et al, 2001).
The T cell line adapted HIV-2 strain CBL 23 and the primary isolate prCBL 23 are 
restricted in HeLa/CD4 cells, as described previously (McKnight et al, 2001). To study 
this post-entry restriction I concentrated on infection of HeLa/CD4 cells as they are 
relatively easy to culture. Fig 3.7 shows that CBL 23 has veiy similar infectivity for 
U87/CD4/CXCR4 and HeLa/CD4 cells. PrCBL 23 infection of U87/CD4/CXCR4 cells 
is comparable to CBL 23, however there is a drop in infectivity from a mean of 2.3 x 
104 FFU on permissive U87/CD4/CXCR4 cells to 5.0 x 102 FFU on restrictive 
HeLa/CD4 cells (fig 3.7). The mean titre of prCBL 23 on U87/CD4/CXCR4 divided by 
the titre on HeLa/CD4 cells reveals a restriction of 45.6-fold. Thus, the restriction of 
prCBL 23 in MDM compared to PBMC is similar to the restriction, seen here, in 
HeLa/CD4 cells compared to U87/CD4/CXCR4 cells
Figure 3.7. HTV-2 PrCBL 23 is restricted in HeLa/CD4 cells.
CBL 23 and prCBL 23 viruses were titrated onto U87/CD4/CXCR4 and HeLa/CD4 cells, fixed and 
stained for infection 3 days lata*. Foci of infection were counted and FFU/ml calculated.
□ U87/CD4/CXCR4 
■ HeLa/CD4
CBL23 prCBL23
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3.2.9 Lv2 is a restriction to HIV infection in some human cell types.
Molecular clones and gene swaps were made from prCBL 23 and CBL 23 by my 
colleague, Christian Schmitz, to study the restriction of prCBL 23 in MDM and 
HeLa/CD4 cells. These molecular clones were named Molecular Clone Restricted 
(MCR) and Molecular Clone Not-restricted (MCN) after prCBL 23 and CBL 23, 
respectively (Schmitz et al., 2004). Restrictive cells are resistant to infection by 
restricted viruses, MCR and prCBL 23 on HeLa/CD4 cells. This pattern of HIV 
restriction in human cells has been named Lentivirus susceptibility factor 2 (Lv2) 
(Schmitz et al., 2004), after the Lentivirus susceptibility factor 1 (Lvl) pattern of 
retroviral restriction in non-human primate cells (Cowan et al., 2002). Figs 3.8a and b 
show infection of a standardised dose (equivalent input determined on unrestrictive 
U87/CD4/CXCR4) of MCR and MCN on the permissive U87/CD4/CXCR4 and the 
Lv2 restricted HeLa/CD4 cells. As expected MCN is not restricted on either of the 
U87/CD4/CXCR4 or HeLa/CD4 cells but there is 42.0-fold less infection of MCR on 
the HeLa/CD4 than the U87/CD4/CXCR4 cells.
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Figure 3.8. Lv2 is a restriction to HIV infection in some human cell types.
(A) The same infectious dose (standardised on permissive U87/CD4/CXCR4 cells) of MCR and MCN 
were plated on permissive U87/CD4/CXCR4 and restrictive HeLa/CD4 cells and fixed and stained for 
HIV-2 infection 3 days later. Infectivity is reported as FFU/ml. (B) The fold restriction was calculated 
by dividing the FFU/ml on permissive U87/CD4/CXCR4 cells by the FFU/ml on restrictive HeLa/CD4 
cells for each virus in (A). Results shown represent at least 10 independent experiments. Error bars 
represent SDM.
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3.2.10 The viral gag and envelope genes act in concert to mediate Lv2 restriction.
All of the Lv2 restriction is accounted for by swapping both the env and gag genes into 
the unrestricted MCN backbone (MCNmcremgag)(Schmitz et al., 2004). Figs 3.9a and 
c show that the MCNmcrgag and MCNmcre/iv swaps are restricted by only 17.0 and 
11.0-fold, respectively. However, the double gag and env swap in figs 3.9b and c 
(MCNmcrewvgag) is restricted by 34.0-fold, similar to MCR. Conversely, the 
MCRmcnenvgag swap is not restricted, like the unrestricted MCN in fig 3.8 (figs 3.9b 
andc).
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Figure 3.9. HIV-2 gag and envelope act in concert to mediate the restriction of 
MCR in HeLa/CD4.
The same infectious dose (standardised on permissive U87/CD4/CXCR4 cells) of (A) gag and env gene 
swaps MCNmcrgag and MCNmcrenv, and (B) MCNmcrenvgog and MCRmcnenvgog were plated on 
U87/CD4/CXCR4 and restrictive HeLa/CD4 cells, fixed and stained for HIV-2 infection 3 days later. 
Infectivity is reported as FFU/ml. (C) The FFU on permissive U87/CD4/CXCR4 cells was divided by the 
FFU obtained from restrictive HeLa/CD4 cells for each virus in (A, B) and plotted as fold restriction. 
Results shown represent at least 5 independent experiments. Error bars represent SDM.
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3.2.11 Lv2 restriction of HIV infection is common among HIV-1 and HIV-2 
isolates.
HIV-1 (NL4.3, RF, IIIB, MN, SF2, 2044, 2005, 2028, 2076, M13, HAN2, and 89.6) and 
HIV-2 (MCR, MCN, MIL, ETP, JAU, ACR23, MIR, AND, prCBL20 and SAB) 
laboratory adapted and primary isolates were tested for infection on U87/CD4/CXCR4, 
HeLa/CD4 and H399 cells to determine the prevalence of Lv2 restriction (fig 3.10a). 
The fold restriction of infection on HeLa/CD4 and H399 cells was determined and half 
of all of the HIV-2 isolates (MCR, ETP, AND, prCBL20, and SAB) and about one third 
of the HIV-1 isolates (2076, Ml 3, HAN2, and 89.6) were restricted in an Lv2 manner.
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Figure 3.10. HIV-1 and HIV-2 isolates are susceptible to Lv2 restriction.
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(A) An array of HIV-2 and (B) HIV-1 isolates was titrated on permissive U87/CD4/CXCR4, H399*, and 
restrictive HeLa/CD4 cells and the FFU/ml calculated. Fold restriction was calculated for (C) HIV-2 and 
(D) HIV-1 by dividing the titre on permissive U87/CD4/CXCR4 cells by the titre on restrictive 
HeLa/CD4 or permissive H399 cells. *H399 cells, described in greater detail in chapter 4, are a 
HeLa/CD4 cell line that expresses a CD4 molecule with a C-terminal tail truncation at the membrane 
proximal amino acid position 399. This cell line that is not Lv2 restrictive, unlike the related HeLa/CD4, 
is used in chapter 4 to further characterise the cellular location of Lv2 restriction.
3.3 Discussion
The data presented here show that apart from a single burst of viral replication HIV-2 
continuous replication in MDM is largely absent. However, latent HIV-2 provirus 
could be stimulated with LPS. In contrast, HIV-1 showed delayed and rebounding 
replication in MDM with no evidence of a latent phase. A molecular clone, MCR was 
made from HTV-2 prCBL 23, which demonstrated a complete block to replication in 
MDM. The models used to study HTV post-entry restrictions in human cells, Lv2, was 
found to be a common pattern of restriction to HIV-1 and HIV-2 infection in human 
cells.
Sequencing of the HTV-2 V3 loop revealed that a high net positive charge of the V3 
loop was associated with CXCR4 use on NP2/CD4/CXCR4 cells. None of the HTV-2 
isolates infected MDM very well when compared to PBMC infection or to HIV-1 on 
MDM, but the HTV-2 isolates that exhibit the highest relative MDM infection are those 
that use CCR5 and have less positive V3 loop charges. However, HTV-2 MLC, an 
isolate that uses CCR5 and has the lowest V3 loop charge demonstrates poor infectivity 
on MDM. The V3 loop charge is only weakly correlated with M0 tropism, so overall, 
the V3 loop fails to determine the lack of replication of HTV-2 in MDM compared to 
PBMC and HTV-1. If the V3 loops were somehow responsible for the lack of MDM 
infection we would expect to see a consistently high charge on all of the HIV-2 V3 
loops and a stronger ability by some of the HIV-2 isolates to infect MDM. A recent 
study has suggested that the env genetic determinants dictating cell tropism of dual 
tropic HIV-1 viruses are “complex”; they include regions of the V1/V2 and V5 hyper 
variable regions, and charged and uncharged amino acids in the V3 loop (Ghaffari et al., 
2005), so too, the HTV-2 env determinants of tropism may be complex as well.
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Low positive and high positive HIV-2 V3 loop charges have been reported to be 
associated with slow/low and fast/high viral phenotypes, respectively (Albert et al., 
1996). It has also previously been reported that shift in the coreceptor usage from 
£CR5 to CXCR4 is associated with an increase in the net positive charge in the V3 
region of HTV-2 molecular clones (Isaka et al., 1999). Here I confirm that an increasing 
net positive charge of the V3 loop correlates with CXCR4 usage of HIV-2 primary 
isolates and that there is a weak association between CCR5 using HTV-2 isolates and 
M0 tropism. There was a broad range of V3 loop charges among the HIV-2 isolates so 
it does not appear as though V3 loops alone are responsible for the lower HTV-2 
TCID50S in MDM compared to HIV-1.
The lower infectivity of HTV-2 compared with HIV-1 in MDM can be attributed to at 
least 2 factors: HIV-1  is more infectious when produced from MDM than PBMC and 
HIV-2 reverts to a latent state in MDM. HIV-2 primary isolates enter MDM and 
reverse transcribe to the same levels as seen in PBMC. However, when later time 
points were analysed they showed significantly less gog-LTR product that suggests 
there is less viral spread in culture or that this is just ‘left-over’ gag-LTR product from 
what could be seen at earlier time points post-infection.
Latency has been demonstrated for HTV-1, Jordan et al. show that the inducible 
replication of latent integrated HTV-1 in the T cell line Jurkat (Jordan et al., 2003). 
They show that a small proportion of HIV-1 integrates into or near alphoid repeats in 
heterochromatin and the natural suppression of transcription in this region of the 
genome inhibits integrated HTV-1 transcription (Jordan et al., 2001). I have shown 
stimulation of HTV-2 production in MDM with LPS. The levels of stimulation of 
latently HTV-1 infected T cell lines has been demonstrated to vary with different 
agonists, particularly those that best stimulate NF-kB, like the phorbol ester, TPA 
(Jordan et al., 2003). Strong NF-kB agonists (LPS) stimulate HIV-2 replication in 
MDM to the same levels that were demonstrated at day 2 in HTV-2 infected MDM.
M0s have been demonstrated to be a stable source of HTV-1 replication due to their 
greater ability to survive virus replication whereas HIV-1 infected PBMC have been 
shown to readily undergo apoptosis and necrosis, several mechanisms have been
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proposed (Meylan et al., 1998; Wang et al., 2001; Zhang et al., 2001) reviewed in 
(Alimonti et al., 2003). Gartner et al. first demonstrated that ex-vivo M0s can be 
infected with HIV-1, and may continue producing virus for more than 40 days (Gartner 
et al., 1986). Certain factors have been shown to promote the survival of M0s infected 
tyith HTV-1. Garaci et al. have shown that Nerve Growth Factor (NGF) is an autocrine 
factor that inhibits apoptosis and is up regulated by HTV-1 infected M0s (Garaci et al.,
1999).
The in vitro experiments conducted here in ex-vivo MDM may have implications for 
disease progression in the host. HTV-2 RNA production can be induced in MDM by 
lipopolysaccharide five days post-infection suggesting that MDM remain infected and 
that provirus remains integrated at later time points. Eitner et al. have demonstrated in 
HTV-2 infected pig-tailed macaques that there is a highly disseminated viral phase 
followed by exclusive localisation of infection to the FDC network with few infected 
cells (Eitner et al., 2000). These findings may reflect the burst of viral RNA that I see 
in HTV-2 infected MDM followed by latent/loss of HIV-2 replication. Perhaps the 
initial burst of replication helps the virus to establish itself in the host and the 
subsequent latency may allow HIV-2 to avoid the immune system.
Individuals infected with HTV-2 have lower plasma viral loads than those infected with 
HTV-1, which reflects the lesser pathogenicity of HTV-2 (Gottlieb et al., 2002; Popper et 
al., 2000; Popper et al., 1999; Shanmugam et al., 2000). However the lower viral load 
does not equate to a lower proviral load than HTV-1 (Ariyoshi et al., 1996; Berry et al., 
1994; Sarr et al., 1999), but to less viral production from the proviral template (Popper 
et al., 2000).
Lv2 restriction of HTV infection was introduced in this chapter. In the next chapter I 
demonstrate that an endocytic pathway delivers HIV to Lv2 restriction in HeLa/CD4 
cells.
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An endocytic route of delivery to Lv2 restriction
4.1 Introduction:
In the last section, chapter 3, the restricted replication of HIV-2 isolates in MDM was 
identified. In particular, prCBL 23 demonstrated no replication in MDM. The 
molecular clone, MCR, derived from prCBL 23 virus swarm was made by my colleague 
Cristian Schmitz, and a restriction model using HeLa/CD4 cells as the restrictive cell 
type was developed (Schmitz et al., 2004). This chapter investigates the route of entry 
taken by Lv2 restricted and unrestricted viruses.
There have been many reports on the involvement of endocytosis in HIV infection 
(Fredericksen et al., 2002; Marsh and Pelchen-Matthews, 2000; Vidricaire et al., 2003; 
Wei et al., 2005), but so far none that have linked retroviral restriction to a particular 
endocytic pathway. Studying the pathways of restriction in the host cell can help to 
understand the pathway of infection and the preferred route of entiy. It may not be the 
entry pathway that is restricting viral entry, per-se, but an anti-viral protein/ saturable 
restriction factor (Stremlau et al., 2004; Towers et al., 2000).
Clathrin mediated endocytosis was the first mechanism of receptor-mediated cellular 
internalisation to be discovered as a means of yolk protein uptake in the mosquito 
oocyte (Roth and Porter, 1964). The “archetypical” cargo to be trafficked by this 
pathway is the Trf receptor that internalises iron-binding protein, Trf (Harding et al., 
1983; Pearse, 1982), and is commonly used as a marker of clathrin activity (Le Roy and
v
Wrana, 2005). Sometimes called the “classical route” of endocytosis clathrin 
trafficking is thought to be the most active route for receptor-mediated internalisation. 
Once the clathrin coated pit has budded from the PM it fuses with an early endosome 
that can become an acidified late-endosome of pH 5.0 to 6.5.
Virus Envs can cause host-virus membrane fusion by pH-dependent and independent 
mechanisms. The best understood mechanism of pH-dependent fusion is that of the
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influenza Haemagglutinin protein (HA), a type I fusion protein. The HA protein is 
folded into a high-energy state that is released upon exposure of the virion to a low pH 
(5.0-6.5) endosomal compartment, exposing the N-terminal fusion peptide (Wiley and 
Skehel, 1987). A chain-direction reversal occurs at the amino terminal end of the 
central coiled coil resulting in the extension of the fusion peptide towards the target 
membrane (Colman and Lawrence, 2003). A second chain-direction reversal occurs in 
the central coiled-coil region, this time projecting the carboxyl terminus back towards 
the amino terminus. This folding of the fusion domain back to the membrane anchor 
acts to bring the viral and target membranes into close apposition for fusion.
Most retroviruses and paramyxoviruses fuse with host target membranes at neutral pH 
and so it is the receptor binding interaction that triggers the fusion mechanism (above).
Clathrin endocytosis has been reported as an entry route for pH-dependent and. 
independent viruses alike. Since the clathrin endocytic route can lead to an acidified 
compartment it is the preferred route of entry by many pH-dependent viruses: Semliki, 
an alphavirus, was the first confirmed pH-dependent virus to use clathrin as its primary 
route of entry (Helenius et al., 1980; Helenius et al., 1982; Marsh et al., 1982; White et 
al., 1980). Vesicular Stomatitis Virus (VSV) has also been shown to use clathrin 
endocytosis as its route of entry by inhibition with amantadine (Schlegel et al., 1982), 
and has been confirmed recently with dominant negative mutants (Sun et al., 2005). Ph- 
dependent viruses such as Influenza, Sindbis, and human rhinovirus 14 (DeTulleo and 
Kirchhausen, 1998) also use this pathway of entry. HIV-1, a pH-independent virus has 
been shown to require clathrin, at least in part, as a route of entry (Daecke et al., 2005; 
Stein et al., 1987).
Caveolae were first described as “omega-like” structures in early morphology studies of 
the PM (Palade, 1961) and have since been shown to require the scaffolding protein 
caveolin to support their shape and function (Rothberg et al., 1992). Caveolin binds 
cholesterol and it is therefore thought that caveolae mediate cholesterol storage and 
homeostasis (Johannes and Lamaze, 2002; Rothberg et al., 1992), and numerous 
signalling and trafficking events (Anderson, 1998; Simons and Toomre, 2000). They 
are expressed on fibroblasts, smooth muscle cells, endothelial, and epithelial cells but 
not T cells (Scherer et al., 1997).
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One of the few and best characterised intracellular parasites that enter via caveolae is 
the SV40 polyoma virus. Fewer viruses have been found that use this internalisation 
mechanism as a portal of entry compared to clathrin endocytosis (Sieczkarski and 
Whittaker, 2002a), perhaps because it is a slowly internalising, non-constitutive 
pathway and is therefore less active than clathrin endocytosis (Thomsen et al., 2002). 
This may be why SV40 requires ligand triggering of caveolae to induce actin 
rearrangements and uptake (Pelkmans et al., 2002). The study of SV40 internalisation 
has also revealed a novel organelle called the caveosome (Pelkmans et al., 2001), used 
as a trafficking intermediate on its way to the ER and nucleus.
Apart from clathrin-mediated and caveolae endocytosis, internalisation of cel 1-surface 
markers independently of clathrin-coated pits has lead to the definition of a new type of 
endocytic mechanism, clathrin independent endocytosis (Nichols and Lippincott- 
Schwartz, 2001). Internalising lipid (Puri et al., 2001) and protein (Nichols et al., 2001) 
markers have been visualised outside of clathrin pits suggesting that clathrin 
independent routes exist, but also in different compartments suggesting the existence of 
numerous non-classical routes of endocytosis (Nichols and Lippincott-Schwartz, 2001). 
The membrane organisation of vesicles in these pathways is thought to be composed, 
primarily of lipid rafts (Simons and Ikonen, 1997), and the organisation of some lipid 
raft markers post-internalisation, such as GPI-linked proteins, is thought to occur in 
discreet compartments independent of the classical early endosome antigen 1 (EEA1) 
endosome (Sabharanjak et al., 2002). Some lipid raft markers such as the M2 
muscarinic acetylcholine receptors internalise independently of clathrin but traffic into a 
classical clathrin/Rab5 positive early endosome post-internalisation (Delaney et al., 
2002).
Virus entry by clathrin/caveolae independent pathways is highly variable and obligate in 
some cases. Murine polyomavirus (MPV) requires actin depolymerisation and stable 
microtubules for infection and a clathrin/caveolae independent pathway for productive 
entry (Gilbert and Benjamin, 2000; Gilbert et al., 2003). Similar to MPV, SV40 can use 
at least one caveolae/clathrin independent route of entry in addition to caveolae (Damm7
et al., 2005). Clathrin independent uptake via “smooth surfaced pits and vesicles” was 
implicated in early studies of influenza virus entry (Matlin et al., 1981). The use of
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dominant negative mutants has confirmed influenza virus entry by both clathrin and 
clathrin/caveolae independent endocytosis in the same cell (Lakadamyali et al., 2004; 
Rust et al., 2004; Sieczkarski and Whittaker, 2002b). Even though influenza does not 
require clathrin for initial entry into the cell it does require the classical Rab 5 and Rab 7 
acidified, late endosomal compartments for productive infection (Sieczkarski and 
Whittaker, 2003).
Depletion of membrane cholesterol (using cyclodextrins) has shown that PM lipid rafts 
are necessary for HTV-1 binding and entry (Liao et al., 2001), and may be required for 
clustering of CD4 receptor and coreceptors to sites of virus binding (Manes et al.,
2000). However, truncation of the CD4 cytoplasmic domain suggests that CD4 does 
not need to be localised to lipid rafts for efficient HTV-1 entry and infection (Bedinger 
et al., 1988; Popik and Alee, 2004). The involvement of lipid rafts in HTV entry may 
occur post-CD4 binding by destabilisation of lipid raft domains (Kozak et al., 2002). It 
has even been suggested that virion associated lipid rafts are required for virus 
infectivity (Graham et al., 2003; Liao et al., 2003).
4.2 Results:
4.2.1 MCR is not restricted when fusion is forced at the ceil surface.
MCR can be rescued in HeLa/CD4 cells when it is pseudotyped with VSV-G (fig 
4.1a)(Schmitz et al., 2004). VSV-G is a pH-dependent Env that requires delivery into 
an acidified endosome compartment to trigger fusion with the host cell (Blumenlhal et 
al., 1987). Since MCR avoids restriction by delivery into an endosomal pathway with a 
VSV Env, I determined if MCR restriction could be overcome if MCR delivery was 
forced, outside of an endosomal compartment, at the cell surface with a VSV Env. The 
fusion of VSV-G at the cell surface by transient acid-shock with acidified (pH 5.5) 
media has been described previously (Marsh and Bron, 1997). The buffering of growth 
media to a pH of 5.0-5.5 emulates the pH of late endosomes and acts to fuse pH- 
dependent Envs at the cell surface when added transiently to pH-dependent-virus and 
cell mixtures (Marsh and Bron, 1997; White et al., 1980).
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Fig 4.1a and b show a comparison of MCR and MCR(VSV). Infection of MCR is 
rescued if restrictive cores are pseudotyped with VSV Env (fig 4.1a). MCR infection in 
HeLa/CD4 cells is not affected by monensin neutralisation of endosomal pH (control) 
or by the transient acid treatment at pH 5.5 compared to normal infection. However 
infection is recovered more than 10-fold when MCR(VSV) is forced to fuse at the cell 
surface by transient acid shock (‘pH 5.5 + monensin’) (fig 4.1b). When VSV-G 
mediated fusion is prevented by monensin it fails to rescue MCR [MCR (VSV) ‘pH 6.8 
+ monensin’, fig 4.1b].
A
B
pH 6.8 pH 6.8 ♦ pH 5.5 +
monsnain monsnain
Figure 4.1. MCR pseudotyped with vesicular stomatitis virus envelope is rescued 
from Lv2 restriction in HeLa/CD4 cells: MCR is not restricted in HeLa/CD4 cells 
when forced to fuse at the cell surface.
(A) MCR and MCR(VSV) were titrated on U87/CD4/CXCR4 and HeLa/CD4 cells and fixed and stained 
fa- HIV-2 infection 3 days later. (B) Surface fusion of MCR(VSV) by transient acid shock. MCR and 
MCR(VSV) were titrated on HeLa/CD4 cells and treated with low pH media for 2 min to induce fusion 
(pH 5.5 + monensin) or controls with physiological pH media with or without monensin (‘pH 6.8 + 
monensin’ and ‘pH 6.8’, respectively), low pH media was replaced with pH 6.8 buffered growth media 
and cells were fixed and stained for HIV-2 infection 3 days later (materials and methods). The results 
shown are representative of at least 4 independent experiments. Error bars represent the SDM.
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4.2.2 Lv2 restriction does not require acidified endosomes to inhibit virus entry.
Bafilomycin Al is a lysosomal tropic agent that neutralises the pH of late endosomes 
and lysosomes, effectively inhibiting the fusion and entry of pH-dependent viruses 
(Drose et al., 1993; Helenius et al., 1982; Marsh et al., 1982; Perez and Carrasco, 1993). 
Previous reports have demonstrated that HTV-1 does not require a low pH for fusion 
(McClure et al., 1988; Stein et al., 1987). I determined the effect of pH on MCR 
restriction in HeLa/CD4 cells. Fig 4.2 shows that treatment of HeLa/CD4 cells with 
bafilomycin Al can inhibit infection by a pH-dependent VSV Env [MCR(VSV)] by 
more than 99%. Bafilomycin does not alter the infectivity of MCR on restrictive 
HeLa/CD4 cells (fig 4.2). Interestingly, MCR infectivity decreased (by approximately 
3-fold) from a mean of 145 to 45 FFU on permissive U87/CD4/CXCR4 cells with 
bafilomycin treatment Though there was no effect on infection in HeLa/CD4 cells 
there was a decrease in restriction from 11-fold to 3-fold, upon bafilomycin treatment. 
This was due entirely to a drop in infection of MCR on permissive U87/CD4/CXCR4 
cells and not any change in infection on restrictive HeLa/CD4 cells (fig 4.2).
Figure 4.2. Neutralisation of intracellular pH with bafilomycin Al doesn’t affect 
MCR restriction in HeLa/CD4 cells.
Viruses and pseudotypes were plated on U87/CD4/CXCR4 and HeLa/CD4 cells in the presence of 
bafilomycin Al. Cells were washed with normal growth media and infection was allowed to proceed in 
the absence of bafilomycin Al. Cells were fixed and stained for HIV-2 infection 3 days later. Results 
shown are representative of 3 independent experiments. Error bars represent SDM.
□ U87/CD4/CXCR4 
■ HeLa/CD4
MCR MCN MCR(VSV) MCR MCN MCR(VSV)
Bafilomycin A1
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4.2.3 Hypertonic media inhibit endocytosis of transferrin and cholera toxin 
binding subunit in U87/CD4/CXCR4 and HeLa/CD4 cells.
I determined the effect of endocytosis inhibition on restriction in HeLa/CD4 cells, 
without affecting the pH of endosomal compartments. Hypertonic sucrose inhibits 
receptor-mediated endocytosis without affecting pH (Daukas and Zigmond, 1985; 
Heuser and Anderson, 1989). As a positive control for inhibition of endocytosis I used 
FITC labelled Trf (Trf-FITC)(fig 4.3a-d), which is internalised by clathrin coated pits 
(Gruenberg, 2001), and FITC labelled CTxB (CTxB-FITC)(fig 4.3e-h) which is 
internalised by a lipid raft dependent pathway (Wolf et al., 2002). Hypertonic sucrose 
inhibited Trf-FITC and CTxB-FITC uptake in both the restrictive HeLa/CD4 and 
permissive U87/CD4/CXCR4 cells, signified by capping of FITC at the cell surface (fig 
4.3b, d, f, h).
Transferrin-FITC
U87/CD4/CXCR4
HeLa/CD4 
Cholera Toxin-FITC
U87/CD4/CXCR4
HeLa/CD4 
Control 0.45M sucrose
Figure 4.3. Sucrose inhibits transferrin and cholera toxin-B uptake.
Transferrin-polylysine-FITC (a-d) or cholera toxin binding-subunit-FITC (e-h) were bound to the 
permissive U87/CD4/CXCR4 or restrictive HeLa/CD4 cells with or without 0.45M sucrose and examined 
by confocal microscopy. Inhibition is shown by Trf-FITC or CTxB-FITC capping at the cell surface with
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simultaneous uptake into perinuclear (endosomal) regions of the cell. White scale bar indicates 10pm 
magnification. Results are representative of at least 4 independent experiments.
4.2.4 Lv2 restriction depends on an endocytic pathway of entry that is directed by 
the viral envelope.
Fig 4.4 shows the effect of hypertonic sucrose on restricted MCR infection. 
Unrestricted MCN and restricted MCR were plated on sucrose treated HeLa/CD4 and 
U87/CD4/CXCR4 cells. The infectivity of MCR on HeLa CD4 cells increased 6.5-fold 
from a mean of 16 to a mean of 105 FFU with sucrose treatment (fig 4.4a). Fig 4.4b 
shows the resultant fold restriction decrease from 12.0-fold to 1.5-fold. There was no 
effect of sucrose treatment on MCR infection of permissive U87/CD4/CXCR4 cells or 
on MCN infection of either HeLa/CD4 or U87/CD4/CXCR4 cells (fig 4.4a).
10*
10*
101
10°
□ U87/CD4/CXCR4 
■ HeLa/CD4
i l n ^ i
MCR MCR 4- MCN MCN + 
sucrose sucrose
B j M
| 10 
I .
MCR
□ Control 
■ 0.45M Sucrose
MCN
Figure 4.4. Treatment of Lv2 restrictive HeLa/CD4 cells with hypertonic sucrose 
recovers restricted MCR infection.
Cells were plated with a U87/CD4/CXCR4 standardised dose of (A) MCR and MCN and treated with 
hypertonic sucrose for 1 hr. Cells were fixed and stained for HIV-2 infection 3 days later. (B) The FFU 
from permissive U87/CD4/CXCR4 infection were divided by the infection on restrictive HeLa/CD4 cells 
to obtain the fold restriction, for control and 0.45M sucrose treatments. Results are representative of 5 
independent experiments. Error bars represent SDM.
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Lv2 restriction maps to both the viral env and gag genes (Schmitz et al., 2004). I 
determined whether the rescue of restriction with hypertonic sucrose was due to env or 
gag or both. Fig 4.5b shows the restriction of MCN containing a restricted Env 
(MCNmcrenv) is rescued from 21.0-fold to 1.0-fold, in this experiment, with hypertonic 
sucrose treatment The MCN molecular clone with a restricted Gag (MCNmcrgng) was 
less restricted but was completely rescued from 4.0-fold to 1.0-fold of restriction (fig 
4.5b). Therefore both the env and gag mediated restrictions of Lv2 are rescued by 
inhibition of endocytosis.
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Figure 4.5. Recovery of MCR infection with hypertonic sucrose is mediated by 
both gag and envelope,
(A) Cells were titrated with MCNmcrgag and MCNmcrenv viruses and treated with hypertonic sucrose. 
Cells were fixed and stained for HIV-2 infection 3 days later. (B) The permissive U87/CD4/CXCR4 
infection was divided by the FFU on restrictive HeLa/CD4 cells to obtain the fold restriction. Results are 
representative of 3 independent experiments. Error bars represent SDM.
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4.2.5 Infectivity of HIV-1 retroviral vectors pseudotyped with MCR and MCN 
envelopes in HeLa/CD4 cells can be improved by inhibition of endocytosis.
HIV-1 retroviral p8.91 particles pseudotyped with MCR and MCN Envs were plated on 
HeLa/CD4 and U87/CD4/CXCR4 cells treated with hypertonic sucrose. Fig 4.6a shows 
that the infectivity of both the MCR and MCN vector pseudotypes was rescued in 
sucrose treated HeLa/CD4 cells by 8.5 and 5.0-fold, respectively. Sucrose treatment 
had little effect on the infectivity of either of the HIV-2 Env pseudotypes on 
U87/CD4/CXCR4 cells (fig 4.6b).
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Figure 4.6. HIV-1 vector pseudotypes with MCR and MCN envelopes are rescued 
by treatment with hypertonic sucrose in restrictive HeLa/CD4 cells.
(A) HeLa/CD4 and (B) U87/CD4/CXCR4 cells were plated with a U87/CD4/CXCR4 standardised dose 
of HIV-1 vector pseudotypes HIV-lg9 )(MCR) and HIV-lg9 ](MCN) and treated with hypertonic sucrose 
for 1 hr. EGFP positive cells were determined by FACS three days post-infection. Results shown are 
representative of 2  independent experiments.
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4.2.6 Depletion of membrane cholesterol with methyl-p-cyclodextrin inhibits 
uptake of cholera toxin binding subunit: membrane trafficking differences 
between restrictive and permissive cells.
Membrane cholesterol is required for the endocytic trafficking of lipid rafts (Sandvig et 
al., 2004). I determined the effect of membrane cholesterol depletion on Lv2 restriction 
using MpCD. As controls, the disruption of lipid rafts by MpCD was followed in 
HeLa/CD4 and U87/CD4/CXCR4 cells with CTxB-FITC and Trf-FITC. Cholera toxin 
trafficking is via a lipid raft dependent endocytic pathway that is disrupted by depletion 
of PM cholesterol (Fujinaga et al., 2003; Nichols, 2002; Sandvig et al., 2004; Sandvig 
and Van Deurs, 2002). Fig 4.7d, e, f  show that internalisation of CTxB in HeLa/CD4 
cells is inhibited by MpCD and can be reconstituted with water-soluble cholesterol. 
However, the internalisation of CTxB-FITC in U87/CD4/CXCR4 cells was not 
inhibited by treatment with MpCD (fig 4.7a, b, c). As expected internalisation of 
clathrin dependent Trf-FITC was not inhibited by depletion of membrane cholesterol 
with MpCD (fig 4.7g-j).
U87/CD4/CXCR4 HeLa/C D4
Control
10mM MpCD
1 0mM MpCD + 0.2 
(iM Cholesterol
CTxB-FITC
U87/CD4/CXCR4
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Figure 4.7. Methyl-p-cyclodextrin differentially inhibits cholera toxin-B uptake in 
Lv2 restricted and permissive cells.
Permissive U87/CD4/CXCR4 or restrictive HeLa/CD4 cells were treated with M(1CD. CTxB-FITC (a-f) 
and Trf-FITC (g-j) were bound to treated or untreated cells for lhr with or without water-soluble 
cholesterol and examined by confocal microscopy. Capping of CTxB-FITC at the cell surface shows 
inhibition. White scale bar indicates lOpm magnification. Results are representative of at least 4 
independent experiments.
MCR, MCN, MCNmcrgag, and MCNmcrenv viruses were plated on MpCD treated 
HeLa/CD4 and U87/CD4/CXCR4 cells. The titre of all viruses was slightly decreased 
on U87/CD4/CXCR4 cells (fig 4.8b). Fig 4.8a shows that MCR titre on restricted 
HeLa/CD4 ceils increased 8.0-fold with M0CD treatment from a mean of 15 to a mean 
of 120 FFU and restriction could be partially reconstituted to a mean of 25 FFU by 
adding back water-soluble cholesterol. The unrestricted MCN was not affected by any 
of these treatments on HeLa/CD4 cells. The titres of MCNmcreov and MCNmcrgag on 
HeLa/CD4 cells were not affected by M0CD treatment (data not shown). M(3CD had no 
effect on the infectivity of a VSV Env pseudotype in fig 4.8c, supporting the evidence 
that the pathway delivered to by VSV-G is different from Lv2.
142
Chapter 4 An endocvtic route o f  delivery to Lv2 restriction
B
10* i HeLa/CD4
10*
101
10° r h n
3
It
MCR MCN □ Control MM0CD 
M MPCD + 
10»! U87/CD4/CXCR4 choleaterol
10*
101
10°
i i
MCR MCN
10*
?  102 | _  1MCR(VSV)
.. ■ ■ ■
Control M0CD MPCD +
cholesterol
Figure 4.8. MCR infection in restrictive HeLa/CD4 cells is rescued by treatment 
with methyl-p-cyclodextrin: MCR gag and envelope are both required for recovery 
of infection by cholesterol depletion.
(A) HeLa/CD4 and (B) U87/CD4/CXCR4 cells were treated with lOmM M0CD for 30 min at 37°C, fixed 
doses (standardised on U87/CD4/CXCR4) of viruses were added on ice for 1 hr, and cells were incubated 
in serum free media +/- 0.20pM cholesterol at 37°C for 2 hr. Growth media was added and cells were 
fixed and stained for HIV-2 infection 3 days later. (C) Cholesterol depletion does not affect entry of VSV 
Env on HeLa/CD4 cells. The results shown are representative of at least 6 independent experiments. 
Error bars represent the SDM. The titres of MCR and MCN pn HeLa/CD4 cells are similar in (A) 
because input doses were equalised for ease of comparison.
4.2.8 Directing CD4 out of lipid rafts rescues restricted virus infection.
CD4 localises primarily within lipid rafts on the PM (Popik et al., 2002). I used a HeLa 
cell line expressing a mutant CD4 with a stop codon at amino acid position 399 (H399) 
in the cytoplasmic tail (fig 4.9a). The locations of wild-type CD4 compared to CD4h399 
within lipid rafts were verified. Lipid rafts were prepared from U87/CD4/CXCR4,
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HeLa/CD4, and H399 cells on a sucrose gradient and densitometry was performed on 
the fractions to determine the precise quantity of CD4 in lipid rafts. The lipid raft 
marker placental alkaline phosphatase (PLAP) was tested in parallel for each fraction. 
Fig 4.9b shows that the CD4 of U87/CD4/CXCR4 and HeLa/CD4 cells is found 
predominantly in the lipid raft fractions 3,4, and 5 as is the lipid raft marker, PLAP in 
fig 4.9c. In contrast, the CD4 of H399 cells is found primarily in fractions 9 and 10 and 
was thus excluded from lipid rafts. C-terminally truncated CD4 localising outside of 
lipid rafts has been verified (Popik and Alee, 2004). This truncation is upstream of 
position 419-427, the poly arginine tract, shown to direct CD4 into lipid rafts (Popik 
and Alee, 2004).
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Figure 4.9. CD4 is directed out of lipid rafts by truncation of its cytoplasmic tail.
(A) Truncation o f CD4 cytoplasmic tail at membrane proximal histidine 399 (H399). Lipid rafts were 
prepared from membrane lysates o f U87/CD4/CXCR4, HeLa/CD4, and H399 and analysed for (B) CD4, 
and (C) placental alkaline phosphatase (PLAP) localisation as a lipid raft marker. Results are 
representative o f 4 independent fractionations.
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Fig 4.10b shows that the restriction of MCR in HeLa/CD4 cells is recovered in H399 
cells from 42.0-fold to 1.4-fold. The restrictions of MCNmcrenv and MCNmcrgag 
were much lower than MCR, as expected (6.0 and 5.0-fold respectively). Interestingly, 
the clones that expressed the MCN Env demonstrated a drop in infection on H399 cells 
and those that expressed the MCR Env showed an enhancement of infection on H399 
cells compared to HeLa/CD4 cells in all 5 independent experiments.
t
MCN
mcrgag
_ ■
MCN 
mcrgag
Figure 4.10. Restricted MCR infection is rescued in HeLa/CD4H399 cells.
(A) An equivalent input of 104 FFU (standardised on U87/CD4/CXCR4) of MCR, MCN, MCNmcrewv, 
and MCNmcrgag were plated on U87/CD4/CXCR4, HeLa/CD4, and H399 cells and the FFU/ml 
calculated. (B) The FFU from permissive U87/CD4/CXCR4 infection were divided by the infection on 
restrictive HeLa/CD4 cells (black bars) or permissive H399 (grey bars) to obtain fold restriction. Results 
are representative of 5 independent experiments. Error bars represent SDM.
4.2.9 Endocytic pathways are specifically inhibited with dominant negative 
mutants.
Inhibition of endocytosis with MpCD is cell-type dependent and hypertonic sucrose 
blocks numerous pathways (fig 4.5). In some cell types, MpCD will also inhibit 
clathrin-mediated endocytosis (Rodal et al., 1999). Dominant negative mutants are used 
here to target the three major pathways of endocytosis specifically: clathrin
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(Epsl5XBenmerah et al., 1999; Benmerah et al., 1998), caveolae (dncaveolin-1) 
(Pelkmans et al., 2001), and non-clathrin non-caveolae (Arf6-T27N) mediated 
endocytosis (Fig 4.1 la)(Radhakrishna and Donaldson, 1997). Dynamin is a ‘pinchase’ 
that is used by both clathrin and caveolae endocytosis, thus the dynamin dominant 
negative mutant K44A will inhibit both of these pathways (fig 4.1 la) (van der Bliek et 
al., 1993), whereas the recycling endosome pathway mediated by Adenosine 
ribosylation factor 6 (Arf6) has been reported to be dynamin independent (Delaney et 
al., 2002).
Arf6 regulates a novel membrane recycling system at the cell periphery, between a 
tubular endosome network and the PM (Donaldson, 2003; Radhakrishna and 
Donaldson, 1997). There are six members of the corf gene family and Arf6 is the only 
member of the family to localise to the PM early endosomal network (Cavenagh et al., 
1996). Dominant negative mutants of Arf6 have been designed to study the 
consequences of inhibiting GTP binding (T27N) and GTP hydrolysis (Q67L) (Peters et 
al., 1995). Q67L blocks the movement of PM into the endosome and T27N blocks the 
return of the membrane from the endosome to the PM (Donaldson, 2003). The Arf6 
recycling endosomal network is thought to be a member of the non-clathrin non- 
caveolae group of internalisation pathways that are cholesterol dependent (Naslavsky et 
al., 2004).
Thus far, the Arf6 pathway has not been implicated in the entry of any virus. Although 
Arf6 has been implicated in the HTV-1 Nef mediated down regulation of MHC class I 
molecules from the cell surface (Blagoveshchenskaya et al., 2002), however the 
physiological relevance of this work remains disputed (Larsen et al., 2004).
The Arf6 tubular endosome recycles MHC-I from the cell surface and is involved in the 
trafficking of the IL-2 receptor alpha subunit (Tac). When trafficking is inhibited with 
the Arf6 T27N dominant negative mutant or RNAi MHC-I is directed down a 
degradative clathrin mediated pathway and results in less expression at the cell surface 
(fig 4.1 lb) (Naslavsky et al., 2003; Naslavsky et al., 2004). The dynamin K44A mutant 
and the clathrin Epsl5 mutant inhibit entry of VSV into an acidified endosomal 
pathway for fusion and entry (Sun et al., 2005). Fig 4.lid  shows that expression of 
these mutants knocked down VSV infection by 70% in HeLa/CD4 cells. Arf6 has been
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reported to direct some endosomal traffic into low pH compartments (Delaney et al.,
2002), thus there is a limited (28%) inhibition of VSV infection in the Arf6 T27N 
knockdown cells (fig 4.1 Id).
Caveolae have been implicated as an entry pathway for SV40 and (Pelkmans et al.,
2001), more recently, amphotropic-MLV (MLV-A) (Beer et al., 2005). The MLV-A 
receptor, PiT-2 colocalises with caveolin-1, directing MLV-A into this pathhway (Beer 
et al., 2005). N-terminally eGFP-tagged caveolin-1 (dnCav) behaves in a dominant 
negative fashion when transfected into cells that endogenously express caveolin-1, 
whereas C-terminally eGFP-tagged caveolin-1 acts in a wild-type fashion (Pelkmans et 
al., 2001). The dynamin K44A and dnCavl mutants inhibited HTV(MLV-A) infection 
by 93 and 95%, respectively, compared to the transfection control in fig 4.11c. 
However, HTV-1 NL4.3 was not affected by any of these treatments (fig 4.1 lc).
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Figure 4.11. Dominant negative mutants targeted at key endocytic proteins block 
specific endocytic pathways.
(A) Diagram of the different endocytic pathways targeted by dominant negative mutants in this study.
(B) HeLa/CD4 cells were transfected with the Arf6  T27N mutant or Arf6  RNAi for 48 hr and stained 
with primary MHC-I mAb and FITC conjugated secondary antibody as described in materials and 
methods. Cells were visualised by confocal microscopy. (C) HeLa/CD4 cells were transfected with 
dominant negative mutants and infected with HIV-1 NL4.3 and an amphotropic-MLV Env pseudotype of 
HIV-2 [HIV(MLV-A)], fixed and stained for HIV-1 and HIV-2 infection two days later. (D) HeLa/CD4 
cells were transfected with control, Arf6 , dynamin (K44A), and clathrin (Eps 15) dominant negative 
mutants for 48 hr, infected with an HIV(VSV) pseudotype and fixed and stained for HIV infection 3 days 
later.
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4.2.10 Dynamin K44A and Arf6 T27N dominant negative mutants recover 
infection by Lv2 restricted HIV-1 89.6 and HIV-2 MCR in HeLa/CD4 cells.
Expression of dominant negative mutants dynamin K44A and Arf6 T27N in HeLa/CD4 
resulted in the rescue of both MCR (5.0-fold for both) and 89.6 (6.0 to 7.0-fold 
respectively). In contrast, the clathrin dominant negative mutant, Eps 15 and the 
dncaveolin-1 (data not shown) had little effect on the infectivity of either MCR or 89.6 
in HeLa/CD4 cells (1.0 and 2.0-fold respectively, fig 4.12b). The unrestricted HTV-2 
MCN and HIV-1 NL4.3 viruses were relatively unaffected by the dynamin, Arf6, 
caveolin-1, or clathrin dominant negative mutants.
RNAi knockdown of Arf6 expression was used to confirm the specificity of the Arf6 
T27N dominant negative mutant. Fig 4.12c shows that RNAi knockdown of Arf6 
recovered 3.0-fold of MCR infection in HeLa/CD4 cells over the RNAi control, 
compared to 3.7-fold when the Arf6 T27N construct was used, in this experiment. 
MCN was unaffected by any of these treatments, confirming a role for Arf6 in Lv2 
restriction.
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Figure 4.12. Arf6 and dynamin dominant negative mutants recover Lv2 restricted 
HIV-1 and HTV-2 infection in HeLa/CD4 cells.
(A) HeLa/CD4 cells were transfected with specific endocytosis knockdown mutants or (C) siRNA 
oligomers directed against control and Arf6, and infected two days later with titrations of restricted (A) 
HIV-1 89.6, (A,C) HIV-2 MCR and unrestricted (A) HIV-1 NL4.3 and (A,C) HIV-2 MCN. Control 
represents infection of cells transfected with an eGFP repressing construct or siRNA directed against the 
D6 blood group antigen. (B) Infection on cells transfected with each dominant negative mutant in (A) 
was divided by the infection from the control in (A) to obtain fold recovery of infection. Results are 
representative of 7 independent experiments. Error bars represent SDM.
4.2.11 HeLa/CD4 cells expressing Arffi T27N and dynamin K44A dominant 
negative mutants rescued Lv2 restricted infection by MCR gag and envelope gene 
swap molecular clones.
Similar to the results in fig 4.12, the recovery of MCR with dynamin K44A and Arf6 
T27N was 4.5 and 5.0-fold, respectively (fig 4.13b). The gene swap molecular clone 
viruses each showed about half the recoveiy of MCR with the Arf6 and dynamin 
dominant negative mutants: MCNmcrgag and MCNmcrewv were rescued between 2.0 
and 3.0-fold with dynamin K44A, or Arf6 T27N mutant on HeLa/CD4 cells (Fig 4.13b).
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Figure 4.13. Arf6 and dynamin dominant negative mutants recover gag and 
envelope gene swap virus infection in HeLa/CD4 cells.
HeLa/CD4 cells were transfected with endocytosis knockout mutants and infected 2 days later with (A) 
MCR gag and env swaps, MCNmcrgag and MCNmcrewv, and fixed and stained for HIV-2 infection three 
days later. (B) Infection on cells transfected with each dominant negative mutant was divided by the 
infection from the control to obtain fold recovery of infection. Results shown are representative of 3 
independent experiments. Error bars represent SDM.
The restriction of HIV-2 MCR and HIV-1 89.6 is recovered by inhibiting Arf6 or 
dynamin activity so it is interesting to see what effect knocking out both of these 
pathways, at the same time, has on restricted virus infection. Fig 4.14e shows that the 
double knockdown of Arf6 and dynamin doesn’t increase recovery of infection of MCR 
over that seen with the single knockdowns but there is an additive effect of double 
Arf6/dynamin knockdown on recovery of 89.6 infection. 89.6 was recovered 2.2-fold 
and 4.3-fold with the dynamin and Arf6 mutants, respectively, but the recovery 
increased to 10.5-fold with the dynamin/Arf6 double knockout (fig 4.14b).
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Figure 4.14. Cotransfection of Arf6 and dynamin dominant negative mutants has 
an additive effect on restriction recovery of HIV-1 89.6 in HeLa/CD4 cells.
(A) Arf6 T27N and dynamin K44A mutants were cotransfected into HeLa/CD4 cells (Dyn/Arf) or 
individually, infected with restricted HIV-2 MCR, HIV-1 89.6, and unrestricted MCN. (B) The FFU 
obtained from infection on cells transfected with each dominant negative mutant was divided by the 
infection from the control to obtain fold recovery of infection. Results are representative of 3 
independent experiments. Error bars represent SDM.
4.3 Discussion:
This chapter demonstrates that a lipid raft dependent endocytic pathway mediates Lv2 
restriction in HeLa/CD4 cells. Restricted virus Env directs the viral core into this 
restrictive Lv2 compartment, where trafficking of the retrovirus to the nucleus is 
terminated. Specific pathways of endocytosis were blocked with dominant negative 
mutants and it was demonstrated that direction into the restrictive compartment is via an 
Arf6 and dynamin dependent pathway, and at least partly explains Lv2. Furthermore, 
the Lv2 compartment is pH-independent and the classical clathrin and caveolae 
endocytic pathways are not involved. These data support the model that Lv2 restriction 
is dependent on a specific pathway of entry (Schmitz et al., 2004).
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The role of endocytosis and PM trafficking of CD4 in HIV infection has been reported 
previously, and cells that do not actively internalise CD4 are more infectable than cells 
that rapidly endocytose CD4 (Pelchen-Matthews et al., 1995). In keeping with this, Lv2 
restricted virus infection is recovered by inhibiting endocytosis with hypertonic sucrose, 
by depletion of lipid rafts and by directing CD4 outside of lipid rafts, which supports 
the notion of an endocytic route of restricted virus internalisation.
CD4 is internalised by HeLa/CD4 cells in a clathrin dependent manner (Pelchen- 
Matthews et al., 1992; Pelchen-Matthews et al., 1995) and hypertonic media inhibit the 
formation of the clathrin triskelion on the PM (Heuser and Anderson, 1989). 
Cholesterol depletion has been suggested to inhibit clathrin dependent endocytosis as 
well as lipid raft dependent pathways in a Chinese hamster ovary cell line (Subtil et al.,
1999), but there was no inhibition of Trf-FITC uptake in either HeLa/CD4 or 
U87/CD4/CXCR4 cells. Indirect evidence that Lv2 acts independently of clathrin is 
that restricted virus pseudotyped with a clathrin dependent VSV Env is rescued from 
Lv2 restriction (McKnight A, 2001; Schmitz et al., 2004; Sun et al., 2005). Lastly, the 
clathrin dominant negative mutant, Eps 15 did not have an effect on restricted virus 
infection in restrictive cells confirming that a clathrin route of entry has little or no role 
in Lv2 restriction.
Recovery of HTV infection by treatment of target cells with pH neutralising reagents has 
been described previously and is dependent on the HTV isolate used (Fredericksen et al., 
2002; Wei et al., 2005). However the pH-independence of Lv2 restriction shown by 
monensin and bafilomycin Al treatment of restrictive cells suggest that acidified 
endosomes are not involved in Lv2 restriction. Furthermore, pseudotyping MCR with a 
pH-dependent VSV Env rescues Lv2 restricted virus infection (McKnight A, 2001; 
Schmitz et al., 2004), which further supports the model that Lv2 restriction occurs in a 
pH-independent compartment.
A more precise identification of the specific endocytic route(s) leading to Lv2 was 
determined using dominant negative mutants. Restricted virus infection is recovered 
when the Arf6 T27N dominant negative mutant is over-expressed in restrictive cells.
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Additionally, infection is recovered when the dynamin K44A dominant negative mutant 
is over-expressed in HeLa/CD4 cells.
Double Arf6 and dynamin knock down experiments indicated that there was no additive 
effect on MCR suggesting that these mechanisms may be interconnected. The 
iiftemalisation of M2 muscarinic acetylcholine receptor in HeLa cells is Arf6 dependent 
but dynamin independent (Delaney et al., 2002). In MDCK cells, Arf6 endocytic 
recycling requires the action of dynamin (Altschuler et al., 1999). Therefore, dynamin 
involvement in Arf6 trafficking may be cell-type dependent. But dynamin is involved 
in Lv2 restriction in HeLa/CD4 cells and is a part of the Arf6 component of restriction. 
HIV-2 MCR infection is not recovered more with the double Arf6/dynamin 
knockdowns compared to Arf6 or dynamin single knockdowns suggesting that these 
mechanisms are not mutually exclusive. HTV-1 89.6 on the other hand shows additive 
infection recovery when both Arf6 and dynamin are knocked down. This may be 
because, in this case, some restricted 89.6 is internalised by an Arf6-independent 
dynamin dependent pathway that eventually traffics 89.6 to the Arf6 early endosome. 
Indeed, the dominant negative clathrin Eps 15 mutant recovers some restricted 89.6 but 
not MCR infection. The majority of 89.6 restricted virus may enter the Arf6 endosome 
by the Arf6/dynamin route, like MCR (fig 4.15). The transfer of proteins in HeLa cells 
between the Arf6 early endosome and the clathrin Rab5 early endosome via an 
intermediate compartment has been described (fig 4.15) (Delaney et al., 2002). This 
model is certainly favoured by the additive recovery of 89.6 infection in the double 
dynamin/Arf6 dominant negative knockout cells but not by die MCR infection 
recovery. To conclude, MCR and 89.6 may enter the restricting Arf6 compartment by 
different pathways.
154
C hapter 4 An endocvtic route o f  delivery to Lv2 restriction
MCR, 89.6 19.6
Dynamm (v la clathrin?)tamin
<^ArfB+(Lv2 r—trtctton]
Figure 4.15. Dynamin and Arf6 mediated pathways of restricted HIV entry.
The viral env and gag genes act in concert to mediate Lv2 restriction (Schmitz et al., 
2004), and mediate rescue of infection upon hypertonic sucrose treatment (Marchant et 
al., 2005). This suggests that the restricted virus Env targets the susceptible capsid 
cargo into the Lv2 compartment where the virus is restricted. The recovery of HIV 
infection in HeLa/CD4 cells with lysosomotropic agents has been reported 
(Fredericksen et al., 2002; Pelchen-Matthews et al., 1995) and like Lv2, the viral Env 
mediates the recoveiy of infection in this system (Wei et al., 2005). Interestingly, an 
MCN Env pseudotype of HTV-1 was rescued from an apparent restriction in HeLa/CD4 
cells with sucrose treatment This suggests that MCN Env directs HTV-1 into the Lv2 
compartment (or Lv2-like) for restriction, suggesting that in the wild-type unrestricted 
MCN virus, the Gag and Env cooperate their activities to avoid Lv2 restriction. In other 
words, MCN Gag core has evolved to infect HeLa/CD4 cells via the Lv2 restriction 
route lending support to the theory that the viral env and gag must co-evolve to avoid 
restriction (Schmitz et al., 2004).
MpCD had little effect on the infectivity of the gene swap, MCNmcrewv and 
MCNmcrgag, and only wild-type MCR infection was recovered on HeLa/CD4 cells 
with this treatment. This is in contrast to the recovery of MCR and MCNmcrewv 
infection in HeLa/CD4 cells with sucrose treatment. However, if the sucrose treatment 
and MpCD were acting at different stages along the restriction pathway this result may 
not be so surprising (fig 4.16). As reported previously, hypertonic media inhibit early 
events in endocytic uptake (Heuser and Anderson, 1989), HIV Env may direct the
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virion into these sites hence the Env mediated recovery of restriction with hypertonic 
sucrose. Only wild-type MCR, with both MCR Env and Gag together, was rescued 
with MpCD treatment. This may suggest that by the time the virus reaches the MpCD 
compartment, Env has already performed its, restriction-targeting, role.
MCR and MCN env
Hypertonic
sucrose
MCR gag 
(Lv2 restriction)
gag
Nucleus
Figure 4.16. Methyl-p-cyclodextrin and sucrose may act on different stages of the 
restriction pathway.
In this chapter I show that both an (1) endocytic lipid raft pathway, elucidated with 
sucrose treatment and MpCD, and (2) a dynamin dependent Arf6 pathway, elucidated 
with dominant negative mutants, are involved in Lv2 restriction. However it has not 
been shown whether these two mechanisms of entry are the same or different pathways. 
Experiments where endocytosis was inhibited with MpCD or sucrose in cells expressing 
dominant negative endocytosis mutants proved too toxic for accurate analysis of results. 
Regardless, there are interesting similarities between the cholesterol requirements of the 
restriction and the Arf6 pathway; both the Arf6 pathway and Lv2 require lipid rafts and 
cholesterol (Hiroyama and Exton, 2005; Kirkham et al., 2005; Naslavsky et al., 2004). 
It is therefore possible that the Arf6 dominant negative characterisation o f the restriction 
and the MpCD and hypertonic sucrose studies represent the same pathway of restriction.
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5.1 Introduction:
Numerous mechanisms of innate immunity against retroviral infection have been 
described previously (reviewed in (Bieniasz, 2003; Goff, 2003; Goff, 2004)). While 
some of these mechanisms act prior to virus entry into cells the recently described 
‘restriction factors’ act post-entry. The first of these to be discovered and investigated 
in detail is the Friend virus susceptibility-1 restriction (Fvl) (Lilly, 1967). B-tropic and 
N-tropic Murine Leukaemia Viruses (MLV) readily infect cells from BALB/c and NIH 
Swiss mice, respectively, however BALB/c mouse cells restrict N-tropic MLV infection 
by approximately 1000-fold and NIH cells restrict B-tropic virus by 100-fold. The aptly 
named NB-tropic MLV can infect both cell types equally as well (Hartley et al., 1970). 
When the genetic locus of the Fvl restriction was mapped it was discovered that the 
Fvln and Fvlb restriction phenotypes are alleles of the same jv l  gene (Pincus et al., 
1971).
Fvl has been cloned and shares sequence similarity to a mouse endogenous retrovirus 
gag that is unrelated to MLV. Localised to mouse chromosome 4, Fvl has its own 
retroviral major homology region (MHR) that it requires for restriction activity (Best et 
al., 1996). Regions at the N and C-terminal ends are also required to restrict N or B- 
tropic MLV infection (Bishop et al., 2001).
MLV can infect human cells if the MLV ecotropic Env is replaced with a pantropic 
VSV Env. These mixed MLV (VSV) pseudotypes were used to show that N-tropic 
MLV is restricted in human cells (Towers et al., 2000). The N-MLV restriction in 
human cells, termed ‘R efl’, was later shown to also target EIAV (Hatziioannou et al.,
2003). The pattern of Refl restriction, whereby N-tropic MLV but not B-tropic MLV is 
restricted, is also present in cells from a wide variety of mammals (Towers et al., 2000).
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The target of Fvl and Refl restrictions is the MLV capsid protein (CA). When residue 
110 of the MLV CA is an acidic amino acid it is sufficient to confer B-tropism to MLV, 
whereas if a basic amino acid is substituted at this site the tropism switches to N-tropic 
(Kozak and Chakraborti, 1996). Refl was discovered using the N-tropic and B-tropic 
MLV Gag-Pol packaging constructs that differ at amino acid position 110 of capsid. 
Thus, it was apparent that, like Fvl, Refl was a CA directed restriction (Towers et al.,
2000). However, unlike Fvl, Refl restriction was shown to occur before reverse 
transcription (Jolicoeur and Rassart, 1980; Towers et al., 2000; Yang et al., 1980). It 
has even been proposed that Fvl requires the action of huTRIM 5a to effect viral 
restriction when Fvl is expressed in human cells (Keckesova et al., 2004).
Lvl is a post-entry restriction to VSV-G pseudotyped HTV, SIV, and MLV in non­
human primate cells (Cowan et al., 2002). However its activity in different primate 
cells varies slightly. Generally, Lvl is more restrictive towards HIV-1 than S IV m ac and 
MLV in Old World monkey cells (Hofmann et al., 1999). However, S IV m ac is more 
restricted than HTV-1 in New World monkey cells (Hofmann et al., 1999). Examination 
of primary cells from various tissues suggests that the species and not the tissue of 
origin determine this restriction (Bieniasz, 2003; Hofmann et al., 1999). Lvl in African 
green monkey cells has broader activity than Lvl in other non-human primates or Refl 
in human cells because it can restrict N-tropic MLV, STVmac, HTV-1 and 2, and EIAV, 
(Besnier et al., 2002; Bieniasz, 2003; Cowan et al., 2002; Hatziioannou et al., 2003). 
Lvl is known to restrict HTV-1 in Rhesus macaque, and even rabbit and pig cells 
(Hatziioannou et al., 2003; Hofmann et al., 1999). Like Refl, Lvl activity is directed 
against the CA of the incoming retrovirus and occurs pre-reverse transcription (Owens 
et al., 2004; Owens et al., 2003).
A characteristic of the Fvl, Refl, and Lvl restrictions is that they can be “abrogated”
v
with saturating doses of ‘decoy’ virus-like particles (VLPs). The in-vitro saturation of 
restriction factors by pre-treatment with genome-defective particles was first described 
for Fvl (Boone et al., 1990; Duran-Troise et al., 1977). Restriction abrogation 
experiments are performed by saturating cellular restriction factors with concentrated 
doses of VSV Env pseudotypes of MLV, HIV, and STV Gag cores, as has been 
described for Refl and Lvl [(Towers et al., 2002) and (Besnier et al., 2002)
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respectively], prior to challenge with sensitive virus resulting in loss of restriction 
(apparent increase in sensitive/reporter virus infection).
Lv2 is a restriction to HIV infection in human cells that is mediated by both the HIV 
Env and CA (Schmitz et al., 2004). In chapter 3 I introduced the model of Lv2 
restriction of the molecular clones MCR and MCN in HeLa/CD4 cells and the 
prevalence of Lv2 among HTV-1 and HTV-2 viruses. Chapter 4 investigated how 
restricted viruses are directed into Lv2 restriction via an endocytic pathway (Arf6 and 
dynamin dependent) (Marchant et al., 200S), and reinforced the model that HTV Gag 
and Env act in concert to mediate Lv2 restriction.
In this chapter I set out to examine whether, similar to Refl, Lvl and Fvl, Lv2 is 
saturable. N and B-tropic MLV (MLV-N/B) Gag-Pol cores with MCR and MCN Env 
could saturate the Lv2 restriction factor and rescue restricted virus infection, however 
MLV-N/B with VSV Env had no effect. In contrast to Refl, which restricts N but not B 
tropic MLV, I show that Lv2 can restrict both N and B tropic cores and that MLV-B has 
the most potent ability to absorb and abrogate Lv2 restriction factors. Thus in this way I 
was able to investigate the relationship between Refl and Lv2.
5.2 Results:
5.2.1 Lv2 is distinct from Refl in human cells.
Viruses that are susceptible to Refl restriction in human cells and Lvl restriction in 
non-human primate cells are rescued by pre-absorption of the Refl restriction factors 
with saturating doses of decoy virus particles (Besnier et al., 2002). I sought to 
determine whether the pre-absorption of Refl by susceptible virus like particles (VLPs) 
on Lv2 restrictive cells could rescue restricted MCR. As a positive control, Refl 
saturating doses of VSV-G pseudotyped MLV-N and B VLPs with a zeomycin 
resistance transfer vector were used to rescue VSV Env pseudotypes of MLV-N Gag- 
Pol cores with an eGFP reporter vector from Refl restriction. Fig 5.1 shows that 
infection by MLV-B(VSV) pseudotypes are not enhanced by absorption with the decoy 
VLPs. The MLV-N(VSV) pseudotype infections were rescued in all of the cells tested
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when absorption was carried-out with MLV-N(VSV) but not MLV-B(VSV) saturating 
VLPs (data not shown). MLV-N(VSV) titre increased by 7.5-fold in HeLa/CD4 cells. 
These results are consistent with those previously described for Refl restriction 
(Hatziioannou et al., 2003).
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Figure 5.1. Refl can be saturated in HeLa/CD4 cells by pre-treatment with 
vesicular stomatitis virus envelope pseudotyped N-tropic MLV particles.
To confirm that Refl could be saturated with N-tropic MLV, stocks of MLV-N(VSV) were added to 
HeLa/CD4 cells at an MOl of 10. Four hr later, MLV-N(VSV) with a GFP reporter transgene was 
titrated onto the cells and GFP was detected 3 days later by flow cytometry. The results shown are 
representative of 2 independent experiments.
Fig 5.2 shows the titration of MLV-N(VSV) and MLV-B(VSV) on the Fvl-null cell 
line, mus-dwmi tail fibroblasts (MDTF), a permissive cell, to determine the actual 
infectious units per ml of pseudotype stocks in the absence of an Fvl restriction 
phenotype (Lander and Chattopadhyay, 1984). The infectious titre of MLV-N(VSV) 
and MLV-B(VSV) in MDTF cells are 3.5 x 105 and 4.0 x 105 infectious units per ml, 
respectively, as shown in fig 5.2. The titre of MLV-N(VSV) on HeLa/CD4 and 
U87/CD4/CXCR4 cells is 5.2 x 103 and 20 infectious units per ml respectively, 
indicating that both Lv2 restrictive and permissive cells are Refl positive.
40.6%
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Figure 5.2. Permissive U87/CD4/CXCR4 cells have more Refl activity than Lv2 
restricted HeLa/CD4 cells.
MLV-N(VSV) and MLV-B(VSV) are equivalent titre in Fvl null MDTF cells. MLV-N(VSV) and MLV- 
B(VSV) vector pseudotypes were titrated in Refl positive U87/CD4/CXCR4, HeLa/CD4, and on Fvl 
null MDTF cells. Infectious units were determined by flow cytometry. Results shown are representative 
of 3 independent experiments. Error bars represent the SDM.
To determine whether MLV-N(VSV) vector pseudotype could saturate Lv2 I performed 
a saturation experiment. Lv2 sensitive MCR was titrated on restrictive HeLa/CD4, 
GHOST, and permissive U87/CD4/CXCR4 cells (McKnight A, 2001; Schmitz et al.,
2004), that had been pretreated with Refl-saturating doses of MLV-N(VSV) (fig 5.3). 
The titre of MCR increased in the MLV-N(VSV) treated HeLa/CD4, GHOST, and 
U87/CD4/CXCR4 cells by factors of 5.0, 2.0, and 2.5-fold, respectively, over the mock 
transfection control. Therefore, pre-treatment of all cells with MLV-N(VSV), 
regardless of whether they were Lv2 susceptible or not, resulted in increases in MCR 
titres. Thus there was no abrogation of Lv2 restriction with MLV-N or B(VSV).
Figure 5.3. The infectious titre of Lv2 restricted MCR is not affected by saturation 
of Refl with vesicular stomatitis virus envelope pseudotypes of N-tropic MLV.
□  U87/CD4/CXCR4 
■ HeLa/CD4 
II GHOST/CXCR4
MLV-N MLV-B Transfection Control
(VSV) (VSV) control
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MCR was titrated on U87/CD4/CXCR4, HeLa/CD4, and GHOST cells that had been pre-treated with 
Refl-saturating doses of MLV-N(VSV). MLV-B(VSV) was added as a Refl negative control.
5.2.2 MCR envelope confers Lv2-Iike restrictions to N-tropic, B-tropic, and
%
Moloney MLV virus-like particles.
It has been reported that a VSV Env rescues MCR in restrictive cell types. Furthermore 
MCR Env will confer restriction to resistant HIV-2 MCN and HTV-1 NL4.3 (Schmitz et 
al., 2004). The effect that MCR, MCN, and VSV Envs have on infection of MLV-N, B, 
and Mo Gag-Pol cores in HeLa/CD4, H399 and U87/CD4/CXCR4 cells was 
determined. The results of the flow cytometric analysis are illustrated in figs 5.4a, c, 
and e. The fold restriction (U87/CD4/CXCR4 divided by either the restricted 
HeLa/CD4 titre or permissive H399 titre) is shown in fig 5.4b, d, f.
The titres of VSV-G pseudotyped MLV-N, B and Mo Gag-Pol cores are equivalent on 
U87/CD4/CXCR4, HeLa/CD4, and H399 cells. The 55.0-fold lower titre of MLV- 
N(VSV) compared to MLV-B(VSV) is expected, due to Refl. However when the MCR 
Env was used to pseudotype MLV cores this conferred fold restrictions in HeLa/CD4 
cells of 35.7, 57.0-fold and 65.0-fold to MLV-B, MLV-N and MLV-Mo cores, 
respectively (figs 5.4b, d, and f). Interestingly, the ‘unrestricted’ MCN Env conferred a 
14.9-fold restriction to the MLV-B core and a small but noteworthy 8.3-fold restriction 
to the MLV-Mo core. No restriction by MCN Env to MLV-N was detected in 
HeLa/CD4 cells. Where MCR and MCN Env conferred an Lv2-like restriction to the 
MLV cores in HeLa/CD4 cells there was almost complete recovery of restriction by 
H399 cells, as demonstrated for Lv2 restricted HIV-2 MCR in chapter 4.
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Figure 5.4. MCR envelope confers Lv2 restriction to N-tropic, B-tropic and 
Moloney MLV Gag-Pol cores.
(A) MLV-B (C) MLV-N (E) and MLV-Mo pseudotypes with VSV, MCR, and MCN Envs were titrated 
on U87/CD4/CXCR4, HeLa/CD4, and H399 cells. Three days later, eGFP positive cells were determined 
by flow cytometry and the infectious units per ml were calculated. Fold restriction of the (B) MLV-B (D) 
MLV-N and (F) MLV-Mo pseudotypes were calculated by dividing the infectious titre on 
U87/CD4/CXCR4 by the titre from HeLa/CD4 or H399.
5.2.3 Restriction of MLV occurs pre-reverse transcription whereas restriction of 
HIV-2 occurs post-reverse transcription.
Lv2 restriction occurs post-reverse transcription but Refl occurs pre-reverse 
transcription (McKnight A, 2001; Towers et al., 2002). I therefore wanted to determine 
the point at which MLV-N and B are restricted in these human cells.
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U87/CD4/CXCR4, HeLa/CD4, and H399 cells were challenged with MLV-N and 
MLV-B MLV Gag-Pol cores pseudotyped with VSV, MCR, and MCN Envs and 
analysed by quantitative PCR (qPCR) (to first strand synthesised proviral DNA) 10 min, 
3 and 18 hr post-infection (fig 5.5a). QPCR of gag-LTR was also performed to detect 
full-length reverse transcribed provirus of HIV-2s MCR and MCN as a comparison to 
the qPCR of the MLV vector pseudotypes in fig 5.5a (fig 5.5b).
Fig 5.5a shows that MLV-B(VSV) is synthesising the first strand of the MLV vector 
genome to equivalent levels in U87/CD4/CXCR4, HeLa/CD4, and H399 cells. As 
expected, MLV-N(VSV) synthesised 111.2, i 1.0 and 76.5-fold fewer first strand 
reverse transcripts (18 hr) in U87/CD4/CXCR4, HeLa/CD4, and H399 cells, 
respectively, than MLV-B(VSV). The MLV vector pseudotypes that have an MCR Env 
demonstrated less first strand synthesis on HeLa/CD4 than U87/CD4/CXCR4 cells. 
MLV-N(MCR) synthesised 14.0 eGFP copies in U87/CD4/CXCR4 compared to 2.0 
copies in HeLa/CD4 cells and MLV-B(MCR) synthesised 307.0 copies compared to 6.0 
in U87/CD4/CXCR4 and HeLa/CD4 cells, respectively. The 48.0-fold difference in 
MLV-B(MCR) first strand synthesis in U87/CD4/CXCR4 compared to HeLa/CD4 cells 
is reminiscent of the 35.7-fold restriction of this pseudotype in fig 5.4b. The 7.0-fold 
drop in first strand copies of MLV-N(MCR) from 14.0 to 2.0 copies in 
U87/CD4/CXCR4 and HeLa/CD4 cells, respectively, is considerably less than the 57.0- 
fold restriction of this pseudotype in fig 5.4d. This number of qPCR copies is however 
at the lower limit of detection and therefore less accurate. The MLV-N(MCN) 
pseudotype was also at the lower limit of qPCR detection and the number of copies in 
U87/CD4/CXCR4 and HeLa/CD4 cells was an equivalent 9.0 and 7.0 copies but this is 
reminiscent of the lack of restriction of MLV-N(MCN) in U87/CD4/CXCR4 and 
HeLa/CD4 cells in fig 5.4d. Since the synthesis of the first strand qPCR in fig 5.5a 
matches the drop in titre of these vector pseudotypes during restriction in fig 5.4 the 
restriction of MCR and MCN pseudotyped MLV cores is therefore occurring pre­
reverse transcription.
The above data is in contrast to that seen for Lv2 restriction. The restriction of HIV-2 
MCR in HeLa/CD4 cells occurs post-reverse transcription as shown in fig 5.5b, and 
described previously (McKnight A, 2001; Schmitz et al., 2004). At 18 hr post­
infection, HIV-2s MCR and MCN demonstrate 20.0 and 40.0 copies, respectively, of
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full-length gag-LTR provirus. This 2.0-fold difference does not account for the 40.0- 
fold restriction between MCR and MCN in HeLa/CD4 cells in fig 3.8 of chapter 3.
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Figure 5.5. Lv2 restricted MLV is blocked pre-reverse transcription whereas Lv2 
restriction of MCR occurs post-reverse transcription.
(A) qPCR of first-strand cDNA synthesis by MLV-N and B Gag-Pol pseudotypes. Infections were 
synchronised on ice then incubated at 37°C for 10 min, 3 hr, and 18 hr time points and eGFP qPCR was 
performed on the cellular DNA. Envs used to pseudotype MLV-N and B Gag-Pol are indicated in 
brackets: (MCR), (MCN) and (VSV). (B) QPCR for full-length reverse transcripts of MCR and MCN 1, 
2, 6, 18 hr post-infection in U87/CD4/CXCR4, HeLa/CD4, and H399 cells. The results shown are 
representative of 4 independent experiments in (A) and 3 independent experiments in (B). Error bars 
represent the standard error of the mean.
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5.2.4 B-tropic MLV pseudotype with an HTV-2 envelope can abrogate Lv2 and 
rescue restricted HTV-2 MCR and HTV-1 89.6 infection.
As shown in fig 5.3, MLV-N or B(VSV) vector pseudotypes do not rescue Lv2 
restriction. But as previously reported (Schmitz et al., 2004), VSV-G overcomes Lv2 
and saturation may require delivery by a different viral Env. I sought to determine if 
MLV Gag-Pol cores could saturate-out Lv2 restriction when targeted using an HTV-2 
Env rather than VSV-G. Since MCR Env was the most potent at restricting MLV-N 
and B these pseudotyped viruses were added at high MOI (approximately 104 pg RT 
ELISA activity) after challenge with sensitive HIV-2 MCR, HIV-1 89.6, and resistant 
HIV-2 MCN, and HIV-1 NL4.3. To prevent receptor interference, binding of the 
indicator and abrogating/saturating viruses was done on ice and uptake into the cell was 
triggered at 37°C (materials and methods).
Fig 5.6 shows the results of this abrogation assay in U87/CD4/CXCR4 and HeLa/CD4 
cells. Interestingly, both the MLV-B(MCN) and MLV-B(MCR) pseudotypes were able 
to saturate Lv2 restriction in HeLa/CD4 cells (fig 5.6c and d). Suggesting that MCN 
Env delivers to a restrictive compartment. Fig 5.6d shows that MCR infection on 
HeLa/CD4 cells was recovered 3.5 and 3.0-fold, by saturation with MLV-B(MCR) and 
MLV-B(MCN), respectively. MCN was unaffected by any of the treatments in 
HeLa/CD4 cells and neither MCR nor MCN were affected by abrogating doses in 
U87/CD4/CXCR4.
Infection by HTV-1 89.6, the Lv2 restricted HTV-1, in HeLa/CD4 cells increased from 
18 to 120 FFU upon abrogation with the MLV-B(MCR) pseudotype and 72.5 FFU with 
MLV-B(MCN) (fig 5.6c). This corresponds to recovery of 89.6 infection of 6.7-fold 
and 4.0-fold for the MLV-B(MCR) and MLV-B(MCN) pseudotypes, respectively (fig 
5.6d). HIV-1 NL4.3 infection in U87/CD4/CXCR4 and HeLa/CD4 cells was relatively 
unaffected by these treatments.
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Figure 5.6. B-tropic MLV pseudotypes with HIV-2 envelopes abrogate Lv2 
restriction and recover restricted HIV-1 and HIV-2 virus infection.
Fixed doses of HIV-2s MCR, MCN and HIV-Is 89.6 and NL4.3 were plated on (A) U87/CD4/CXCR4, 
and (C) HeLa/CD4 cells on ice. Neat pseudotype supernatant was plated over the HIV-2 and HIV-1 
challenge virus on ice for a further 30 min, incubated at 37°C, then fixed and stained for HIV-2 infection 
3 days later. (B,D) The FFU from the MLV(HIV-2) saturations were divided by the FFU from the 
control to obtain fold recovery. Results shown are representative of 12 independent experiments. Error 
bars represent the SDM.
5.2.5 Refl (human tripartite motif protein 5a) reduces the potency of HIV-2 
envelope pseudotypes of N-tropic MLV to saturate out the factor responsible for 
Lv2 restriction.
Figs 5.6 and 5.7a show that MLV-B(HIV-2) pseudotyped particles can saturate Lv2 
restriction and partially rescue some restricted HIV-1 and 2 infection. Since MLV- 
N(VSV) is known to be Refl restricted by huTRIM 5a, I wanted to determine if the 
potency of MLV-N(HIV-2) particles to saturate Lv2 restriction could be improved by 
knocking down TRIM 5a. I noted that MLV-N pseudotypes with HIV-2 Envs were 
unable to saturate Lv2 and recover MCR infection as in the experiment in fig 5.7a. 
HeLa/CD4 cells were treated with TRIM 5a RNAi before carrying-out an Lv2
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saturation experiment as in fig 5.6. Fig 5.7b and c show that MLV-N(HIV-2) particles 
are as potent as MLV-B(HIV-2) particles at rescuing Lv2 restricted MCR when TRIM 
5a is first knocked down. Suggesting that Refl can also restrict HIV-2 Env 
pseudotyped cores. Interestingly, the MLV-N(MCN) was as efficient as the MLV- 
N(MCR) at recovering MCR infection by 5.3-fold. This also suggests, as in fig 5.6, that 
MCN Env also delivers into a restrictive compartment.
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Figure 5.7. N-tropic MLV Gag-Pol core can abrogate Lv2 restriction if 
Refl/TRIM  5a is 'knocked down’ p rio r to challenge.
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HeLa/CD4 cells were (B) treated with RNAi oligomers directed against TRIM 5a or (A) without and 
abrogation experiments were performed as in fig 5.6. (C) The fold recovery (shown below) was obtained 
by dividing the FFU from the MLV(HIV-2) pseudotype treated infection by the FFU from the control 
infection in (B). Results are representative of 3 independent experiments. Error bars represent the SDM.
5.2.6 Infection by HIV-2 envelope pseudotypes of B-tropic MLV can be enhanced 
in Lv2 restrictive HeLa/CD4 and permissive H399 cells with abrogating doses of 
HIV-2: evidence for other restriction pathways.
HIV-2 Env pseudotypes of MLV-N and -B can saturate Lv2 and partially recover HIV- 
2 and HIV-1 infection on HeLa/CD4 cells (figs 5.6 and 5.7). To determine whether the 
same pattern of recovery would occur with saturation of Lv2 with high MOI of HIV-2 
virus followed by challenge with MLV-B(MCR) and MLV-B(MCN). Dilutions of 
MLV-B(MCR) and MLV-B(MCN) vector pseudotypes were bound to cells on ice 
together with high MOI doses of HIV-2. In HeLa/CD4, the titre of MLV-B(MCR) was 
not rescued to a large extent by pre-treatment with MCN, MCR, and MCR(VSV) (fig 
5.8a). Infectivity of MLV-B(MCN) on HeLa/CD4 was enhanced more than 5-fold by 
pre-treatment with MCN, MCR, and MCR(VSV) respectively (fig 5.8b). Rescue of 
both MLV-B(MCR) and MLV-B(MCN) on H399 cells was more pronounced with 7 to 
10-fold recovery with MCN, MCR, and MCR(VSV) generally seen, in figs 5.8c and d. 
The results suggest alternative mechanisms of Lv2 restriction are operating and that 
saturation experiments need to be interpreted with caution.
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Figure 5.8. Reciprocal abrogation: infection by HIV-2 envelope pseudotypes of B- 
tropic MLV is rescued on both Lv2 restrictive and permissive cell types upon 
abrogation with HIV-2.
RT ELISA standardised inputs of MLV pseudotypes were added to (A, B) HeLa/CD4 and (C, D) H399 
cells on ice. Neat supernatant (approx 104 pg RT U) of MCR, MCN, and MCR(VSV) were used to pre­
treat cells. Cells were harvested two days later and eGFP positive cells were determined by flow 
cytometry. (# x) denotes the fold recovery over control. The results shown are representative of 3 
independent experiments.
5.3 Discussion:
The results shown here demonstrate that MLV-N and -B pseudotyped with VSV-G are 
unable to saturate Lv2, resulting in no recovery of HIV-2 MCR infection. Substitution 
with either an MCR or MCN Env results in abrogation of Lv2 and recovery of restricted 
HIV-1 89.6 and HIV-2 MCR. These results support the model that Env plays a 
significant role in the susceptibility of virus to restriction factors. Thus MLV-B Gag- 
Pol particles with either HIV-2 MCR or MCN Envs can saturate-out Lv2 restriction and 
rescue restricted HIV-1 and HIV-2 virus infection. Initial experiments indicated, 
however, that MLV-N could not saturate in an Lv2 manner. Later experiments 
demonstrated that MLV-N could saturate Lv2 if the TRIM 5a activity of Refl was first
170
knocked down. Thus Lv2 is independent from Refl restriction, Lv2 is able to recognise 
MLV-N, B, and Mo cores and is dependent on the Env route of entry.
Lv2 is an independent restriction directed by the viral env-receptor interaction. VSV 
Env overcomes Lv2 (Schmitz et al., 2004), indicating localisation of the Lv2 restriction 
factor in a distinct compartment.
This chapter further supports the model that Refl and Lv2 are distinct factors in human 
cells because; MLV-N Gag-Pol VLPs have lower titre on human cells than MLV-B 
VLPs, regardless of their Env, which is probably due to Refl restriction, however all 
MLV Gag-Pols tested became susceptible to Lv2 restriction in HeLa/CD4 cells when 
pseudotyped with MCR Env; MLV-B(MCR) is restricted by Lv2 but not by Refl; the 
discreet compartmentalisation requires that Lv2 is only saturable by MLV Gag-Pol 
cores with HIV-2 Envs and finally, MLV-N(HIV-2) can saturate Lv2 restriction if 
TRIM 5a is knocked down. This suggests that Lv2 and Refl compete for incoming 
retroviral cores and that Refl may occur before Lv2 in the host cell. Alternatively, Refl 
could be dominant over Lv2 activity when competing for incoming retroviral capsids.
Lv2, like refl, can be abrogated by saturation with MLV Gag ‘decoy’ VLPs. However, 
unlike Refl restriction, both MLV-B and MLV-N cores are able to saturate Lv2 
restriction. Surprisingly, MLV-B VLPs with both restricted MCR and unrestricted 
MCN Envs could saturate Lv2 restriction and recover HIV-1 89.6 and HIV-2 MCR 
infection on HeLa/CD4 cells. Suggesting that MCN Env can deliver to both a 
restrictive and non-restrictive pathway.
A number of experiments presented in this chapter suggest that saturation experiments 
need to be interpreted with caution. 1) The MLV-N and Mo Gag may be targeted by 
additional restriction factors other than those specific to Lv2 thus decreasing their 
potency to knockout Lv2 restriction and rescue MCR infection; TRIM 5a knockdown 
by RNAi improved the potency of MLV-N to saturate Lv2. 2) The ability of one 
species of virus core to saturate a restriction and rescue infectivity of another species of 
virus core cannot always be reciprocated
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In the ‘reciprocal abrogation’ experiments MLV-B(HIV-2) vectors were rescued with 
saturating doses of HIV-2. Recovery of MLV-B(HIV-2) was in a non-Lv2 manner; 
there was recovery of MLV-B(HIV-2) in Lv2 permissive cells. Therefore, Lv2 
permissive cells may bypass Lv2 restrictive compartments but direct viruses into 
previously undescribed restrictive routes.
This chapter has shown that, like Refl, Lv2 is a saturable restriction factor but, unlike 
Refl, Lv2 is compartment specific. Since Lv2 is saturable it suggests that a specific 
protein is responsible for the restriction of HIV-1 and HIV-2 in human cells. Chapter 6 
describes the identification and characterisation of TRIM proteins that mediate Lv2 and 
these TRIMs can be bypassed with a VSV Env, further confirming that Lv2 and Refl 
are distinct restrictions.
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6.1 Introduction:
In chapter 4 I partially characterised a specific compartment/pathway that leads to Lv2 
restriction, and in chapter 5 I demonstrated the saturable nature of Lv2. This chapter 
characterises the restriction more specifically; identifying the cellular TRIM proteins 
involved in restriction of HIV-1 89.6 and HIV-2 MCR, and their cell-type specific 
expression.
TRIMs have been implicated as antiviral molecules (Nisole et al., 2005; Reymond et al., 
2001). Indeed, TRIM 5a was cloned from humans and rhesus macaques and identified 
as the Refl and Lvl restriction factors, respectively (Keckesova et al., 2004; Perron et 
al., 2004; Stremlau et al., 2004; Yap et al., 2004). TRIM 5a (Keckesova et al., 2004; 
Perron et al., 2004; Stremlau et al., 2004; Yap et al., 2004) and TRIM 1 (Yap et al., 
2004) are responsible for the Refl and Lvl restrictions and as outlined in the 
introduction to the last chapter, Refl is the human model for resistance to infection of 
MLV-N and EIAV (Hatziioannou et al., 2003; Towers et al., 2000). Lvl restriction is 
the model for resistance of Rhesus macaque cells to HIV-1 and SIVagm infection 
(Hatziioannou et al., 2003), and African green monkey cells to HIV-1 and SIVmac 
infection (Besnier et al., 2002; Cowan et al., 2002; Hatziioannou et al., 2003). 
Therefore, TRIM 5a and TRIM 1 are thought to be responsible for the cross-species 
lentivirus restrictions in humans and simians (Hatziioannou et al., 2004; Keckesova et 
al., 2004; Stremlau et al., 2004; Yap et al., 2004).
Because TRIM 1 and TRIM 5a from humans and African green monkeys were shown 
to have Refl activity and TRIM 19 has been shown to have anti-viral activity against 
VSV, it was suggested that the TRIM protein family has very broad anti-viral activity 
(Yap et al., 2004).
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TRIMs have also been associated with restrictions of viruses other than retroviruses. 
The promyelocytic leukaemia protein (PML), TRIM 19, has been demonstrated to have 
suppressive activity against numerous viruses including influenza and VSV (Chelbi- 
Alix et al., 1998), however this activity was shown to be at the stage of virus expression 
and not entry (Chelbi-Alix et al., 1998). PML has also been shown to inhibit 
Arenavirus infection in mice and may have antiviral effects on Herpes Simplex virus in 
human cells (Bonilla et al., 2002; Chee et al., 2003). With regards to HIV, there has 
been one report of PML associating with the incoming HIV-1 PIC in human cells and 
inhibiting HIV integration (Turelli et al., 2001). In this study, an enhancement of HIV- 
1 infection was shown upon treatment of cells with arsenic, however this treatment has 
been shown to suppress Refl restriction and recover HIV-1 infection in human cells by 
a PML independent mechanism (Berthoux et al., 2003; Keckesova et al., 2004; Sayah 
and Luban, 2004; Turelli et al., 2001).
Since the discovery of TRIM 5a there has been great interest in the regions of this 
protein that are responsible for retroviral restriction. The SPRY (B30.2) domain was 
cited as the principal TRIM 5 domain responsible for antiviral activity (Stremlau et al., 
2004; Stremlau et al., 2005). In particular, residues 320 to 345 have been proposed to 
be responsible for the species-specific restriction activity of TRIM 5a (Nakayama et al., 
2005; Perez-Caballero et al., 2005; Sawyer et al., 2005; Yap et al., 2005). More 
specifically, a proline to arginine alteration at aa position 332 in the SPRY domain has 
been shown to confer anti-HIV-1 activity to human TRIM 5a, which does not normally 
have activity against this virus (Yap et al., 2005). There are four splice variants of 
TRIM5: a, 8, y and e [reviewed in (Nisole et al., 2005)]. However, of these, only the a 
splice variant can effect Refl and Lvl activity (Keckesova et al., 2004; Stremlau et al., 
2004; Yap et al., 2004). In fact, antiviral activity of the SPRY domain was first 
implicated by comparing the activities of TRIM 5a with TRIM 5y, which is identical to 
TRIM 5 a except that TRIM 5y lacks most of the SPRY domain due to alternative 
splicing (Stremlau et al., 2004). In addition to the SPRY domain, MLV-N restriction by 
TRIM 5a requires regions in the coiled-coil domain (Perez-Caballero et al., 2005; Yap 
et al., 2005).
Because Lv2 is a saturable restriction factor (shown in chapter 5), and CA dependent as 
reported previously (Schmitz et al., 2004), I investigated whether the TRIM proteins are
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responsible for Lv2 and if one of them is TRIM 5a, like for Refl. Since TRIM 1 and 
TRIM 5a both have SPRY domains and TRIM 5a restricts via this domain the main 
criteria for choosing candidate Lv2 TRIMs, from the 69 TRIM genes identified, was the 
presence of a SPRY domain [reviewed in (Nisole et al., 2005)].
6.2 Results:
6.2.1 Tripartite motif protein 5a is not responsible for Lv2 restriction in 
U87/CD4/CXCR4 and HeLa/CD4 cells.
I used RNAi to determine whether TRIM 5a is responsible for Lv2 restriction. MLV 
cores with VSV Env could not saturate Lv2 restriction [chapter 5, (Schmitz et al., 
2004)]. However, MCR pseudotyped with a VSV Env is not restricted. Thus it is still 
possible that TRIMs in the appropriate compartment could act as Lv2.
I first confirmed that the siRNA designed could knockdown TRIM 5a activity in the 
cells used in this study. U87/CD4/CXCR4, HeLa/CD4, and H399 cells were transfected 
with TRIM 5a and control RNAi oligomers, then infected with MLV-N(VSV) and 
MLV-B(VSV) VLPs (fig 6.1a). The titre of MLV-B(VSV) on the TRIM 5a 
knockdown cells is not altered when compared to the control cells. MLV-N(VSV) titre 
increased by 50.0, 24.1, and 35.5-fold on the TRIM 5a knockdown U87/CD4/CXCR4, 
HeLa/CD4, and H399 cells, respectively, over the control cells (fig 6.1a). These 
observations are consistent with those published previously (Keckesova et al., 2004).
The TRIM 5a RNAi knockdown cells were titrated with restricted MCR, HIV-1 89.6 
and unrestricted MCN and HIV-1 NL4.3 (fig 6.1b). There was little or no effect on the 
titre of HIV-2 MCR (5.3 x 104 FFU/ml vs 2.6 x 104 FFU/ml) or HIV-1 89.6 (1.5 x 104 
FFU/ml vs 1.5 x 104 FFU/ml) on HeLa/CD4 cells, demonstrating no rescue of Lv2 
restriction. 89.6 titre on control U87/CD4/CXCR4 cells was 1.53xl05 FFU/ml 
increasing to 2.39x105 FFU/ml on the TRIM 5a knockdown, increasing 89.6 restriction 
from 10.2 to 15.4-fold upon TRIM 5a knockdown, however this does not appear to be 
an Lv2 specific result. Thus knockdown of TRIM 5a/Refl activity did not alleviate Lv2 
restriction.
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Figure 6.1. Knockdown of the tripartite motif protein 5a/RefL restriction factor 
has no effect on Lv2 in restrictive HeLa/CD4 cells.
(A) TRIM 5a RNAi knockdown cells rescue Refl restriction of MLV-N. Cells knocked down for TRIM 
TRIM 5a expression with RNAi were infected with MLV-N(VSV) and MLV-B(VSV). EGFP positive 
cells were determined by FACS and eGFP positive cells per ml were calculated. (B) RNAi directed 
against TRIM 5a has no effect on Lv2 restriction. Cells transfected with TRIM 5a RNAi or control 
RNAi oligomers were challenged with HIV-ls 89.6, NL4.3, and HIV-2s MCR, and MCN. (C) Fold 
restriction. The titre from permissive U87/CD4/CXCR4 was divided by the titre from restrictive 
HeLa/CD4 cells for both the control and the TRIM 5a RNAi experiments. Shown are the results of one 
experiment. Results in this fig are representative of 3 independent experiments. Error bars represent the 
SDM.
6.2.2 Members of the tripartite motif family of proteins can be knocked down 
specifically.
RNAi knockdown of TRIM 5a had no effect on Lv2 restriction of HIV-1 89.6 or HIV-2 
MCR. However, because of the similarity between the restriction of HIV-1 by rhTRIM 
5a in macaque cells and Lv2 restriction of HIV (Lv2 is saturable), other members of the 
TRIM family were screened for Lv2 activity.
I next investigated other SPRY domain containing TRIMs for anti-HIV Lv2 activity. 
TRIMs 1,6, 18, and 34 were first investigated. There have been reports of non-specific 
silencing of non-target mRNA and protein expression in RNAi experiments (Doench et 
al., 2003; Jackson et al., 2003; Persengiev et al., 2004; Scacheri et al., 2004). I first 
determined the specificity of the various siRNAs used in the RNAi knockdown 
experiments by monitoring expression of TRIM-eGFP and endogenous TRIM mRNA 
production. RNAi oligomers directed against TRIMs 1, 6, 18, and 34 were designed, 
HeLa/CD4 cells were transfected with the RNAi oligomers, transfected with TRIM 1, 6 
and 18-GFP plasmid constructs and fig 6.2a shows approximately 90% knockdown of
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eGFP expression. TRIM RNAi did not inhibit expression of heterologous TRIM-eGFP 
constructs (data not shown).
To semi-quantify the amount of RNAi inhibition of endogenous TRIM mRNA 
knockdown, 5.0-fold serial dilutions were made of cDNA from the RT reaction of RNA 
extracted from siTRIM treated HeLa/CD4 cells (this work was done by Keith Aubin). 
Fig 6.2b shows that RNAi for TRIMs 1, 18 and 34 could knockdown their respective 
targets, however TRIM RNAi didn’t knockdown the mRNA of a heterologous TRIM. 
TRIM knockdown is indicated by 5.0-fold less cDNA/RNA expression than a 
heterologous TRIM or the p-actin control (fig 6.2b).
C ontrol
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s/Control
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Z  £
s/TRIM 18 
s/TRIM 34
TRIM  1
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TRIM  18 TRIM  34 p-actin
Figure 6.2. RNA interference knocks down the expression of tripartite  motif 
proteins 1, 18 and 34 specifically and exclusively.
(A) The expression o f eGFP-tagged TRIMs 1, 6, and 18 transfected into HeLa/CD4 cells is knocked 
down specifically by siRNA as visualised by epifluorescence. (B) TRIM 1, 18 and 34 endogenous 
mRNA transcript levels are down regulated by specific siRNAs. Five pg total RNA from siRNA treated 
HeLa/CD4 cells was reverse transcribed and PCR was performed on 5.0-fold serial dilutions o f cDNA. 
TRIM specific primers did not down modulate expression o f other TRIMs or P-actin loading control. For
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primer sequences see materials and methods. The results shown are representative of 3 independent 
experiments for (A) and (B).
6.2.3 Knockdown of tripartite motif proteins 1, 18 and 34 by RNA interference 
rescues restricted HIV-1 and HIV-2 infection in Lv2 restrictive HeLa/CD4 cells.
Fig 6.3b shows that there is little effect of any of the TRIM RNAi on the unrestricted 
viruses, HIV-1 NL4.3 and HIV-2 MCN, however TRIM 1 RNAi alone recovered the
10.0-fold restriction (10.0-fold in fig 6.1c) of HIV-1 89.6 in HeLa/CD4 cells. TRIM 1 
RNAi rescued 15.0-fold of HIV-2 MCR restriction in HeLa/CD4 cells and when all 3 
TRIMs were knocked down together the entire 25.0-fold restriction of MCR (compared 
to 20-fold of restriction in fig 6.1c) was recovered. Fitting with the Lv2 model, fig 6.3c 
shows that RNAi knockdown had little effect on restriction of MCR or 89.6 virus 
titrations in permissive U87/CD4/CXCR4 cells.
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Figure 6.3. Knockdown of tripartite motif proteins 1, 18 and 34 with RNA 
interference rescues Lv2 restricted MCR and 89.6 infection in HeLa/CD4 cells.
(A) HeLa/CD4 and (C) U87/CD4/CXCR4 cells were transfected with RNAi oligomers directed against 
TRIM or irrelevant cellular protein and infected with HIV 2 days later, and fixed and stained for HIV 
infection 3 days later. (B) Fold recovery of HIV infection on HeLa/CD4 cells. The virus titre from 
infection on TRIM RNAi treated HeLa/CD4s was divided by the titre from the control RNAi HeLa/CD4 
cells to obtain fold recovery. The results shown in (A) represent the mean of the results pooled from 7 
independent experiments. The error bars in (A) represent the SDM of the pooled results from 7 
independent experiments. The results shown in (B) are the product of 1 experiment but represent the 
results of 2 independent experiments and error bars represent the SDM.
6.2.4 Tripartite motif proteins 1, 18 and 34 are expressed to higher endogenous 
levels in restrictive HeLa/CD4 than in permissive U87/CD4/CXCR4 or 
NP2/CD4/CXCR4 cells.
To determine whether TRIMs 1, 18 and 34 were expressed endogenously in the 
permissive U87/CD4/CXCR4 and NP2/CD4/CXCR4 cell types I used specific 
polyclonal Abs to detect these TRIMs in HeLa/CD4, U87/CD4/CXCR4 and 
NP2/CD4/CXCR4 cells.
Figs 6.4a and b show the detection of TRIMs 1, 18 and 34 by western blot. Despite 
almost identical actin input, TRIMs 1, 18 and 34 are expressed to significantly higher 
levels in restrictive HeLa/CD4 than permissive U87/CD4/CXCR4 or NP2/CD4/CXCR4 
cells. There are higher levels of TRIM la  expression in HeLa/CD4 cells compared to 
permissive NP2/CD4/CXCR4 and U87/CD4/CXCR4 cells (fig 6.4a, top panel). 
Difference in expression of TRIM 18a and p between restrictive and permissive cells is 
the most apparent in that there is no detectable expression of either of these splice 
variants in NP2/CD4/CXCR4 or U87/CD4/CXCR4 cells despite strong expression in 
HeLa/CD4 cells (fig 6.4a, middle panel). Detection of the TRIM 34 splice variants 
yielded the a  and ‘short’ isoforms in addition to an as yet uncharacterised 80 kDa band 
(fig 6.4a, bottom panel). The difference in expression of the a  variant between 
HeLa/CD4 and permissive NP2/CD4/CXCR4 and U87/CD4/CXCR4 cells was most 
apparent. There is less expression of the short variant in permissive NP2/CD4/CXCR4
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compared to HeLa/CD4 cells, however, like HeLa/CD4, U87/CD4/CXCR4 cells 
express high amounts o f this variant (fig 6.4a).
The effect on TRIM 1 protein expression from TRIM 1 RNAi treated restrictive and 
permissive cells was determined. A 5.0-fold reduction in TRIM 1 mRNA production 
was seen in HeLa/CD4 cells upon TRIM 1 RNAi treatment and considerable 
knockdown was also seen with the TRIM 1-eGFP transfected construct in these cells, 
however the western blot protein band is only marginally smaller than the control band 
in fig 6.4b.
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Figure 6.4. Tripartite m otif proteins 1, 18 and 34, are expressed to higher levels in 
restrictive HeLa/CD4 than in permissive U87/CD4/CXCR4 and NP2/CD4/CXCR4 
cells.
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(A) Cell lysates were western blotted and probed with anti-TRIM 1, 18 and 34 polyclonal antibodies. 
Detection of actin with an actin mAh was used as an input control and band intensity was measured by 
densitometry, below (see materials and methods). Arrows denote position of detectable splice variants on 
western blots. The a, P and ‘Short’ isoforms are indicated and the long uncharacterised 80kDa TRIM 34 
isoform is denoted as #. (B) Cell lysates from control and TRIM 1 RNAi treated cells were western 
blotted and probed with anti-TRIM 1 polyclonal antibody and anti-actin mAb as an input control. The 
figs shown are the product of one experiment but represent the results from at least 7 different western 
blots of each of the TRIM proteins.
6.2.5 Permissive cells expressing human tripartite motif proteins 1, 18 or 34 
become restrictive.
The RNAi knockdown of TRIM expression (controls in fig 6.3) resulted in recovery of 
restricted HIV infection in restrictive HeLa/CD4 cells. If TRIMs 1, 18 and 34 are 
indeed responsible for Lv2 then it is important to recapitulate the restriction by 
expressing these candidate TRIMs in permissive cells and demonstrating restriction of 
Lv2 susceptible HIV. Fig 6.5c shows that HIV-1 89.6 infection in TRIM lp expressing 
NP2/CD4/CXCR4 cells is restricted 6.0-fold compared to infection on the parental 
NP2/CD4/CXCR4 cells. TRIM 18p also restricted 89.6 by about 6.0-fold as well, and 
TRIM 34a displayed weaker restriction activity at only 2.0-fold less infection than the 
NP2/CD4/CXCR4 parental cells. So it would appear that individually expressed 
TRIMs 1 and 18 effect the majority of restriction on HIV-1 89.6. Trim 18p and 34a 
expressing NP2/CD4/CXCR4 cells each restricted HIV-2 MCR by about 6.0-fold 
whereas TRIM 1 p expressing NP2/CD4/CXCR4 cells restricted MCR by 11.0-fold (fig 
6.5c). HIV-1 NL4.3 and HIV-2 MCN were relatively unaffected by any of the 
NP2/CD4/CXCR4 cells expressing any of the TRIM constructs (fig 6.5c).
MCR(VSV) was titrated onto TRIM lp expressing NP2/CD4/CXCR4 cells alongside 
MCR. Fig 6.5g shows that TRIM ip restriction is bypassed in NP2/CD4/CXCR4 cells 
by a VSV Env, supporting the implication of TRIM ip in the Lv2 model of restriction.
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6.2.6 The variable expression of tripartite motif proteins in permissive cells may 
explain the different restriction activities of the over-expressed tripartite motif 
proteins.
Cell lysates from TRIM 1(3, 18J3 and 34a expressing NP2/CD4/CXCR4 cells were 
western blotted and probed with TRIM 1, 18 and 34 specific antibodies (fig 6.5d).
The detection of TRIM 18p and 34a expression by western blot is less apparent. Figs 
6.4a and 6.5e show the differential expression of TRIM 18a and (3 in HeLa/CD4 cells 
compared to the parental NP2/CD4/CXCR4 cells. Additional expression of TRIM 18|3 
can be seen in NP2/CD4/CXCR4 cells, transduced and stably expressing this protein 
over the parental NP2/CD4/CXCR4 (fig 6.5e; the two arrows). Although the over­
expressed band sizes are not the expected sizes of approximately 60 and 100 kDa for 
TRIM 18P and a, respectively, as seen in restrictive HeLa/CD4 cells.
The over-expression of TRIM 34 reveals one band at approximately 115 kDa on the 
western blot (fig 6.5f). This size is reminiscent of the size of the over-expressed TRIM 
18, however there is only one band at 115 kDa on the TRIM 34a western blot (fig 6.5f).
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Figure 6.5. Permissive NP2/CD4/CXCR4 cells can be made restrictive to HIV-1
89.6 and HIV-2 MCR infection by expressing tripartite motif proteins 10,180 and 
34a.
(A) TRIMs 10, 34a and (B) 18p were cloned from HeLa/CD4 cells, sub cloned into an MLV retroviral 
vector, then transduced into permissive NP2/CD4/CXCR4 cells. Cells were infected with HIV or (G) 
Hiy(VSV) pseudotype, fixed and stained for infection 3 days later. Error bars represent the SDM. (C) 
Fold restriction was calculated by dividing the infection on control NP2/CD4/CXCR4 cells by the TRIM 
transduced cells. All three TRIMs are shown together. (D-F) Lysates from U87/CD4/CXCR4 and 
NP2/CD4/CXCR4 cells stably expressing (D) TRIM ip, (E) TRIM 18p or (F) TRIM 34a were western 
blotted and probed with anti-TRIM 1, TRIM 18, or TRIM 34 pAbs, respectively. All of the cell lysates in 
(D), (E) and (F) were western blotted and probed with an actin mAb as an input control. The upper arrow 
in (D) indicates the position of TRIM la  and the lower arrow indicates the position of TRIM ip. The figs 
shown are the product of one experiment but results represent the results of at least 4 independent 
experiments.
6.2.7 The tripartite motif protein 10 -SPRY (butyrophilin 30.2) domain possesses 
the majority of restriction activity of tripartite motif protein 10.
A research assistant in the lab, Keith Aubin cloned TRIM 10 without a SPRY domain 
(TRIM 10 ASPRY). The antiviral activity of TRIM 5a has been reported to reside, 
primarily, in the SPRY (B30.2) domain at the C-terminal end of the protein (Stremlau et 
al., 2004; Stremlau et al., 2005). In TRIM 10 this corresponds to aa position 397 to 685, 
the last 288 amino acids. NP2/CD4/CXCR4 cells stably expressing TRIM 10-ASPRY 
lose the majority of their restriction activity towards HIV-1 89.6 and MCR. Fig 6.6b 
shows that restriction of 89.6 goes from 6.0-fold in the TRIM 10 expressing 
NP2/CD4/CXCR4 cells to 2.0-fold restriction in the TRIM 10-ASPRY expressing 
NP2/CD4/CXCR4 cells. The restriction of MCR in the TRIM 10-ASPRY cells 
decreases to 4.0-fold from 11.0-fold in the TRIM 10 expressing NP2/CD4/CXCR4 
cells. As was seen with TRIM 10 in fig 6.5c, the TRIM 10-ASPRY had little effect on 
the infection of HIV-1 NL4.3 or HIV-2 MCN in NP2/CD4/CXCR4 cells (fig 6.6b)
Fig 6.6c shows the level of expression of TRIM 10-ASPRY in NP2/CD4/CXCR4 cells 
with an anti-HA mAb. TRIM 10-ASPRY was cloned with an HA tag at the C-terminus 
because the TRIM 10 antibody used to detect TRIM 10 over-expression in fig 6.5d 
recognises a motif in the SPRY region of TRIM 1. Therefore, in this system, direct
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comparisons between western blots o f over-expressed TRIM 1 (3 and TRIM 10-ASPRY 
are difficult to make. The western blots in figs 6.5d and 6.6c show that TRIM lp  and 
TRIM ip- ASPRY proteins, respectively, are over-expressed in the parental 
NP2/CD4/CXCR4 cells to roughly similar levels.
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Figure 6.6. Tripartite m otif protein ip  without a SPRY (butyrophilin 30.2) 
domain (tripartite m otif protein lp  ASPRY) has limited restriction activity against 
HIV-1 and HIV-2 compared to full-length tripartite motif protein ip .
(A) TRIM lp  ASPRY was stably expressed in NP2/CD4/CXCR4 cells. Cells were challenged with HIV 
and fixed and stained for infection 3 days later. (B) The fold restriction o f HIV infection on TRIM 1 
NP2/CD4/CXCR4 cells calculated from (A) compared to infection on TRIM 10 ASPRY 
NP2/CD4/CXCR4 cells. Fold restriction was obtained by dividing the infectious titre on control 
NP2/CD4/CXCR4 cells by the titre on TRIM lp  ASPRY NP2/CD4/CXCR4 cells in (A). (C) Cell lysates
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from NP2/CD4/CXCR4 cells stably expressing TRIM 1[J ASPRY were western blotted and probed with 
an anti-HA-tag mAb or an anti-actin mAb as an input control.
6.2.8 Infection by HIV-2 envelope pseudotypes of MLV can be recovered in 
HeLa/CD4 cells when the expression of tripartite motif proteins 1, 18 and 34 is 
knocked down.
TRIMs 1,18, and 34 mediate Lv2 restriction of HTV-1 and HIV-2 as described above. I 
determined what effect these TRIMs would have on the replication of HTV-2 Env 
pseudotypes of MLV in Lv2 restrictive cells. MLV vector pseudotypes were used as a 
tool in Chapter 5 to demonstrate the saturable nature of Lv2 restriction. Saturable doses 
of MLV-N and B vector pseudotypes with HIV-2 Envs could recover Lv2 restricted 
HIV-1 and HIV-2 infection. Identifying the TRIMs being saturated by incoming MLV- 
N and B (that have HTV-2 Envs) will provide insight into which TRIMs are responsible 
for Lv2 restriction of HIV-1 and HTV-2 in HeLa/CD4 cells. HeLa/CD4 cells were 
transfected with RNAi oligomers directed against TRIMs 1, 18, and 34, infected with 
HTV-2 Env-MLV pseudotypes, and infection was determined by flow cytometry of the 
MLV-eGFP reporter vector. As expected, since VSV overcomes Lv2 restriction, MLV- 
B(VSV) infection of HeLa/CD4 cells was unaffected by the TRIM 1, 18 or 34 
knockdowns (fig 6.7f). Infection of HeLa/CD4 cells by MLV-N(VSV) was rescued by
4.0-fold by the TRIM 1 knockdown in fig 6.7f as has been reported previously (Yap et 
al., 2004). The 8.0-fold recovery of MLV-N(VSV) infection in TRIM 34 knockdown 
HeLa/CD4 cells has not been previously reported (fig 6.7f).
In chapter 5 (titration of MLV vector pseudotypes) MCR Env confers restriction to 
MLV cores (N and B-tropic) in HeLa/CD4 cells. MCN Env also confers restriction to 
MLV-B cores (but to a lesser extent) and no further restriction to MLV-N capsid cores. 
I postulated that the lack of MLV-N restriction was because it is already restricted by 
Refl in human cells. Figs 6.7a to d show that MLV-N(HIV-2) pseudotypes are more 
susceptible to recovery with RNAi TRIM knockdown in HeLa/CD4 cells than the 
MLV-B (HIV-2) pseudotypes.
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The TRIM knockdown cells recovered MLV-N infection differently, depending on the 
Env provided. Infections by both MLV-N(MCR) and MLV-N(MCN) were rescued by 
the TRIM 1 knockdowns by 6.8 and 4.4-fold, respectively, in figs 6.7b and d. The 
TRIM 18 knockdown didn’t affect the MLV-N(MCN) infection but recovered MLV- 
N(MCR) infection by 3.0-fold (fig 6.7b), which is consistent with the restriction of 
HIV-2 MCR and HIV-1 89.6 by TRIM 18 in fig 6.3b. The co-knockdowns of all three 
TRIMs is additive for MLV-N(MCN) but not MLV-N(MCR) (figs 6.7b and d).
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Figure 6.7. MCR and MCN envelope pseudotypes of N and B-tropic MLV are 
rescued on restrictive HeLa/CD4 cells knocked down for tripartite motif proteins 
1,18, and 34.
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(A-F) HeLa/CD4 cells treated with control, TRIM 1, 18 or 34 RNAi and all three pooled together were 
infected with MLV-N and B pseudotypes with MCR, MCN, and VSV Envs. (A, C, E) EGFP positive 
cells were determined by flow cytometry, and infectious units per ml were calculated. (B, D, F) Fold 
recovery of pseudotype infection with TRIM RNAi knockdown. The TRIM RNAi infection was divided 
by the control RNAi infection to obtain fold recovery. Results are representative of 6 independent 
experiments. Error bars represent SDM.
6 . 3  D i s c u s s i o n :
This chapter demonstrates that TRIMs 1, 18 and 34, mediate Lv2. By gene silencing in 
restrictive HeLa/CD4 and by rendering permissive NP2/CD4/CXCR4 cells restrictive I 
show that most Lv2 restriction activity lies in the activity of TRIM 1. Furthermore, die 
SPRY domain of TRIM 1 is implicated as an important determinant of antiviral activity 
of TRIM ip. This chapter also shows that the difference in restriction activity between 
Lv2 permissive and restrictive cells lies in the expression of monomeric TRIM proteins 
in restrictive cell types compared to permissive ones. Infection of TRIM knockdown 
cells with HIV-2 Env pseudotypes of MLV-N and B cores suggests that the MLV 
capsid cores are ‘hit’ by different TRIMs when delivered into one compartment by 
HIV-2 Envs than when delivered to another compartment by a VSV Env. Thus the 
compartmentalisation models of TRIM proteins (Reymond et al., 2001) and Lv2 
retroviral restriction (Schmitz et al., 2004) are mutually supportive.
Some endogenous expression of TRIM 1 in permissive cells is detectable. The western 
blots show trace amounts of TRIM 1 protein expression, however significant levels of 
recovery of MLV-N(VSV) with TRIM 1 RNAi, in permissive cells, suggests that TRIM 
1 is normally expressed in these cells as well as restrictive ones and that only small 
amounts are required to inhibit MLV-N.
PH-dependent VSV-G delivers its contents from an acidic compartment whereas pH- 
independent HTV can fuse outside acidic compartments. Acid-dependent VSV-G can 
only fuse in a low pH compartment (Mannen et al., 1982). TRIM 5a activity is 
associated with this pathway of entry because MLV-N(VSV) is restricted in a Refl- 
dependent manner. However, in chapter 5 the knockdown of TRIM 5a recovered the 
potency of MLV-N(HIV-2) vectors to saturate-out Lv2 restriction suggesting a more 
ubiquitous localisation of TRIM 5a in the cell than Lv2 activity.
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I showed that individual TRIMs are responsible for restriction of HIV-1 89.6 and HTV-2 
MCR. However, I have not shown what happens when all of these proteins are over­
expressed simultaneously. The over-expression of these three proteins together may 
very well result in recapitulation of the full Lv2 restriction.
The ability to target different viruses (via the different viral entry pathways) may, in 
part, lie in the differing nuclear and cytoplasmic localisations of the 69 TRIM gene 
products (Nisole et al., 2005), that can form homo and hetero-oligomers in different 
cellular compartments (Reymond et al., 2001). This particular chapter is especially 
pertinent to the Lv2 model of restriction, because Lv2 restriction (Schmitz et al., 2004), 
like TRIM localisation (Reymond et al., 2001), is a model based on 
compartmentalisation. Depending on the virus and target cell type, virus Envs target 
different cellular entry pathways (Marchant et al., 2005).
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Chapter 7
Summary and future directions
7.1 Summary
In chapter 3 I observed that although HIV-1 and HTV-2 both infect PBMC and MDM 
the replication kinetics of HTV-2 in MDM are different. HIV-2 primary isolates could 
enter MDM and reverse transcribe efficiently but entered a latent state after an initial 
burst of replication.
The V3 loop of Env is a MDM cell tropism determinant in HTV-1 and I show that this is 
also true for HIV-2, although weaker. The correlation suggests that there are other 
factors associated with HIV-2 infection of MDM. One HTV-2 isolate in particular, 
prCBL 23, demonstrated efficient infection of PBMC but lacked the ability to infect 
MDM. In chapter 4 I show that the role of Env in Lv2 restriction may be explained by 
its delivering susceptible cores into restrictive compartments via an endocytic pathway.
I demonstrate the saturable nature of the Lv2 restriction for HTV-1 and HTV-2 in chapter 
5 and in chapter 6 1 demonstrate that TRIMs 1, 18, and 34 mediate Lv2.
7.2 Future directions
To better understand the role that restriction plays in viral infection it would be 
interesting to investigate the tissue specific expression of viral restrictions and which 
types of viruses are targeted by these factors. Work resulting from this thesis might also 
involve investigating the possible localisation of TRIMs in endocytic compartments. 
Arf6 was implicated as a restrictive compartment thus this may be a region of high 
TRIM density. Site directed mutagenesis would also be a useful tool to relocalise 
TRIMs to other cellular compartments and observe the effect on restriction to further 
investigate the compartmentalisation model of restriction.
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